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1Introduction
1 General
Streptococcus pneumoniae
Since the first isolation of the Gram-positive bacterium Streptococcus pneumoniae
in 1881 [1,2], this microorganism has been extensively studied [3-5]. The
importance of studying this pathogenic bacterium lies in its heavy load on society,
especially on children. This is indicated by the total number of deaths caused by
pneumococcal diseases in children less than five years of age, which is estimated to
be at least one million each year [6,7]. Furthermore, the mortality rate due to
pneumococcal diseases is increasing [8] and severe illnesses cause many people to
suffer. Finally, the economic costs for hospitalisation and treatment of these
patients are enormous.
Many healthy adults carry S. pneumoniae in the respiratory tract. Rarely,
pneumococcal diseases like pneumonia, meningitis or otitis media (infection of the
lungs, meninges or middle ear) are caused by primary infection of the lungs.
However, several factors predispose to infection such as damage to the respiratory
tract, fatigue, malfunctioning of the immune system or viral diseases [9]. Groups at
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high-risk that are especially vulnerable to pneumococcal infection include elderly
persons, infants, especially under the age of two, and patients with chronic medical
conditions such as heart, lung and kidney diseases, diabetes, alcoholism or
immunosuppressive illnesses [10]. Multiplication of pneumococci in the lungs,
middle ear or meninges will result in pneumococcal lysis and the release of
bacterial products such as the toxin pneumolysin. The release of pneumolysin in the
respiratory tract may perturb host defences, allowing bacterial proliferation and
spread. Pneumococcal lysis will trigger the inflammatory process by activating
phagocytes and complement. Inflammation is hypothesised to be responsible for
the morbidity and mortality of pneumococcal infection [11]. Once the
microorganism has breached the mucocutaneous barrier, opsonisation by type-
specific antibodies and complement is required for clearance of the bacterium from
tissue and blood.
S. pneumoniae belongs to the class of encapsulated bacteria that are enveloped by a
carbohydrate coat. This serves as a cover against external influences and renders
the bacterium more or less resistant to non-specific host defence. Antibodies raised
against this capsular polysaccharide (CPS) were found to be essential for removal
of the bacterium from the body [12]. S. pneumoniae is divided into different
serotypes according to the chemical composition and structure of the CPSs as
discovered by Avery, Heidelberger and Goebel [13-15]. A recent survey gives an
update of the known structures of pneumococcal CPSs [16]. The total number of
serotypes known today is 90 [17] that are numbered according to an American or
Danish system [18]. The last is being commonly used and places serotypes with a
similar CPS structure in one group such as types 6A and 6B that differ only in their
rhamnose-ribitol linkage. The distribution of serotypes differs in time, geographical
area [19-21], and with age [22,23] and is important for the composition of
carbohydrate-based vaccines that are to be used in a specific area or age-group.
Vaccination
Antibiotics have long been an adequate way for treatment of bacterial diseases,
including pneumococcal. Despite its use, death rates are still high and even
increasing. The development of resistance against antibiotics in the last decades is a
serious threat for successful treatment of infection [24-27]. For example, during a
surveillance in the US from 1993-1996 the number of isolates nonsusceptible to
penicillin or ceftriaxone doubled throughout the 3-year period [28,29]. An
alternative approach is to prevent pneumococcal diseases by vaccination with CPSs
isolated from bacterial cultures, which was shown to afford protection as early as
1923 [13].
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As stated above, the capsular polysaccharide of the bacterium is the most
immunogenic surface structure that can induce highly protective anti-CPS
antibodies [30,31]. Thus, the CPS has been the main target for vaccine
development. Vaccines containing isolated polysaccharides of 23 serotypes are
commercially available as Pneumovax 23 (Merck) or Pnu-Immune 23 (Wyeth-
Lederle). These vaccines cover over 90% of the infections caused by Streptococcus
pneumoniae in the US [32].
Mainly IgM
Mainly IgG + memory B-cells
T-cell
TCR
MHC
B-cellB-cell
IL-5
A) B)
Figure 1. Simplified view on the humoral immune response to A) T-cell
independent (TI) CPS antigens and B) T-cell dependent (TD) glycoprotein
antigens. TCR: T-cell receptor; MHC: Major Histocompatibility Complex class II;
IL-5: Interleukins.
Carbohydrates belong to the class of T-cell independent (TI) antigens. This type of
antigens stimulates B-cells to produce antibodies without the involvement of T-
cells. An immune response is elicited when surface-bound immunoglobulins are
cross-linked (Figure 1A) and specific receptors interact with interleukins (IL-5). As
a result of the absence of T-helper cells in this process, the antibodies formed are
mainly of the IgM isotype and no memory B-cells are produced. Due to the
immature immune system of children, they respond poorly to T-cell independent
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carbohydrate antigens. As a consequence, the use of capsular polysaccharides
(CPS) for vaccination is convenient in the short-term protection of healthy adults
[30,33,34], and can give some protection in the elderly [35]. However, the results
of vaccination of the high-risk groups with CPSs are not satisfactory, as described
for example for children [36,37] and immunocompromised persons such as patients
that are splenectomised or have a renal failure [38].
In contrast to carbohydrates, glycoproteins belong to the class of T-cell dependent
(TD) antigens (Figure 1B). After recognition of a glycoprotein by surface bound
immunoglobulins, proteolysis of the protein part in the B-cell generates peptide
fragments, so-called T-cell epitopes, that interact with MHC class II molecules. The
peptide-MHC complex is recognised by the T-cell receptor (TCR), thereby
initiating the formation of both antibody-producing and memory B-cells and a class
switch of the produced antibody from IgM to IgG. Thus, by immunisation with
non-natural glycoproteins, so-called neoglycoproteins, containing carbohydrates
from the bacterial capsule coupled to an immunogenic protein, long lasting
immunity to encapsulated bacteria can be achieved.
Proteins that are used as carrier in human vaccines are tetanus [39,40] and
diphtheria toxoid [41-43] (TT and DT), cross-reacting material of diphtheria toxoid
(CRM197) [44], and the outer membrane protein complex of Neisseria meningitidis
(OMPC) [45]. Polysaccharide-protein conjugates have been described to give long-
lasting protection in adults and persons of high-risk groups, especially in young
children, as shown for S. pneumoniae types 6A and 23F [46] and H. influenzae type
b conjugates [47]. Besides isolated polysaccharides, oligosaccharides derived from
the CPS can be used for the preparation of conjugate vaccines. Both
polysaccharide- and oligosaccharide-protein conjugates are being used as
commercial vaccines against several encapsulated bacteria. A Haemophilus
influenzae type b polysaccharide-protein vaccine is being routinely used in children
vaccination programs in several countries [48], and a Neisseria meningitidis type C
oligosaccharide-protein vaccine has been introduced in the UK in November 1999
[49,50]. In both cases death rates declined dramatically. A commercial conjugate
vaccine against S. pneumoniae has become available recently, known as Prevnar in
the US and as Prevenar in the EU [51-54]. So far, this vaccine has not yet been
implemented in routine vaccination programs. The vaccine is safe and efficient in
infants as shown in several reports [55] and effective in certain high-risk groups
such as persons with sickle cell anaemia [56]. It consists of polysaccharides from
serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, covering about 80% of invasive
pneumococcal diseases in children less than six years of age in the US [23].
Serotypes that will be introduced later are types 1 and 5 for a 9-valent, and types 3
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and 7F for an 11-valent vaccine [57]. Due to differences in type distribution the
composition of this vaccine should be adjusted to age and geographical area. One
of the problems concerning the use of the 7-valent conjugate vaccine is the possible
increase of infections by non-vaccine types of S. pneumoniae. Therefore, active
epidemiological surveillance will remain important.
Alternative immunisation strategies
The combination of conjugates containing different serotypes into a single
immunisation may result in competition among the constituents. As this feature
may adversely affect the immunogenicity of the individual conjugates, it can lead
to side-reactions and immune suppression upon immunisation [58,59].
Furthermore, the use of single component vaccines facilitates the manufacturing
process and analysis of the products. For these reasons, other surface components
of S. pneumoniae are investigated as vaccine candidates. Pneumolysoid, a non-
toxic mutant of the highly conserved protein pneumolysin, gives some protection in
animal models [60]. Both phosphocholine and pneumococcal surface protein A
(PspA) can elicit antibodies and protect mice from experimental S. pneumoniae
[61,62]. However, several different PspAs have been identified and the protective
ability of the antibodies was consistently shown to be less than that of anti-CPS
antibodies [63,64]. Immunisation with other cell-wall components failed to induce
protective antibodies. Nevertheless, several authors have described the need to
study alternatives to neoglycoprotein vaccines such as pneumococcal surface
proteins [65-67].
Another strategy comprises the use of pneumococcal proteins as carrier in
conjugate vaccines. For this purpose, the meningococcal outer membrane protein
complex (OMPC) [68] and pneumolysoid, a non-toxic pneumolysin derivative
[69,70] are most often used. In addition to the protection by type-specific
carbohydrates, this approach affords aspecific protection, irrespective of the
serotypes used.
An alternative approach is to use only the minimal structural elements required to
elicit a protective immune response. Examples in this category are oligosaccharide-
peptide conjugates in which the peptide contains a T-cell epitope [71-74] and the
use of multiple antigenic glycopeptide (GMAP) constructs [75,76]. In this way,
defined products are obtained, and the amount of carrier protein is reduced, which
could help to solve the problems described above.
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2. Well-defined neoglycoproteins
Guidelines for the preparation of defined neoglycoproteins
The currently used conjugate vaccines are heterogeneous products, which is caused
by the preparation process. Conjugation of polysaccharides to a protein by random
activation results in lattice-type complexes with an undefined structure. In
oligosaccharide-protein conjugates the carbohydrates are usually present as
mixtures with respect to chain length and presented epitope. This heterogeneity has
a few disadvantages. The presence of lattice-type structures or oligosaccharide
mixtures complicates the analysis of the products, which is increasingly important
for product control. This is especially true for a pneumococcal conjugate vaccine,
wherein many serotypes have to be included. Furthermore, carbohydrate material
isolated from bacterial culture can be contaminated, which complicates the results
obtained from immunological assays [77]. Another disadvantage is that these
conjugates can not be used to study the influence of structural parameters in the
immune response of conjugate vaccines. This can only be done when well-defined
structures are available with a variation in only one parameter. Subtle differences in
the nature of the carbohydrate part (i.e. chain length, presented epitope, and
conformation), the protein part, the carbohydrate-protein ratio, the linker and the
coupling chemistry can influence the immunogenicity of the vaccine.
In many studies it has been tried to correlate the length of the carbohydrate to the
immunogenicity of the neoglycoproteins. With respect to polysaccharide-protein
conjugates, in two cases polysaccharide conjugates were found to be more
immunogenic than oligosaccharide formulations. However, the conjugates were
prepared by random activation of the poly- and oligosaccharides with cyanogen
bromide [78] or with sodium periodate [79], which resulted in both cases in
undefined structures and therefore no general rules could be deduced.
As stated by Jennings [80], coupling methods are preferred, in which saccharides
are coupled to a protein via their reducing end, since the resulting products are
better defined. In the case of a Group B Streptococcus type III TT-conjugate the
optimal length of oligosaccharides was found to be 14 repeating units (70
monosaccharides), while fragments of 8 and 19 repeating units showed decreased
immunogenicity [81]. In a similar report on several pneumococcal oligosaccharide
conjugates, no variation in antibody titres was found with increasing chain length
[82]. For type 3, fragments of 8, 16, and 27 repeating units were tested. In the two
examples described above, oligosaccharide mixtures were used with a wide range
of chain lengths coupled to protein in varying oligosaccharide loadings. Long
oligosaccharides (> 10 repeating units) were said to express the same
conformational epitope as the polysaccharide [83] and should therefore be used.
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Short oligosaccharides (1-3 repeating units) were said to be insufficient to generate
an efficient immune response.
The use of synthetic oligosaccharides
In contrast to the findings described in 2.1, several studies have revealed the
potency of oligosaccharide-protein conjugates containing the minimum antigenic
determinant needed to induce CPS-specific antibodies. Synthetic tri- and tetrameric
fragments of Haemophilus influenzae type b could induce anti-CPS antibodies in
mice and monkeys [84], and a pneumococcal type 23F conjugate containing one
synthetic repeating unit could induce type-specific antibodies in rabbits, although it
was shown that human IgG recognised a larger epitope [85]. Recent studies with
Streptococcus pneumoniae type 6B neoglycoproteins showed that a synthetic
tetrasaccharide fragment, i.e. one repeating unit of the CPS, coupled to KLH
(keyhole limpet hemocyanin) was sufficient to generate a protective antibody
response in mice [86]. In a study on Shigella dysenteriae type 1 [87], synthetic
oligosaccharides (1-4 tetrasaccharide repeating units) were coupled to HSA (human
serum albumin) in varying oligosaccharide loadings ranging from 4 to 23. The
conjugate containing the largest carbohydrate with an intermediate loading of 9
induced the highest IgG levels in mice. Conjugates with higher loadings showed a
decreased level of IgG. This effect was explained by the inaccessibility of the T-
cell epitopes to proteolytic enzymes due to covering of the protein by the
carbohydrates. Clearly, neoglycoconjugates containing a unique carbohydrate
structure as described in this last example, are useful to unravel the structural
parameters that are important for their immunogenicity. In a recent publication
[88], an overview is given of the immunological results obtained with this type of
well-defined conjugates.
As described above, synthetic oligosaccharide-protein conjugates can be useful in
establishing the chain length and number of incorporated carbohydrate residues that
are required for optimal immunological activity. Furthermore, they can overcome
the problems of product heterogeneity and biological contamination associated with
the use of native carbohydrate material. Finally, they can help to elucidate the
structural and antigenic characteristics of different parts of a CPS by synthesising
overlapping repeating units [89], analogs [90] or mimics [91]. A review about
Streptococcus pneumoniae summarises the synthetic oligosaccharides related to
several serotypes [16].
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Conjugation procedures
Besides the use of defined carbohydrates, another prerequisite to obtain defined
neoglycoconjugates is the establishment of a specific linkage between carbohydrate
and protein. As stated above, single point attachment via the reducing end of the
oligosaccharide is the preferred mode of coupling. Activation of the protein carrier
like bromoacetylation [84,92] introduces additional immunogenic determinants.
This could lead to unwanted side-reactions that should be avoided. Instead,
methods based on the coupling of saccharides to more defined positions on the
protein such as cysteine [93] or lysine residues are preferred. Different methods are
in use for linking carbohydrates to lysine, like the conjugation of oligosaccharides
that contain an amino spacer with thiophosgene [94,95], diethyl squarate [96,97] or
N-hydroxysuccinimide active diesters [98]. Furthermore, reductive amination of
oligosaccharides with an aldehyde-containing spacer [99,100] can be used, and
introduction of an amide bond via the carboxylic acid containing Lemieux-spacer
[101,102]. In several reviews on neoglycoconjugate vaccines [103,104,16], other
less defined coupling procedures have been summarised.
Analysis of neoglycoprotein antigens
Detailed analysis of neoglycoproteins is of equal importance as the preparation of
defined antigens. First, analysis of the structural parameters of a neoglycoprotein,
i.e. its integrity, size, carbohydrate structure and heterogeneity, is important for
product control and batch-to-batch consistency in the manufacturing process.
Furthermore, knowing the structure of the conjugate into more detail, for example
the attachment sites of the oligosaccharide with respect to the T-cell epitopes, will
help to establish a more thorough understanding of the immune response at a
molecular level.
A growing number of studies report on the use of modern analytical techniques for
characterisation of the conjugates. Several methods are used to analyse the
carbohydrate part. For example, high-pH anion-exchange chromatography
(HPAEC) with pulsed amperometric detection (PAD) [105,106] can be used to
analyse the carbohydrate composition, and 1H, 13C and 31P NMR spectroscopy
[107,108] are in use for the analysis of the structure and identity of the saccharides.
For establishment of the polysaccharide size, high-performance size-exclusion
chromatography (HPSEC) with multi-angle laser light scattering (MALLS) and
refractive index (RI) detection is the most commonly used technique [109].
Investigation of the structure of neoglycoproteins as a whole is complicated by their
size and heterogeneous nature. Some approaches, however, can give valuable
information. The conformational difference between uncoupled protein and
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conjugate was studied with optical spectroscopy [110], and the integrity of two
Meningococcal C-CRM197 conjugates was compared by using size exclusion
chromatography, HPAEC-PAD and fluorescence spectroscopy [111]. Mass
spectrometry in combination with enzymatic digestion of CRM197-conjugates was
applied to determine the carbohydrate attachment sites [112]. Among the 39 lysine
residues, at least five have been shown to be highly reactive, and one histidine
residue was found to be reactive to iodoacetylation [113]. A look at the amino acid
sequence of CRM197 [114] shows that conjugation of saccharides to lysine will not
occur within close vicinity of an assumed T-cell epitope [74]. This could lead to an
easier processing of the T-cell epitope that can interact with MHC-II molecules to
generate a T-cell dependent immune response. More analytical investigations are
needed to get a more thorough understanding of the immune response of
neoglycoprotein antigens.
3. Streptococcus pneumoniae type 3
Structural characteristics
The first isolation of a type specific polysaccharide was performed by Heidelberger
and Avery in 1923 and was shown to be of Streptococcus pneumoniae type 3 [13].
The capsular polysaccharide (CPS) of this type can be isolated from bacterial
cultures and it was the first of which the structure was elucidated. The CPS of S.
pneumoniae type 3 consists of [→3)-β-D-GlcpA-(1→4)-β-D-Glcp-(1→] repeating
units [115,116] (Figure 2) and is cross-reactive with serotype 8 [117]. Its size is
estimated to be around 37 repeating units, and its average molecular mass 14 kDa
[82]. X-ray crystallographic data of purified CPS and conformational analysis [118]
revealed that the CPS crystallises with a slowly winding extended helix.
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Figure 2. Two repeating units of the CPS of Streptococcus pneumoniae type 3.
Epitope A can be obtained by acid hydrolysis, epitope B by degradation with an
enzyme from Bacillus palustris.
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Oligosaccharide fragments from Streptococcus pneumoniae type 3
Acid hydrolysis of the polysaccharide has been described [119-121] to generate
oligosaccharide fragments with glucuronic acid at the nonreducing end, i.e. epitope
A (Figure 2). Enzymatic digestion of the polysaccharide using a depolymerase from
Bacillus palustris [119,120,122-124] generates the alternative epitope (B). Isolation
of individual fragments has been described [125,126], however mostly mixtures of
oligosaccharides were used for conjugation. Synthetic oligosaccharide fragments
have been prepared by Chernyak et al. [127,128] as copolymers of acrylamide. The
glycopolymer consisting of a disaccharide with sequence A (Figure 2) showed a
slightly weaker interaction with S. pneumoniae type 3 antiserum than the native
CPS, but much stronger than the glycopolymer with disaccharide B.
The oligosaccharides obtained by any of these methods can be used to study
antibody characteristics with well-established methods like the precipitin reaction
[121,129,130], ELISA inhibition assays [126] or for coupling to a protein carrier.
These studies are helpful in finding the minimal and optimal antigenic determinant
using oligosaccharides of different chain length and repeating unit (Figure 2).
Experimental Streptococcus pneumoniae type 3 vaccines
Immunisation experiments using carbohydrate material from S. pneumoniae type 3
have been carried out with purified capsular polysaccharide (CPS) [131,132],
polysaccharide-protein conjugates [15,132,133] and oligosaccharide-protein
conjugates [82,125]. In most cases, the obtained oligosaccharides were conjugated
to a carrier protein as mixtures with an average chain length [82] or via multiple
point attachment [132]. The CPS vaccines elicited mainly IgM antibodies and no
memory B-cells were produced, whereas the protein-containing conjugates elicited
both IgM and IgG antibodies and induced memory. A conjugate of a
hexasaccharide of type 3 incorporated into a liposome [134] induced mainly IgM
antibodies and no memory, thus showing the characteristics of a TI-antigen.
4. Aim of the thesis
As outlined in the introduction, well-defined neoglycoconjugates are valuable tools
for studying the influence of the structural parameters on the immune response of
conjugate vaccines. Furthermore, the use of this type of structures facilitates
product analysis and will eventually lead to the development of more efficient
vaccines. The goal of the research presented in this thesis was to develop methods
for the preparation of well-defined oligosaccharides related to the capsular
polysaccharide of Streptococcus pneumoniae type 3. Furthermore, these structures
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were aimed to be used in the preparation of neoglycoproteins with a defined
carbohydrate part for studying the influence of the carbohydrate structure on the
immune response of conjugate vaccines.
For the preparation of defined oligosaccharides, two methods were investigated.
Chemical synthesis (Chapters 2 and 4) was used to prepare spacer-containing
oligosaccharide fragments of 1-3 repeating units and to prepare glycoclusters of a
synthetic disaccharide repeating unit (Chapter 6). Partial acid hydrolysis (Chapter
5) of the capsular polysaccharide was studied to obtain larger fragments of 1-7
repeating units. To study the effect of the structural parameters oligosaccharide
chain length and carbohydrate-protein ratio on the immune response of conjugate
vaccines, the synthetic oligosaccharide fragments were coupled to a protein carrier
(Chapter 2). The immune response of the saccharide-CRM197 conjugates was
investigated by immunisation experiments in mice (Chapter 3).
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2Synthesis of Streptococcus
pneumoniae type 3 neoglycoproteins
varying in oligosaccharide chain
length, loading and carrier protein
Dirk J. Lefeber, Johannis P. Kamerling, and Johannes F.G. Vliegenthart
Abstract
The preparation is described of a range of neoglycoproteins containing synthesised
fragments of the capsular polysaccharide of Streptococcus pneumoniae type 3, i.e.
β-D-GlcpA-(1→4)-β-D-Glcp-(1→O-(CH2)3NH2 (1), β-D-Glcp-(1→3)-β-D-GlcpA-
(1→4)-β-D-Glcp-(1→O-(CH2)3NH2 (2), and β-D-GlcpA-(1→4)-β-D-Glcp-(1→3)-
β-D-GlcpA-(1→4)-β-D-Glcp-(1→O-(CH2)3NH2 (3). A blockwise approach was
developed for the synthesis of the protected carbohydrate chains, in which the
carboxylic groups were introduced prior to deprotection by selective oxidation of
HO-6 in the presence of HO-4 by using TEMPO (2,2,6,6-tetramethyl-1-
piperidinyloxy). After deprotection, the 3-aminopropyl spacer of the fragments was
elongated with diethyl squarate (3,4-diethoxy-3-cyclobutene-1,2-dione) and the
elongated oligosaccharides were conjugated to CRM197 (cross-reacting material of
diphtheria toxin), KLH (keyhole limpet hemocyanin) or TT (tetanus toxoid). The
resulting neoglycoconjugates varied in oligosaccharide chain length,
oligosaccharide loading and protein carrier. These well-defined conjugates are ideal
probes for evaluating the influence of the different structural parameters in
immunological tests.
Chapter 226
Introduction
The Gram-positive bacterium Streptococcus pneumoniae is one of the most
prevalent infectious pathogens that causes life-threatening diseases like meningitis,
pneumonia and otitis media. In the past, these infections could be efficiently treated
with antibiotics. However, death rates have not declined and furthermore,
resistance to pneumococcal strains is still growing [1]. Immunocompetent people
can be protected efficiently by vaccination with the available 23-valent capsular
polysaccharide (CPS) vaccines [2]. The highest incidence of pneumococcal
infections is, however, in young children, the elderly and immunocompromised
patients. People in these groups do not benefit from the mentioned vaccines, since
they do not respond adequately to the T-cell independent polysaccharides [3].
However, conjugation of carbohydrate antigens to a protein results in a T-cell
dependent neoglycoconjugate antigen that can give an efficient immune response in
the population at high risk [4].
Currently, neoglycoconjugate vaccines are in use against Haemophilus influenzae
type b [5], Neisseria meningitidis type C [6], and Streptococcus pneumoniae
serotypes [7]. These neoglycoproteins are prepared by conjugation of isolated
capsular polysaccharides or a mixture of polysaccharide-derived oligosaccharides
to a protein carrier. The polysaccharide-protein conjugates have a very complex
and undefined structure, whereas the oligosaccharide-protein conjugates contain the
carbohydrate as mixtures with respect to chain length and presented epitope.
Especially in the case of a pneumococcal conjugate vaccine, wherein many
serotypes have to be included, the presence of mixtures complicates the analysis of
the products, which is increasingly important for product control. The use of
synthetic polysaccharide-related oligosaccharide fragments with a unique structure
could help to solve these problems. Furthermore, it creates the opportunity for the
preparation of tailor-made neoglycoproteins that can be used for vaccination, for
ELISA tests not hindered by bacterial contamination [8], and for studying the
immune response at a molecular level. Although synthetic neoglycopeptides
contain a defined carbohydrate and a defined peptide part, the use of
neoglycoproteins with a defined carbohydrate part allows a comparison with the
currently used vaccines.
Recent studies with Streptococcus pneumoniae type 6B neoglycoproteins showed
that a synthetic tetrasaccharide fragment, i.e. one repeating unit of the 6B CPS,
coupled to KLH was sufficient to generate a protective antibody response in mice
[9]. An overview of the synthetic oligosaccharides from several serotypes of S.
pneumoniae has been given by Kamerling [10], and an overview of well-defined
neoglycoconjugates related to several encapsulated bacteria by Pozsgay [11].
To obtain well-defined products for the simplification of product control, and to
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investigate the influence of oligosaccharide chain length, oligosaccharide loading
and carrier protein on the immunogenicity of the neoglycoproteins, here we present
the development of a versatile synthetic route for the preparation of
oligosaccharides related to the CPS of S. pneumoniae type 3 and their conjugation
to a protein in varying ratios. For the conjugation, the defined coupling chemistry
of diethyl squarate (3,4-diethoxy-3-cyclobutene-1,2-dione) was applied, and as
carrier proteins were used CRM197 (cross-reacting material of diphtheria toxin) and
TT (tetanus toxoid), which are relevant for human vaccination, and KLH (keyhole
limpet hemocyanin), which is suitable for animal studies.
Results and discussion
1. Retrosynthetic strategy
The CPS of S. pneumoniae type 3 consists of β(1→3)-linked cellobiuronic acid
repeating units. A route for the synthesis of small fragments has been reported by
Chernyak et al. [12], based on 3,6-lactonisation of glucuronic acid containing
structures to prepare acceptors with a free HO-3 group for the introduction of the
(1→3)-linkage. However, the yields for lactonisation and opening of the lactone
were moderate in the synthesis of the disaccharide acceptor and can be expected to
be even lower in the preparation of larger fragments. During the progress of our
work, the synthesis of a protected disaccharide was described by Garegg et al. [13].
In contrast to these earlier reports, in our approach the carboxylic functions are
introduced in a late stage of the synthetic route by regioselective oxidation using
TEMPO. This approach avoids elaborate protecting group manipulations and
possibly low yielding coupling steps. Furthermore, the blockwise strategy
employing disaccharide building blocks paves the way for the versatile preparation
of larger fragments.
For the synthesis of the target oligosaccharide fragments 1, 2 and 3 (Figure 1),
three monosaccharide building blocks were designed (Scheme 1).
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Figure 1. Synthesised oligosaccharide fragments to be coupled to a carrier protein.
Coupling of imidate donor 12 with acceptor 7 or 17 results in the formation of
disaccharide 19 or 22, respectively. Dechloroacetylation of 22 results in an acceptor
for the synthesis of the tri- and tetrasaccharide fragments. Disaccharide 19 can be
deallylated and imidated to obtain a disaccharide donor, which can be coupled with
dechloroacetylated 22 to give 30. Introduction of the carboxylic groups is achieved
by selective 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) mediated oxidation of
the primary hydroxyl groups after liberation of the benzylidene protecting groups.
This selective oxidation eliminates the need for protection of HO-4. After
debenzoylation, the azide can be hydrogenated and the resulting aminopropyl
spacer coupled via diethyl squarate to lysine residues of CRM197, KLH or TT. The
tetrasaccharide acceptor can be elongated to obtain longer fragments by coupling
with the mentioned disaccharide or other donors.
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Scheme 1. Retrosynthetic strategy.
2. Synthesis of the saccharide fragments
Monosaccharide acceptor allyl 2,3,6-tri-O-benzoyl-β-D-glucopyranoside (7) was
prepared as depicted in Scheme 2. Benzoylation of allyl 4,6-O-benzylidene-β-D-
glucopyranoside (4, [14]) by using benzoyl chloride (→5, 92%), and subsequent
debenzylidenation with trifluoroacetic acid afforded 6 in a yield of 92%. Selective
benzoylation of the primary hydroxyl function with benzoyl imidazole [15] gave
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monosaccharide acceptor 7 in 95% yield.
For the synthesis of imidate donor 12 (Scheme 2), selective protection of allyl 4,6-
O-benzylidene-β-D-glucopyranoside (4) was attempted. However, several methods,
for example, using stannylene acetals (Bu2SnO) [16], benzoyl chloride at -50 °C,
benzoyl imidazole, heterogeneous catalysis with tetrabutylammonium iodide and
potassium carbonate [17], or silylation [18] failed to give satisfactory isolated
yields of compounds with a protecting group on HO-2 or HO-3. In the related α-
glucoside of 4 the acidity of HO-2 is increased by H-bond formation with the
anomeric oxygen [19], thereby increasing the difference in reactivity between HO-
2 and HO-3. For this reason, selective benzoylation of allyl 4,6-O-benzylidene-α-
D-glucopyranoside (8, [20]) was performed with benzoyl imidazole, which resulted
in the formation of 9 in a good yield of 74%. Subsequent chloroacetylation [21]
(→10, 96%), deallylation by isomerisation of the double bond with Wilkinson's
catalyst [22] and removal of the 1-propenyl group with N-iodosuccinimide and
water [23] (→11, 77%), and trichloroacetimidation [24] afforded monosaccharide
donor 12 (93%).
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Scheme 2. Synthesis of the monosaccharide building blocks 7 and 12. Reagents and
conditions: a) PhCOCl, C5H5N, CH2Cl2, 92%; b) CF3COOH, H2O, CH2Cl2, 92%;
c) PhCOCl, imidazole, CH2Cl2, 95%; d) PhCOCl, imidazole, CH2Cl2, 74%; e)
ClAcCl, C5H5N, CH2Cl2, 96%; f) i (PPh3)3Rh(I)Cl, CH3C6H5/EtOH (9:4), ii NIS,
H2O, THF, 77%; g) Cl3CCN, DBU, CH2Cl2, 93%.
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Monosaccharide acceptor 17, containing a 3-azidopropyl spacer, was prepared from
5 (Scheme 3). Deallylation of 5 by using Wilkinson's catalyst and N-
iodosuccinimide (→13, 75%) and subsequent trichloroacetimidation afforded
monosaccharide donor 14 (82%). Coupling of 14 with 3-azido-1-propanol (18),
prepared in 74% from 3-bromo-1-propanol by treatment with sodium azide, was
performed in dichloromethane using 8% TMSOTf as a promoter (→15, 65%).
Debenzylidenation of 15 by using trifluoroacetic acid (→16, 63%) and selective
benzoylation of HO-6 with benzoyl imidazole afforded acceptor 17 in 96% yield.
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Scheme 3. Synthesis of the monosaccharide building block 17. Reagents and
conditions: a) i (PPh3)3Rh(I)Cl, CH3C6H5/EtOH (5:2), ii NIS, H2O, THF, 75%; b)
Cl3CCN, DBU, CH2Cl2, 82%; c) 18, 8% TMSOTf, CH2Cl2, 65%; d) CF3COOH,
H2O, CH2Cl2, 63%; e) PhCOCl, imidazole, CH2Cl2, 96%.
The preparation of disaccharide donor 21 is presented in Scheme 4. Coupling of
donor 12 with acceptor 7 using 5% TMSOTf as a promoter afforded disaccharide
19 in an excellent yield of 96%. Deallylation with
tris(triphenylphosphine)rhodium(I) chloride and N-iodosuccinimide (→20, 70%)
and subsequent trichloroacetimidation gave disaccharide donor 21 (88%).
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Scheme 4. Synthesis of disaccharide donor 21. Reagents and conditions: a) 5%
TMSOTf, CH2Cl2, 96%; b) i (PPh3)3Rh(I)Cl, DABCO, CH2Cl2/CH3C6H5/EtOH
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(0.6:9:4), ii NIS, H2O, THF, 70%; c) Cl3CCN, DBU, CH2Cl2, 88%.
In Scheme 5, the strategies for the preparation of the disaccharide acceptor (23) and
target disaccharide (1) are shown. Test-oxidations with TEMPO [25] of
monosaccharide 6 showed that the allyl group was incompatible with the reaction
conditions. Therefore, the 3-azidopropyl spacer was introduced prior to oxidation.
Coupling of disaccharide imidate 21 to 3-azido-1-propanol 18 to afford 22 was
very troublesome and gave irreproducible yields of around 50% due to orthoester
formation (J1,2 = 5.1 Hz). Coupling via the glycosyl bromide, prepared from 20 by
reaction with Vilsmeier reagent, [26] gave similar problems. Alternatively, the
synthesis of disaccharide 22 was achieved by coupling of donor 12 and the spacer-
containing monosaccharide acceptor 17 using 8% TMSOTf as a promoter in a yield
of 75%. Subsequent dechloroacetylation with diazabicyclo[2.2.2]octane (DABCO)
[27] gave disaccharide acceptor 23 (98%).
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Scheme 5. Synthesis of disaccharide acceptor 23 and target disaccharide 1.
Reagents and conditions: a) 8% TMSOTf, CH2Cl2, 78%; b) 15 eq DABCO,
CH3C6H5/EtOH (1:1), 55 °C, 98%; c) CF3COOH, H2O, CH2Cl2, 90%; d) TEMPO,
aqueous NaOCl, KBr, Bu4NBr, aqueous NaCl, aqueous NaHCO3, CH2Cl2, 85%; e)
i NaOMe, MeOH (pH 11), ii NaBH4, 10% Pd/C, H2O, 90%.
For the synthesis of the target disaccharide fragment 1, first 23 was
debenzylidenated using trifluoroacetic acid (→24, 90%). Then, selective oxidation
by using TEMPO and aqueous sodium hypochlorite afforded the protected
cellobiuronic acid derivative 25 (85%). 1H NMR analysis after methylation by
using diazomethane proved the identity of the compound (δ = 3.37, COOCH3).
Debenzoylation of 25 using sodium methoxide in methanol at pH 11, followed by
hydrogenation of the azide should give 1. However, using the conventional
hydrogenolysis method with 10% Pd/C and hydrogen, a side-product in about 20%
was generated. 1H NMR analysis showed the removal of some of the spacer
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signals, but the full identity of the compound could not be disclosed. When using
dithiothreitol and DBU [28], the same side-product was formed. Reduction with
sodium borohydride and 10% Pd/C in H2O afforded disaccharide fragment 1 in
90% yield over two steps with the formation of only small amounts of the
mentioned side-product.
Focusing on target trisaccharide fragment 2, the synthesis of protected trisaccharide
27 (Scheme 6) was quite troublesome.
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Scheme 6. Synthesis of target trisaccharide 2. Reagents and conditions: a) NIS,
TfOH, Et2O/CH2Cl2 (1:2), 82%; b) CF3COOH, H2O, CH2Cl2, 70%; c) TEMPO,
aqueous NaOCl, KBr, Bu4NBr, aqueous NaCl, aqueous NaHCO3, CH2Cl2, 76%; d)
i NaOMe, MeOH (pH 11), ii NaBH4, 10% Pd/C, H2O, 89%.
Coupling of 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl trichloroacetimidate with
23 using 10% TMSOTf as a promoter gave a complex reaction mixture. The use of
the corresponding glucosyl bromide or thioglucoside as a donor resulted in the
same complex mixture with one of the main side-products being the orthoester
(J1'',2'' = 5.2 Hz). Coupling of 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl
trichloroacetimidate with 23 using 10% TMSOTf as a promoter gave trisaccharide
27 in 70% yield. The yield was, however, irreproducible due to the formation of
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orthoester and some other side-products. Finally, the use of ethyl 2,3,4,6-tetra-O-
benzoyl-1-thio-β-D-glucopyranoside (26) as donor was found to result in an
efficient glycosylation of 23. Activation with triflic acid and N-iodosuccinimide
gave trisaccharide 27 in a reproducible yield of 82%. Debenzylidenation using
trifluoroacetic acid (→28, 70%) and subsequent oxidation of HO-6 using TEMPO
and aqueous sodium hypochlorite gave the protected trisaccharide fragment 29
(76%) (1H NMR: δ = 3.62, d, J4',5' = 9.3 Hz, 1 H; H-5'). Deprotection of 29 as
described for 25 afforded trisaccharide fragment 2 in 89% yield over two steps.
In the synthesis of target tetrasaccharide fragment 3 (Scheme 7), as a first step
disaccharide donor 21 was coupled with disaccharide acceptor 23 using 10%
TMSOTf as a promoter, resulting in 30 (75%). Dechloroacetylation of 30 using
thiourea (→31, 84%), followed by debenzylidenation using trifluoroacetic acid
(→32, 70%), and selective oxidation using TEMPO and aqueous sodium
hypochlorite gave 33 in a yield of 65%. 1H NMR analysis after methylation with
diazomethane showed two singlets at δ = 3.39 and 3.34 (COOCH3). Deprotection
of 33 as described for 25 gave tetrasaccharide fragment 3 in 60% yield over two
steps.
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Scheme 7. Synthesis of target tetrasaccharide 3. Reagents and conditions: a) 10%
TMSOTf, CH2Cl2, 75%; b) thiourea, EtOH/C5H5N (8:1), 90 °C, 84%; c)
CF3COOH, H2O, CH2Cl2, 70%; d) TEMPO, aqueous NaOCl, KBr, Bu4NBr,
aqueous NaCl, aqueous NaHCO3, CH2Cl2, 65%; e) i NaOMe, MeOH (pH 11), ii
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NaBH4, 10% Pd/C, H2O, 60%.
In order to make a comparison possible of the immunological studies of the aimed
di-, tri- and tetrasaccharide-protein conjugates with relevant blanks, the glucose and
glucuronic acid conjugates were also prepared. To this end, 3-aminopropyl
glucopyranoside (35) and 3-aminopropyl glucopyranosiduronic acid (37) (Scheme
8) were prepared from 16. Debenzoylation of 16 (→34), followed by reduction of
the azide with sodium borohydride and 10% Pd/C in water gave 35 in 88% over
two steps. Oxidation of 34 with TEMPO and aqueous sodium hypochlorite in water
gave 36, which was purified by conventional acetylation with acetic anhydride and
pyridine, column chromatography, and deacetylation using sodium methoxide.
Glucuronic acid derivative 37 was obtained after reduction of 36 as described for
34 (80% over three steps).
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Scheme 8. Synthesis of 3-aminopropyl glucopyranoside 35 and 3-aminopropyl
glucopyranosiduronic acid 37. Reagents and conditions: a) NaOMe, MeOH (pH
10); b) NaBH4, 10% Pd/C, H2O, 88%; c) TEMPO, aqueous NaOCl, KBr, H2O; d)
NaBH4, 10% Pd/C, H2O, 80%.
The 1H NMR data of the target saccharide fragments 1-3, 35 and 37, derived from
2D TOCSY and ROESY measurements, are presented in Table 1.
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Table 1. 500 MHz 1H NMR data of 1, 2, 3, 35, and 37 at 300K (in ppm)[a]. J1,2
couplings are presented in parentheses.
H-1 H-2 H-3 H-4 H-5 H-6a H-6b
35 4.49
(7.9)
3.29 3.50 3.38 3.48 3.93 3.73
37 4.48
(7.9)
3.33 3.51 3.51 3.72
1 4.51
(7.7)
3.33 3.66 3.61 3.61 3.98 3.81
1' 4.51
(7.7)
3.36 3.52 3.52 3.75
2 4.51
(7.7)
3.33 3.66 3.61 3.61 3.98 3.80
2' 4.54
(8.3)
3.57 3.79 n.d.[b] n.d.
2'' 4.79
(7.7)
3.36 3.51 3.40 3.46 3.92 3.72
3 4.51
(8.2)
3.33 3.65 3.62 n.d. 3.98 3.81
3' 4.54
(7.7)
3.58 3.79 n.d. n.d.
3'' 4.82
(8.2)
3.38 3.68 3.61 n.d. 3.98 3.82
3''' 4.51
(8.2)
3.36 3.52 3.52 3.76
[a] The signals for the 3-aminopropyl spacer were similar for all compounds: δ =
4.03 and 3.84 (OCH2CH2CH2NH2), 3.15 (OCH2CH2CH2NH2), 2.00
(OCH2CH2CH2NH2). [b] n.d. = not determined.
3. Preparation of the protein conjugates
Studying neoglycoconjugates in which only one parameter is varied is important to
understand the different factors that influence the immunogenicity of the
conjugates. To this end, focusing on CPS-related oligosaccharides from S.
pneumoniae type 3, neoglycoproteins with a different oligosaccharide chain length,
carbohydrate-protein ratio, and protein carrier have been prepared.
The synthesised saccharide fragments were conjugated to CRM197, TT or KLH,
using diethyl squarate as linker (Figure 2) [29,30]. Elongation of the saccharides
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with diethyl squarate was performed in ethanol/0.1 M sodium phosphate (pH 6.9).
The reaction products were purified by solid phase extraction and coupled to
protein in 0.1 M sodium borate buffer at pH 9.5.
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Figure 2. Coupling of saccharide fragments to a protein via diethyl squarate. a)
EtOH/sodium phosphate buffer (0.1 M, pH 6.9); b) sodium borate buffer (0.1 M,
pH 9.5), CRM197, KLH or TT.
CRM197 is a non-toxic product of a single mutation in the diphtheria toxin gene
[31] and exists as a pure and well-defined protein that is often used as a carrier in
human neoglycoconjugate vaccines [32].
Table 2. Oligosaccharide loading and coupling efficiency for the conjugation of 1,
2, 3, 35 and 37 to CRM197.
Entry Glycoconjugate Oligosaccharide
loading (mol/mol)
Coupling
efficiency (%)
1 CRM197-35 8.5 77
2 CRM197-37 6.6 67
3 CRM197-1 3.1 56
4 CRM197-1 6.7 52
5 CRM197-2 4.9 45
6 CRM197-2 6.8 41
7 CRM197-2 12.0 54
8 CRM197-3 2.9 26
9 CRM197-3 6.7 32
10 CRM197-3 8.1 37
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As can be seen from the coupling efficiencies in Table 2, the yield for the
conjugation of the saccharides to CRM197 decreases when charged structures are
coupled (entries 1 and 2), or when the oligosaccharides become larger (entries 1, 3,
5, and 8).
The amount of carbohydrate incorporation (Table 2) was measured by MALDI-
TOF analysis (see Figure 3 for some representative spectra). It should be noted that
analysis of the CRM197-conjugates by MALDI-TOF was possible only when about
10 mM sodium borate buffer was still present in the sample. Attempts to measure
the molecular mass in water failed.
Figure 3. MALDI-TOF spectra of CRM197 and entries 4, 6 and 10 (Table 2).
To investigate the immunological effect of the protein carrier, two other proteins
were coupled with the saccharide fragments. Tetanus toxoid (TT), prepared by
inactivation of the crude toxin with formalin, is frequently used in human
immunisation studies, and KLH is frequently used for immunisation studies in
animals. The results for the coupling of the saccharide fragments to TT and KLH
are shown in Table 3. Since TT and KLH are heterogeneous protein preparations,
the carbohydrate loading of these conjugates could not be derived reliably by
MALDI-TOF analysis. Therefore, the loading was determined by analysis of the
carbohydrate (Dubois, [33]) and protein content (Pierce, [34]).
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Table 3. Oligosaccharide loading and coupling efficiency for the conjugation of 1,
2 and 3 to KLH and TT.
Entry Glycoconjugate Oligosaccharide
loading (µg/mg)
Coupling
efficiency (%)
1 KLH-1 14.1 9
2 KLH-2 13.3 15
3 KLH-3 24.6 9
4 TT-1 31.3 16
5 TT-2 23.6 11
6 TT-3 22.9 8
In conclusion, we have synthesised a range of neoglycoproteins related to S.
pneumoniae type 3. The immunological properties of these well-defined
neoglycoconjugates will be evaluated in order to gain insight in the structural
factors influencing the immune response of this type of neoglycoconjugate
vaccines. Preliminary results of the immunisation of mice with the CRM197-
conjugates show that they can induce a protective immune response [35].
Acknowledgements
This work was supported by the European Union program VACNET (grant ERB
BIO 4CT960158). We thank Dr. P. Hoogerhout for the kind gift of tetanus toxoid.
Experimental section
General: All chemicals were of reagent grade, and were used without any further
purification. A solution of tetanus toxoid (TT; 6.12 mg mL-1) was obtained from the Dutch
National Institute of Health (RIVM, Bilthoven, The Netherlands); a solution of keyhole
limpet hemocyanin (KLH; 50 mg mL-1) was obtained from the Eijkman-Winkler Institute
for Microbiology (Utrecht University, Utrecht, The Netherlands); a solution of a non-toxic
variant of diphtheria toxin (cross-reacting material, CRM197; 61.15 mg mL
-1) was obtained
from Chiron (Siena, Italy). Reactions were monitored by TLC on Silica gel 60 F254
(Merck); after examination under UV light, compounds were visualised by heating with
10% (v/v) ethanolic H2SO4, orcinol (2 mg mL
-1) in 20% (v/v) methanolic H2SO4, or
ninhydrin (1.5 mg mL-1) in BuOH/H2O/HOAc (38:1.75:0.25). In the work-up procedures
of reaction mixtures, organic solutions were washed with appropriate amounts of the
indicated aqueous solutions, then dried (MgSO4), and concentrated under reduced pressure
at 20-40 °C on a water-bath. Column chromatography was performed on Silica gel 60
(Merck, 0.063-0.200 mm). Optical rotations were measured in CHCl3, unless stated
otherwise, with a Perkin-Elmer 241 polarimeter, using a 10-cm l-mL cell. 1H NMR spectra
in CDCl3 were recorded at 27 °C with a Bruker AC 300 spectrometer; the δH values are
given in ppm relative to the signal for internal Me4Si (δ = 0). 13C (APT, 75 MHz) NMR
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spectra in CDCl3 were recorded at 27 °C with a Bruker AC 300 spectrometer; indicated
ppm values for δC are relative to the signal of CDCl3 (δ = 76.9). 1H NMR spectra in D2O
were recorded at 27 °C with a Bruker AMX 500 spectrometer, and the δH values are given
in ppm relative to the signal for internal acetone (δ = 2.225). Two-dimensional TOCSY
and ROESY spectra in D2O were recorded using a Bruker AMX 500 apparatus (500 MHz)
at 27 °C to assign the spectra of compounds 1, 2, 3, 35 and 37. Fast-atom-bombardment
mass spectrometry (FABMS) was performed on a JEOL JMS SX/SX 102A four-sector
mass spectrometer. Matrix-assisted laser desorption ionisation time-of-flight (MALDI-
TOF) spectra were obtained on a Voyager-DE mass spectrometer using 2,4-
dihydroxybenzoic acid (DHB) in H2O as a matrix. Elemental analyses were carried out by
H. Kolbe Mikroanalytisches Laboratorium (Mülheim an der Ruhr, Germany).
Allyl 2,3-di-O-benzoyl-4,6-O-benzylidene-β-D-glucopyranoside (5): To a solution of
allyl 4,6-O-benzylidene-β-D-glucopyranoside 4 [14] (10.5 g, 34.1 mmol) in CH2Cl2 (80
mL) and pyridine (10 mL) was added dropwise benzoyl chloride (10.3 mL, 88.7 mmol).
After 3 h, the mixture was diluted with CH2Cl2, washed twice with 10% (w/v) aqueous
NaCl, and the organic layer was dried, filtered, and concentrated. The residue was purified
by column chromatography (CH2Cl2) to obtain 5 as a white solid (16.2 g, 92%). Rf 0.81
(CH2Cl2/EtOAc 9:1); [α]D20= +19 (c = 1); 1H NMR (CDCl3): δ = 7.98-7.94 and 7.39-7.29
(2 m, 15 H; PhCH, 2 PhCO), 5.84-5.70 (m, 1 H; OCH2CH=CH2), 5.79 (t, J2,3 = 9.5, J3,4 =
9.5 Hz, 1 H; H-3), 5.54 (s, 1 H; PhCH), 5.51 (dd, J1,2 = 7.8 Hz, 1 H; H-2), 5.27-5.10 (m, 2
H; OCH2CH=CH2), 4.85 (d, 1 H; H-1), 4.43 (dd, J5,6a = 4.9, J6a,6b = 10.3 Hz, 1 H; H-6a),
4.39-4.32 and 4.17-4.09 (2 m, each 1 H; OCH2CH=CH2), 3.94 (t, J4,5 = 9.5 Hz, 1 H; H-4),
3.88 (t, J5,6b = 10.3 Hz, 1 H; H-6b), 3.69 (ddd, 1 H; H-5); 
13C NMR (CDCl3): δ = 165.4
and 165.0 (2 PhCO), 117.6 (OCH2CH=CH2), 101.3 (PhCH), 100.3 (C-1), 78.7, 72.3, 72.0,
and 66.5 (C-2,3,4,5), 70.1 (OCH2CH=CH2), 68.5 (C-6); elemental analysis calcd (%) for
C30H28O8 (516.6): C 69.76, H 5.46; found C 69.88, H 5.38.
Allyl 2,3-di-O-benzoyl-β-D-glucopyranoside (6): To a solution of 5 (1.50 g, 2.90 mmol)
in CH2Cl2 (40 mL) were added CF3COOH (1.64 mL) and H2O (0.22 mL). The mixture
was stirred for 3 h, diluted with CH2Cl2, washed with 10% (w/v) aqueous NaHCO3 (2 x)
and 10% (w/v) aqueous NaCl, and the organic layer was dried, filtered, and concentrated.
The residue was purified by column chromatography (CH2Cl2/MeOH 98:2) to obtain 6
(1.14 g, 92%). Rf 0.15 (CH2Cl2/acetone 9:1); [α]D20= +90 (c = 1); 1H NMR (CDCl3): δ =
7.97-7.94 and 7.51-7.26 (2 m, 10 H; 2 PhCO), 5.85-5.72 (m, 1 H; OCH2CH=CH2), 5.27-
5.10 (m, 2 H; OCH2CH=CH2), 4.78 (d, J1,2 = 7.7 Hz, 1 H; H-1), 4.38-4.31 and 4.18-4.11
(2 m, each 1 H; OCH2CH=CH2), 3.58 (ddd, J4,5 = 9.6, J5,6a, J5,6b = 3.6, 4.5 Hz, 1 H; H-5);
13C NMR (CDCl3): δ = 165.2 (2 PhCO), 117.6 (OCH2CH=CH2), 99.8 (C-1), 77.3, 75.7,
71.3, and 69.9 (C-2,3,4,5), 70.1 (OCH2CH=CH2), 62.1 (C-6); elemental analysis calcd (%)
for C23H24O8 (428.4): C 64.48, H 5.65; found C 64.32, H 5.64.
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Allyl 2,3,6-tri-O-benzoyl-β-D-glucopyranoside (7): To a solution of imidazole (0.15 g,
2.2 mmol) in CH2Cl2 (4 mL) was added dropwise benzoyl chloride (0.15 mL, 1.28 mmol).
The suspension was filtered, and the filtrate was added dropwise to a solution of 6 (0.50 g,
1.17 mmol) in CH2Cl2 (4 mL). After stirring for 36 h, the mixture was diluted with
CH2Cl2, washed with 10% (w/v) aqueous NaCl, and the organic layer was dried, filtered,
and concentrated. The crude residue was purified by column chromatography
(CH2Cl2/EtOAc 95:5) to obtain 7 (0.59 g, 95%). Rf 0.73 (CH2Cl2/EtOAc 9:1); [α]D20= +63
(c = 1); 1H NMR (CDCl3): δ = 8.09-7.94 and 7.47-7.33 (2 m, 15 H; 3 PhCO), 5.85-5.72
(m, 1 H; OCH2CH=CH2), 5.24-5.07 (m, 2 H; OCH2CH=CH2), 4.81 (d, J1,2 = 7.6 Hz, 1 H;
H-1), 4.75 (dd, J5,6b = 4.5, J6a,6b = 12.1 Hz, 1 H; H-6b), 4.68 (dd, J5,6a = 2.5 Hz, 1 H; H-6a),
4.38-4.31 and 4.18-4.10 (2 m, each 1 H; OCH2CH=CH2), 3.83 (ddd, J4,5 = 9.7 Hz, 1 H; H-
5); 13C NMR (CDCl3): δ = 167.1, 166.8, and 165.1 (3 PhCO), 117.5 (OCH2CH=CH2),
99.6 (C-1), 76.5, 74.3, 71.4, and 69.5 (C-2,3,4,5), 69.9 (OCH2CH=CH2), 63.4 (C-6);
elemental analysis calcd (%) for C30H28O9 (532.5): C 67.66, H 5.29; found C 67.53, H
5.20.
Allyl 2-O-benzoyl-4,6-O-benzylidene-α-D-glucopyranoside (9): To a solution of
imidazole (0.80 g, 11.73 mmol) in CH2Cl2 (10 mL) was added dropwise benzoyl chloride
(0.68 mL, 5.81 mmol). The suspension was filtered and the filtrate was added dropwise to
a solution of allyl 4,6-O-benzylidene-α-D-glucopyranoside 8 [20] (1.50 g, 4.86 mmol) in
CH2Cl2 (9.5 mL). After stirring at boiling under reflux for 36 h, the mixture was diluted
with CH2Cl2, washed with 10% (w/v) aqueous NaCl, and the organic layer was dried,
filtered, and concentrated. The crude residue was purified by column chromatography,
whereby the 2,3-di-O-benzoylated compound was eluted with toluene/EtOAc (95:5), and
9 with toluene/EtOAc (9:1) (1.48 g, 74%). Rf 0.61 (toluene/EtOAc 7:3); [α]D20= +99 (c =
1); 1H NMR (CDCl3): δ = 8.09-8.06 and 7.56-7.35 (2 m, 10 H; PhCH, PhCO), 5.87-5.74
(m, 1 H; OCH2CH=CH2), 5.54 (s, 1 H; PhCH), 5.30-5.22 and 5.15-5.10 (2 m, each 1 H;
OCH2CH=CH2), 5.20 (d, J1,2 = 3.8 Hz, 1 H; H-1), 5.04 (dd, J2,3 = 9.6 Hz, 1 H; H-2), 4.36
(bt, J3,4 = 9.4 Hz, 1 H; H-3), 4.29 (dd, J6a,6b = 10.2, J5,6a = 4.8 Hz, 1 H; H-6a), 3.75 (t, J5,6b
= 10.2 Hz, 1 H; H-6b), 3.59 (t, 1 H; H-4), 2.68 (s, 1 H; HO-2); 13C NMR (CDCl3): δ =
166.0 (PhCO), 136.9 (PhCH, quaternary C), 129.4 (PhCO, quaternary C), 117.5
(OCH2CH=CH2), 101.8 (PhCH), 95.8 (C-1), 81.3, 73.8, 68.7, and 62.2 (C-2,3,4,5), 68.7
and 68.6 (C-6, OCH2CH=CH2); elemental analysis calcd (%) for C23H24O7 (412.4): C
66.98, H 5.86; found C 67.18, H 5.76.
Allyl 2-O-benzoyl-4,6-O-benzylidene-3-O-chloroacetyl-α-D-glucopyranoside (10): To
a solution of 9 (0.35 g, 0.84 mmol) in CH2Cl2 (30 mL) and pyridine (1.5 mL) was added
chloroacetyl chloride (70 µL, 0.88 mmol) at 5 °C. After stirring for 2 h, another portion of
chloroacetyl chloride (35 µL, 0.44 mmol) was added, and stirring was continued for 1 h.
Then, the mixture was co-concentrated with toluene, diluted with CH2Cl2, and washed
with 10% (w/v) aqueous NaCl. The organic layer was dried, filtered, and concentrated.
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The residue was purified by column chromatography (toluene/EtOAc 95:5) to afford 10
(0.38 g, 96%). Rf 0.50 (toluene/EtOAc 9:1); [α]D20= +104 (c = 1); 1H NMR (CDCl3): δ =
8.04-8.02 and 7.35-7.48 (2 m, 10 H; PhCH, PhCO), 5.88-5.75 (m, 1 H; OCH2CH=CH2),
5.87 (t, J2,3 = 9.9, J3,4 = 9.8 Hz, 1 H; H-3), 5.54 (s, 1 H; PhCH), 5.31-5.23 and 5.16-5.12 (2
m, each 1 H; OCH2CH=CH2), 5.28 (d, J1,2 = 3.8 Hz, 1 H; H-1), 5.12 (dd, 1 H; H-2), 4.33
(dd, J6a,6b = 10.3, J5,6a = 4.8 Hz, 1 H; H-6a), 4.00 and 3.94 (2 d, Jgem = 14.8 Hz, each 1 H;
ClCH2CO), 3.81 (t, J5,6b = 10.3 Hz, 1 H; H-6b), 3.78 (t, J4,5 = 9.6 Hz, 1 H; H-4); 
13C NMR
(CDCl3): δ = 166.3 and 165.7 (PhCO, ClCH2CO), 136.6 (PhCH, quaternary C), 128.7
(PhCO, quaternary C), 117.8 (OCH2CH=CH2), 101.5 (PhCH), 95.7 (C-1), 78.8, 72.0,
70.8, and 62.5 (C-2,3,4,5), 68.7 and 68.6 (C-6, OCH2CH=CH2), 40.4 (ClCH2CO);
elemental analysis calcd (%) for C25H25ClO8 (488.9): C 61.41, H 5.15; found C 61.22, H
5.03.
2-O-Benzoyl-4,6-O-benzylidene-3-O-chloroacetyl-D-glucopyranose (11): To a solution
of 10 (0.10 g, 0.21 mmol) in absolute EtOH (20 mL) and toluene (45 mL) was added
tris(triphenylphosphine)rhodium(I) chloride (70 mg). After stirring at boiling under reflux
for 2.5 h, TLC (toluene/EtOAc 9:1) showed the formation of a new spot (Rf 0.52), and the
mixture was concentrated. The residue was dissolved in THF (18 mL), and water (2 mL)
and NIS (0.13 g) were added. After 20 min, the mixture was concentrated, diluted with
CH2Cl2, washed with 10% (w/v) aqueous NaHSO3 (2 x) and 10% (w/v) aqueous NaCl,
and the organic layer was dried, filtered, and concentrated. The crude residue was purified
by column chromatography. Impurities were eluted with toluene/EtOAc (9:1), and 11 was
obtained as a light brown syrup by elution with toluene/EtOAc (8:2) (71 mg, 77%; α/β =
4:1). Rf 0.29 (toluene/EtOAc 9:1); 
1H NMR (CDCl3): δ = 8.04-8.02 and 7.46-7.34 (2 m, 10
H; PhCH, PhCO), 5.54 (s, 0.8 H; PhCHα), 5.52 (s, 0.2 H; PhCHβ), 5.88 (t, J2,3 = 9.9, J3,4 =
9.8 Hz, 1 H; H-3), 5.57 (d, J1,2 = 3.6 Hz, 0.8 H; H-1
α), 5.19 (dd, J1,2 = 7.9 Hz, 0.2 H; H-
2β), 5.10 (dd, 0.8 H; H-2α), 4.92 (d, 0.2 H; H-1β), 4.01 and 3.95 (2 d, Jgem = 14.8 Hz, each
1 H; ClCH2CO); 
13C NMR (CDCl3): δ = 166.6 and 165.8 (PhCO, ClCH2CO), 136.6
(PhCH, quaternary C), 101.5 (PhCH), 95.8 (C-1α), 90.7 (C-1β), 68.8 (C-6α), 68.3 (C-6β),
40.4 (ClCH2CO
α), 40.3 (ClCH2COβ).
2-O-Benzoyl-4,6-O-benzylidene-3-O-chloroacetyl-α-D-glucopyranosyl
trichloroacetimidate (12): To a solution of 11 (1.06 g, 2.43 mmol) in dry CH2Cl2 (28
mL) were added Cl3CCN (2.7 mL) and DBU (87 µL). After 2 h, the mixture was
concentrated, and the residue was purified by column chromatography (toluene/EtOAc
95:5) to obtain 12 (1.31 g, 93%). Rf 0.49 (toluene/EtOAc 9:1); [α]D20= +67 (c = 1); 1H
NMR (CDCl3): δ = 8.60 (s, 1 H; NH), 8.01-7.98 and 7.48-7.36 (2 m, 10 H; PhCH, PhCO),
6.71 (d, J1,2 = 3.8 Hz, 1 H; H-1), 5.94 (t, J2,3 = 9.9, J3,4 = 9.9 Hz, 1 H; H-3), 5.59 (s, 1 H;
PhCH), 5.40 (dd, 1 H; H-2), 4.41 (dd, J5,6a 4.9, J6a,6b = 10.4 Hz, 1 H; H-6a), 4.21 (dt, J4,5 =
9.9, J5,6b = 10.2 Hz, 1 H; H-5), 4.03 and 3.97 (2 d, Jgem = 14.8 Hz, each 1 H; ClCH2CO),
3.92 (t, 1 H; H-4), 3.84 (t, 1 H; H-6b); 13C NMR (CDCl3): δ = 166.3 and 165.3 (PhCO,
Chapter 242
ClCH2CO), 160.6 (OC(NH)CCl3), 136.3 (PhCH, quaternary C), 101.6 (PhCH), 93.4 (C-1),
78.1, 70.8, 70.5, and 65.1 (C-2,3,4,5), 68.4 (C-6), 40.4 (ClCH2CO); elemental analysis
calcd (%) for C24H21Cl4NO8 (593.1): C 48.59, H 3.56; found C 48.10, H 3.42.
2,3-Di-O-benzoyl-4,6-O-benzylidene-D-glucopyranose (13): To a solution of 5 (3.02 g,
5.84 mmol) in EtOH (100 mL) and toluene (250 mL) was added
tris(triphenylphosphine)rhodium(I) chloride (2.1 g). After stirring at boiling under reflux
for 3 h, TLC (toluene/EtOAc 8:2) showed the formation of a new spot (Rf 0.81), and the
mixture was concentrated. The residue was dissolved in THF (250 mL), and water (30
mL) and NIS (2.0 g) were added. After 20 min, the mixture was concentrated, diluted with
CH2Cl2, washed with 10% (w/v) aqueous NaHSO3 (2 x) and 10% (w/v) aqueous NaCl,
and the organic layer was dried, filtered, and concentrated. The crude residue was purified
by column chromatography. Impurities were eluted with toluene/EtOAc (9:1), and 13 was
obtained as a light brown syrup by elution with toluene/EtOAc (8:2) (2.09 g, 75%; α/β =
3:2). Rf 0.25 (toluene/EtOAc 8:2). 
1H NMR (CDCl3): δ = 7.99-7.94 and 7.45-7.25 (2 m, 15
H, PhCH, 2 PhCO), 6.14 (t, J2,3 = 9.8, J3,4 = 9.8 Hz, 0.6 H; H-3
α), 5.83 (t, J2,3 = 9.6, J3,4 =
9.6 Hz, 0.4 H; H-3β), 5.66 (d, J1,2 = 3.7 Hz, 0.6 H; H-1α), 5.54 (s, 0.6 H; PhCHα), 5.49 (s,
0.4 H; PhCHβ), 5.37 (dd, J1,2 = 7.9 Hz, 0.4 H; H-2β), 5.30 (dd, 0.6 H; H-2α), 4.99 (d, 0.4
H; H-1β); 13C NMR (CDCl3): δ = 166.0 and 165.7 (2 PhCO), 101.4 (PhCHα), 101.3
(PhCHβ), 96.1 (C-1α), 91.0 (C-1β), 68.3 (C-6α), 66.6 (C-6β); elemental analysis calcd (%)
for C27H24O8 (476.4): C 68.06, H 5.08; found C 68.08, H 5.06.
2,3-Di-O-benzoyl-4,6-O-benzylidene-D-glucopyranosyl trichloroacetimidate (14): To a
solution of 13 (1.82 g, 3.82 mmol) in dry CH2Cl2 (65 mL) at 0 °C were added Cl3CCN
(4.1 mL) and DBU (0.14 mL). After 3 h, the mixture was concentrated, and the residue
was purified by column chromatography. Impurities were eluted with toluene/EtOAc
(95:5), and 14 was obtained by elution with toluene/EtOAc (9:1) (1.88 g, 82%; α/β = 3:2).
Rf 0.68 (toluene/EtOAc 8:2). 
1H NMR (CDCl3): δ = 8.72 (s, 0.4 H; NHβ), 8.60 (s, 0.6 H;
NHα), 6.76 (d, J1,2 = 3.8 Hz, 0.6 H; H-1α), 6.23 (d, J1,2 = 7.2 Hz, 0.4 H; H-1β), 6.17 (t, J2,3
= 9.8, J3,4 = 9.9 Hz, 0.6 H; H-3
α), 5.84 (dd, J2,3 = 8.2, J3,4 = 9.1 Hz, 0.4 H; H-3β), 5.75 (t,
0.4 H; H-2β), 5.60 (s, 0.6 H; PhCHα), 5.57 (s, 0.4 H; PhCHβ), 5.56 (dd, 0.6 H; H-2α); 13C
NMR (CDCl3): δ = 165.3 (2 PhCO), 160.7 (OC(NH)CCl3), 101.5 (PhCH), 95.5 and 93.6
(C-1α,1β), 68.4 (C-6).
3-Azidopropyl 2,3-di-O-benzoyl-4,6-O-benzylidene-β-D-glucopyranoside (15): A
solution of 3-azido-1-propanol 18 (1.4 g, 14 mmol) and 14 (1.80 g, 2.90 mmol) in dry
CH2Cl2 (35 mL), containing 4 Å molecular sieves, was stirred under Ar for 1 h. Then,
TMSOTf (42 µL, 0.23 mmol) was introduced, and after 30 min, the mixture was
neutralised with dry pyridine, filtered over cotton, diluted with CH2Cl2, and washed with
10% (w/v) aqueous NaCl. The organic layer was dried, filtered, and concentrated. The
residue was purified by column chromatography (toluene/EtOAc 95:5) to obtain 15 (1.05
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g, 65%). Rf 0.70 (toluene/EtOAc 8:2); [α]D20= +19 (c = 1); 1H NMR (CDCl3): δ = 7.98-
7.94 and 7.52-7.25 (2 m, 15 H, PhCH, 2 PhCO), 5.78 (t, J2,3 = 9.5, J3,4 = 9.5 Hz, 1 H; H-
3), 5.55 (s, 1 H; PhCH), 5.46 (dd, J1,2 = 7.8 Hz, 1 H; H-2), 4.79 (d, 1 H; H-1), 4.44 (dd,
J6a,6b = 10.3, J5,6a = 4.9 Hz, 1 H; H-6a), 3.93 (t, J4,5 = 9.6 Hz, 1 H; H-4), 3.88 (t, J5,6b =
10.1 Hz, 1 H; H-6b), 3.70 (dt, 1 H; H-5), 3.98 (dt, 1 H; OCHHCH2CH2N3), 3.61 (ddd, 1
H; OCHHCH2CH2N3), 3.29-3.17 (m, 2 H; OCH2CH2CH2N3), 1.83-1.72 (m, 2 H;
OCH2CH2CH2N3); 
13C NMR (CDCl3): δ = 136.6 (PhCH, quaternary C), 101.7 and 101.4
(PhCH, C-1), 78.7, 72.4, 71.9, and 66.6 (C-2,3,4,5), 68.5 (C-6), 66.7 (OCH2CH2CH2N3),
47.7 (OCH2CH2CH2N3), 28.9 (OCH2CH2CH2N3); elemental analysis calcd (%) for
C30H29O8N3 (559.5): C 64.39, H 5.22; found C 64.25, H 5.27.
3-azidopropyl 2,3-di-O-benzoyl-β-D-glucopyranoside (16): To a solution of 15 (1.24 g,
2.21 mmol) in CH2Cl2 (40 mL) were added CF3COOH (1.0 mL) and H2O (0.16 mL). The
mixture was stirred for 3 h, diluted with CH2Cl2, washed with 10% (w/v) aqueous
NaHCO3 (2 x) and 10% (w/v) aqueous NaCl, and the organic layer was dried, filtered, and
concentrated. The residue was purified by column chromatography (CH2Cl2/EtOAc
9:1→CH2Cl2/acetone 6:4) to obtain 16 (0.66 g, 63%). Rf 0.07 (CH2Cl2/EtOAc 9:1);
[α]D20= +37 (c = 1); 1H NMR (CDCl3): δ = 8.01-7.94 and 7.51-7.29 (2 m, 10 H, 2 PhCO),
4.73 (d, J1,2 = 7.9 Hz, 1 H; H-1), 3.59 (ddd, 1 H; OCHHCH2CH2N3), 3.33-3.17 (m, 2 H;
OCH2CH2CH2N3), 1.83-1.73 (m, 2 H; OCH2CH2CH2N3); 
13C NMR (CDCl3): δ = 101.0
(C-1), 77.1, 75.8, 71.3, and 69.9 (C-2,3,4,5), 66.3 (OCH2CH2CH2N3), 62.1 (C-6), 47.7
(OCH2CH2CH2N3), 28.9 (OCH2CH2CH2N3); elemental analysis calcd (%) for C23H25O8N3
(471.4): C 58.59, H 5.34; found C 58.32, H 5.40.
3-Azidopropyl 2,3,6-tri-O-benzoyl-β-D-glucopyranoside (17): To a solution of
imidazole (0.14 g, 2.11 mmol) in CH2Cl2 (10 mL) was added dropwise benzoyl chloride
(0.20 mL, 1.69 mmol). The suspension was filtered, and the filtrate was added dropwise to
a solution of 16 (0.66 g, 1.41 mmol) in CH2Cl2 (10 mL). After stirring for 18 h, the
mixture was diluted with CH2Cl2, washed with 10% (w/v) aqueous NaCl, and the organic
layer was dried, filtered, and concentrated. The crude residue was purified by column
chromatography (toluene/EtOAc 95:5) to obtain 17 (0.79 g, 96%). Rf 0.41 (toluene/EtOAc
8:2); [α]D20= +58 (c = 0.8); 1H NMR (CDCl3): δ = 8.09-7.93 and 7.50-7.30 (2 m, 15 H, 3
PhCO), 5.53 (dd, J2,3 = 9.8, J3,4 = 8.6 Hz, 1 H; H-3), 5.41 (dd, J1,2 = 7.8 Hz, 1 H; H-2),
4.76 (d, 1 H; H-1), 3.61 (ddd, 1 H; OCHHCH2CH2N3), 3.26-3.15 (m, 2 H;
OCH2CH2CH2N3), 1.85-1.68 (m, 2 H; OCH2CH2CH2N3); 
13C NMR (CDCl3): δ = 167.0,
166.9, and 165.2 (3 PhCO), 101.0 (C-1), 76.1, 74.3, 71.4, and 69.4 (C-2,3,4,5), 66.4
(OCH2CH2CH2N3), 63.3 (C-6), 47.7 (OCH2CH2CH2N3), 28.8 (OCH2CH2CH2N3);
elemental analysis calcd (%) for C30H29O9N3 (575.5): C 62.60, H 5.08; found C 62.68, H
5.14.
3-Azido-1-propanol (18): To a solution of 3-bromo-1-propanol (1.54 g, 11.1 mmol) in
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DMF (9 mL) was added sodium azide (3.58 g, 55.0 mmol). After stirring at boiling under
reflux for 36 h, the mixture was filtered, and co-concentrated with toluene. The residue
was diluted with CH2Cl2 and washed twice with 10% (w/v) aqueous NaCl. The organic
layer was dried, filtered, and concentrated. An analytically pure sample was obtained by
distillation under reduced pressure (0.83 g, 74%). nD (1.4521, 23 °C); lit [36] (1.4569, 28
°C); 1H NMR (CDCl3): δ = 3.73 (t, 2 H; HOCH2CH2CH2N3), 3.44 (t, 2 H;
HOCH2CH2CH2N3), 1.87-1.79 (m, 2 H; HOCH2CH2CH2N3); IR (KBr; liquid film): ν =
2100 cm-1 (N3).
Allyl (2-O-benzoyl-4,6-O-benzylidene-3-O-chloroacetyl-β-D-glucopyranosyl)-(1→4)-
2,3,6-tri-O-benzoyl-β-D-glucopyranoside (19): A solution of 7 (0.42 g, 0.80 mmol) and
12 (0.85 g, 1.43 mmol) in dry CH2Cl2 (13 mL), containing 4 Å molecular sieves, was
stirred under Ar for 1 h. Then, TMSOTf (15 µL, 84 µmol) was added. After 30 min, the
mixture was neutralised with dry pyridine, filtered over cotton, diluted with CH2Cl2, and
washed with 10% (w/v) aqueous NaCl. The organic layer was dried, filtered, and
concentrated. The residue was purified by column chromatography (toluene/EtOAc 95:5)
to obtain 19 (0.73 g, 96%). Rf 0.35 (toluene/EtOAc 9:1); [α]D20= +29 (c = 1); 1H NMR
(CDCl3): δ = 8.01-7.91 and 7.50-7.25 (2 m, 25 H; PhCH, 4 PhCO), 5.77-5.64 (m, 1 H;
OCH2CH=CH2), 5.69 (t, J2,3 = 9.7 Hz, 1 H; H-3), 5.39 (dd, J1,2 = 7.8 Hz, 1 H; H-2), 5.38
(t, J2',3' = J3',4' = 9.4 Hz, 1 H; H-3'), 5.27 (dd, J1',2' = 7.6 Hz, 1 H; H-2'), 5.20 (s, 1 H;
PhCH), 5.16-5.10 and 5.07-5.03 (2 m, each 1 H; OCH2CH=CH2), 4.77 and 4.71 (2 d, each
1 H; H-1,1'), 3.91 and 3.85 (2 d, Jgem = 14.8 Hz, each 1 H; ClCH2CO); 
13C NMR (CDCl3):
δ = 166.3, 165.6, 165.1 (2 C), and 164.9 (4 PhCO, ClCH2CO), 136.2 (PhCH, quaternary
C), 117.6 (OCH2CH=CH2), 101.5, 101.1, and 99.2 (PhCH, C-1,1'), 69.8 (OCH2CH=CH2),
67.3 (C-6'), 62.2 (C-6), 40.2 (ClCH2CO); elemental analysis calcd (%) for C52H47O16Cl
(963.3): C 64.83, H 4.91; found C 64.59, H 4.97.
(2-O-Benzoyl-4,6-O-benzylidene-3-O-chloroacetyl-β-D-glucopyranosyl)-(1→4)-2,3,6-
tri-O-benzoyl-D-glucopyranose (20): To a solution of 19 (0.74 g, 0.78 mmol) in absolute
EtOH (20 mL), toluene (45 mL), and CH2Cl2 (3 mL) were added a catalytic amount of
DABCO and tris(triphenylphosphine)rhodium(I) chloride (0.82 g). After stirring at boiling
under reflux for 2.5 h, TLC (toluene/EtOAc 9:1) showed the formation of a new spot (Rf
0.38), and the mixture was concentrated. The residue was dissolved in THF (55 mL), and
water (8 mL) and NIS (0.33 g) were added. After 20 min, the mixture was concentrated,
diluted with CH2Cl2, washed with 10% (w/v) aqueous NaHSO3 (2 x) and 10% (w/v)
aqueous NaCl, and the organic layer was dried, filtered, and concentrated. The crude
residue was purified by column chromatography. Impurities were eluted with
toluene/EtOAc (9:1), and 20 was obtained as a light brown syrup by elution with
toluene/EtOAc (8:2) (0.50 g, 70%; α/β = 4:1). Rf 0.29α/0.34β (toluene/EtOAc 8:2); 1H
NMR (CDCl3): δ = 8.06-7.93 and 7.50-7.31 (2 m, 25 H; PhCH, 4 PhCO), 6.04 (dd, J2,3 =
10.2, J3,4 = 9.2 Hz, 0.8 H; H-3
α), 5.48 (d, J1,2 = 3.5 Hz, 0.8 H; H-1α), 5.42 (t, J2',3' = J3',4' =
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9.4 Hz, 1 H; H-3'), 5.30 (dd, J1',2' = 7.6 Hz, 1 H; H-2'), 5.24 (s, 0.8 H; PhCH
α), 5.22 (s, 0.2
H; PhCHβ), 5.14 (dd, 0.8 H; H-2α), 4.89 and 4.81 (2 d, J1,2 ≈ 7.8 Hz, each 0.2 H; H-1β,1'β),
4.85 (d, 0.8 H; H-1'α), 3.93 and 3.87 (2 d, Jgem = 14.9 Hz, each 1 H; ClCH2CO); 13C NMR
(CDCl3): δ = 166.7, 166.4, 165.8, and 165.0 (2 C) (4 PhCO, ClCH2CO), 136.3 (PhCH,
quaternary C), 101.6 and 101.2 (PhCH, C-1'), 95.4 (C-1β), 90.0 (C-1α), 67.4 (C-6'), 62.0
(C-6), 40.3 (ClCH2CO); elemental analysis calcd (%) for C49H43O16Cl (923.3): C 63.74, H
4.69; found C 63.44, H 4.73.
(2-O-Benzoyl-4,6-O-benzylidene-3-O-chloroacetyl-β-D-glucopyranosyl)-(1→4)-2,3,6-
tri-O-benzoyl-α-D-glucopyranosyl trichloroacetimidate (21): To a solution of 20 (0.40
g, 0.44 mmol) in dry CH2Cl2 (9 mL) were added Cl3CCN (0.60 mL) and DBU (18 µL).
After 2 h, the mixture was concentrated and the residue was purified by column
chromatography (toluene/EtOAc 95:5) to yield 21 (0.41 g, 88%). Rf 0.32 (toluene/EtOAc
9:1); 1H NMR (CDCl3): δ = 8.54 (s, 1 H; NH), 8.05-7.90 and 7.49-7.25 (2 m, 25 H; 4
PhCO, PhCH), 6.67 (d, J1,2 = 3.7 Hz, 1 H; H-1), 6.08 (dd, J2,3 = 10.1, J3,4 = 8.8 Hz, 1 H;
H-3), 5.46 (dd, 1 H; H-2), 5.41 (t, J2',3' = 9.2 Hz, 1 H; H-3'), 5.23 (dd, J1',2' = 7.6 Hz, 1 H;
H-2'), 5.28 (s, 1 H; PhCH), 4.87 (d, 1 H; H-1'), 3.91 and 3.85 (2 d, Jgem = 14.8 Hz, each 1
H; ClCH2CO); 
13C NMR (CDCl3): δ = 166.3, 165.4, 165.3, 164.9, and 164.8 (4 PhCO,
ClCH2CO), 160.4 (OC(NH)CCl3), 136.3 (PhCH, quaternary C), 101.7 and 101.2 (PhCH,
C-1'), 92.8 (C-1), 67.5 (C-6'), 61.6 (C-6), 40.2 (ClCH2CO).
3-Azidopropyl (2-O-benzoyl-4,6-O-benzylidene-3-O-chloroacetyl-β-D-
glucopyranosyl)-(1→4)-2,3,6-tri-O-benzoyl-β-D-glucopyranoside (22): A solution of 12
(0.50 g, 0.84 mmol) and 17 (0.28 g, 0.49 mmol) in dry CH2Cl2 (10 mL), containing 4 Å
molecular sieves, was stirred under Ar for 1 h. Then, TMSOTf (11.5 µL, 63 µmol) was
added. After 30 min, the mixture was neutralised with dry pyridine, filtered over cotton,
diluted with CH2Cl2, and washed with 10% (w/v) aqueous NaCl. The organic layer was
dried, filtered, and concentrated. The residue was purified by column chromatography
(toluene/EtOAc 95:5) to obtain 22 (0.38 g, 78%). Rf 0.39 (toluene/EtOAc 9:1); [α]D20=
+42 (c = 1); 1H NMR (CDCl3): δ = 8.06-7.91 and 7.48-7.26 (2 m, 25 H; PhCH, 4 PhCO),
5.69 (t, J ≈ 9.3 Hz, 1 H; H-3), 5.38 (t, J ≈ 9.5 Hz, 1 H; H-3'), 5.35 and 5.27 (2 dd, J1,2, J1',2'
= 7.6, 7.8 Hz, each 1 H; H-2,2'), 5.20 (s, 1 H; PhCH), 4.78 and 4.65 (2 d, each 1 H; H-
1,1'), 4.07 and 3.53 (2 t, J ≈ 9.4 Hz, each 1 H; H-4,4'), 3.91 and 3.86 (2 d, each 1 H;
ClCH2CO), 3.16 (dt, 1 H; OCH2CH2CH2N3), 1.77-1.61 (m, 2 H; OCH2CH2CH2N3); 
13C
NMR (CDCl3): δ = 166.3, 165.5, 165.1, 164.9, and 164.8 (4 PhCO, ClCH2CO), 136.3
(PhCH, quaternary C), 101.5, 101.2, and 100.7 (PhCH, C-1,1'), 67.4 (C-6'), 66.3
(OCH2CH2CH2N3), 62.1 (C-6), 47.7 (OCH2CH2CH2N3), 40.2 (ClCH2CO), 28.7
(OCH2CH2CH2N3); IR (KBr, liquid film): ν = 2096 cm-1 (N3); elemental analysis calcd
(%) for C52H48O16ClN3 (1006.4): C 62.05, H 4.80; found C 62.15, H 4.86.
3-Azidopropyl (2-O-benzoyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1→4)-2,3,6-tri-
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O-benzoyl-β-D-glucopyranoside (23): To a solution of 22 (0.26 g, 0.26 mmol) in toluene
(14 mL) and ethanol (14 mL) was added DABCO (0.43 g, 3.8 mmol). After 2.5 h at 55 °C,
the mixture was diluted with CH2Cl2, washed with aqueous 0.05 M HCl, and the organic
layer was dried, filtered, and concentrated. The residue was purified by column
chromatography (toluene/EtOAc 9:1) to afford 23 (0.23 g, 98%). Rf 0.25 (toluene/EtOAc
9:1); [α]D20= +31 (c = 1); 1H NMR (CDCl3): δ = 8.08-7.91 and 7.50-7.29 (2 m, 25 H;
PhCH, 4 PhCO), 5.68 (t, J2,3 = 9.8 Hz, 1 H; H-3), 5.36 (dd, J1,2 = 7.9 Hz, 1 H; H-2), 5.22
(s, 1 H; PhCH), 5.17 (dd, J1',2' = 8.0, J2',3' = 9.0 Hz, 1 H; H-2'), 4.67 and 4.62 (2 d, each 1
H; H-1,1'), 4.05 and 3.36 (2 t, J ≈ 9.3 Hz, each 1 H; H-4,4'), 3.87 (t, 1 H; H-3'), 3.19-3.11
(m, 2 H; OCH2CH2CH2N3), 1.74-1.60 (m, 2 H; OCH2CH2CH2N3); 
13C NMR (CDCl3): δ =
165.8, 165.3, 165.1, and 165.0 (4 PhCO), 136.6 (PhCH, quaternary C), 101.5, 101.4, and
100.7 (PhCH, C-1,1'), 67.5 (C-6'), 66.3 (OCH2CH2CH2N3), 62.4 (C-6), 47.7
(OCH2CH2CH2N3), 28.7 (OCH2CH2CH2N3); elemental analysis calcd (%) for
C50H47O15N3 (929.9): C 64.58, H 5.09; found C 64.65, H 5.20.
3-Azidopropyl (2-O-benzoyl-β-D-glucopyranosyl)-(1→4)-2,3,6-tri-O-benzoyl-β-D-
glucopyranoside (24): To a solution of 23 (80 mg, 87 µmol) in CH2Cl2 (5 mL) were
added CF3COOH (60 µL) and H2O (8 µL). The mixture was stirred for 3 h, then diluted
with CH2Cl2, washed with 10% (w/v) aqueous NaHCO3 (2 x) and 10% (w/v) aqueous
NaCl, and the organic layer was dried, filtered, and concentrated. The residue was purified
by column chromatography (toluene/EtOAc 8:2→toluene/EtOAc 6:4) to obtain 24 (70
mg, 90%). Rf 0.04 (toluene/EtOAc 6:4); [α]D20= +28 (c = 1); 1H NMR (CDCl3): δ = 8.04-
7.90 and 7.61-7.32 (2 m, 20 H; 4 PhCO), 5.66 (t, J2,3 = 9.7 Hz, 1 H; H-3), 5.38 (dd, J1,2 =
7.8 Hz, 1 H; H-2), 4.97 (dd, J1',2' = 7.8, J2',3' = 9.5 Hz, 1 H; H-2'), 4.67 and 4.65 (2 d, each 1
H; H-1,1'), 3.52 (ddd, 1 H; OCHHCH2CH2N3), 3.19-3.14 (m, 2 H; OCH2CH2CH2N3),
1.79-1.64 (m, 2 H; OCH2CH2CH2N3); 
13C NMR (CDCl3): δ = 165.9 (3 C) and 165.2 (4
PhCO), 100.7 (C-1,1'), 66.4 (OCH2CH2CH2N3), 62.6 and 61.3 (C-6,6'), 47.7
(OCH2CH2CH2N3), 28.8 (OCH2CH2CH2N3); elemental analysis calcd (%) for
C43H43O15N3 (841.3): C 61.35, H 5.14; found C 61.59, H 5.22.
3-Azidopropyl (2-O-benzoyl-β-D-glucopyranosyluronic acid)-(1→4)-2,3,6-tri-O-
benzoyl-β-D-glucopyranoside (25): To a solution of 24 (65 mg, 0.072 mmol) in CH2Cl2
(0.65 mL) were added a catalytic amount of TEMPO, and 0.14 mL of a solution of KBr
(7.8 mg) and Bu4NBr (10.4 mg) in saturated aqueous NaHCO3 (1.4 mL). The mixture was
stirred vigorously at 0 °C, when a solution of saturated aqueous NaCl (0.14 mL), saturated
aqueous NaHCO3 (78 µL), and aqueous NaOCl (13% Cl active; 0.18 mL) was added
dropwise. After 45 min, the mixture was acidified with 4 M HCl (pH 4), diluted with
CH2Cl2, and the organic layer was washed with 10% (w/v) aqueous NaCl, dried, filtered,
and concentrated. The residue was purified by column chromatography. Impurities were
eluted with CH2Cl2/acetone (8:2), and 25 (55 mg, 85%) was eluted with
CH2Cl2/acetone/HOAc (8:2:0.5). Rf 0.30 (CH2Cl2/acetone/HOAc 8:2:1); 
13C NMR
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(CDCl3): δ = 100.6 and 100.4 (C-1,1'), 66.3 (OCH2CH2CH2N3), 62.3 (C-6), 47.6
(OCH2CH2CH2N3), 28.7 (OCH2CH2CH2N3).
A small amount was methylated with diazomethane and acetylated with Ac2O and
pyridine for analysis. 1H NMR (CDCl3): δ = 7.94-7.89 and 7.50-7.26 (2 m, 20 H; 4
PhCO), 4.87 and 4.65 (2 d, J1,2, J1',2' = 7.4, 7.7 Hz, each 1 H; H-1,1'), 3.73 (d, J4',5' = 9.9
Hz, 1 H; H-5'), 3.37 (s, 3 H; COOCH3), 3.16-3.13 (m, 2 H; OCH2CH2CH2N3), 1.93 and
1.84 (2 s, each 3 H; CH3CO), 1.75-1.57 (m, 2 H; OCH2CH2CH2N3); elemental analysis
calcd (%) for C48H47O18N3 (953.9): C 60.44, H 4.97; found C 60.65, H 5.03.
3-Aminopropyl (β-D-glucopyranosyluronic acid)-(1→4)-β-D-glucopyranoside (1): To
a solution of 25 (90 mg, 0.11 mmol) in MeOH (9 mL) was added NaOMe until pH 11.
After stirring for 1.5 h, TLC (EtOAc/MeOH/H2O 12:5:3) showed the formation of a new
spot (Rf 0.37), and the mixture was neutralised with Dowex H
+, filtered, and concentrated.
A solution of the residue in water was washed with CH2Cl2 (3x), and the aqueous layer
was concentrated. MALDI-TOF analysis of the residue showed a peak at m/z 462
[M+Na]+. Then, a solution of the residue in 0.1 M NaOH (1.1 mL) was added dropwise to
a suspension of 10% Pd/C (2 mg) and NaBH4 (8.7 mg) in bidistilled water (0.55 mL).
After 45 min, when TLC (EtOAc/MeOH/H2O 12:5:3) showed the formation of a
ninhydrin-positive spot on the baseline, the mixture was acidified with Dowex H+ (pH 4),
then loaded on a short column of Dowex 50 W × 2 (H+, 200-400 mesh). After elution of
contaminants with water, elution with 1% NH4OH afforded 1 after concentration and co-
concentration with water (2x) (39 mg, 90%). [α]D20= -92 (c = 0.6, H2O); MS (MALDI-
TOF): m/z 414 [M+H]+, 436 [M+Na]+. For 1H NMR data, see Table 1.
3-Azidopropyl (2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→3)-(2-O-benzoyl-4,6-
O-benzylidene-β-D-glucopyranosyl)-(1→4)-2,3,6-tri-O-benzoyl-β-D-glucopyranoside
(27): A solution of 23 (53 mg, 57 µmol) and ethyl 2,3,4,6-tetra-O-benzoyl-1-thio-β-D-
glucopyranoside 26 (62 mg, 96 µmol) in dry CH2Cl2 (0.26 mL), containing 4 Å molecular
sieves, was stirred under Ar for 30 min at 0 °C. Then, 0.48 mL of a solution of NIS (420
mg, 1.87 mmol) and TfOH (12 µL) in Et2O/CH2Cl2 (1:1) (9.6 mL) was added. After 5
min, the mixture was neutralised with dry pyridine, filtered over cotton, diluted with
CH2Cl2, and washed with 10% (w/v) aqueous NaHSO3 (2x) and 10% (w/v) aqueous NaCl.
The organic layer was dried, filtered, and concentrated. The residue was purified by
column chromatography (toluene/EtOAc 9:1) to afford 27 (70 mg, 82%). Rf 0.41
(toluene/EtOAc 85:15); [α]D20= +27 (c = 1); 1H NMR (CDCl3): δ = 5.64 and 5.56 (2 t,
J2'',3'' = 9.3, J3'',4'' = 9.4 Hz, each 1 H; H-3'',4''), 5.62 (dd, J2,3 = 9.8, J3,4 = 9.0 Hz, 1 H; H-3),
5.39 and 5.31 (2 dd, J1,2, J1'',2'' = 7.8 Hz, each 1 H; H-2,2''), 5.29 (s, 1 H; PhCH), 5.27 (dd,
J1',2' = 7.8, J2',3' = 9.0 Hz, 1 H; H-2'), 4.91 (d, 1 H; H-1''), 4.59 and 4.58 (2 d, each 1 H; H-
1,1'), 3.47 (ddd, 1 H; OCHHCH2CH2N3), 3.13 (dt, 2 H; OCH2CH2CH2N3), 1.72-1.58 (m, 2
H; OCH2CH2CH2N3); 
13C NMR (CDCl3): δ = 165.9, 165.1, 164.9, 164.8 (2 C), 164.6, and
164.0 (2 C) (8 PhCO), 136.6 (PhCH, quaternary C), 101.5, 101.2, and 100.5 (2 C) (PhCH,
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C-1,1',1''), 67.5 (C-6'), 66.3 (OCH2CH2CH2N3), 62.8 (2 C) (C-6,6''), 47.7
(OCH2CH2CH2N3), 28.7 (OCH2CH2CH2N3); MS (MALDI-TOF): m/z 1530 [M+Na]
+.
3-Azidopropyl (2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→3)-(2-O-benzoyl-β-
D-glucopyranosyl)-(1→4)-2,3,6-tri-O-benzoyl-β-D-glucopyranoside (28): To a solution
of 27 (0.13 g, 82 µmol) in CH2Cl2 (5 mL) were added CF3COOH (60 µL) and H2O (8 µL).
The mixture was stirred for 3 h, diluted with CH2Cl2, washed with 10% (w/v) aqueous
NaHCO3 (2 x), and the organic layer was dried, filtered, and concentrated. The residue
was purified by column chromatography (toluene/EtOAc 8:2→toluene/EtOAc 7:3) to
obtain 28 (86 mg, 70%). Rf 0.37 (toluene/EtOAc 7:3); [α]D20= +14 (c = 1); 1H NMR
(CDCl3): δ = 5.76, 5.54, and 5.53 (3 t, J ≈ 9.5 Hz, each 1 H; H-3,3'',4''), 5.46 (dd, J1'',2'' =
7.9, J2'',3'' = 9.8 Hz, 1 H; H-2''), 5.35 (dd, J1,2 = 7.7, J2,3 = 9.6 Hz, 1 H; H-2), 5.14 (dd, J1',2'
= 8.0, J2',3' = 9.2 Hz, 1 H; H-2'), 4.81 (d, 1 H; H-1''), 4.56 (d, 1 H; H-1), 4.51 (d, 1 H; H-1'),
3.14 (dt, 2 H; OCH2CH2CH2N3), 1.75-1.62 (m, 2 H; OCH2CH2CH2N3); 
13C NMR
(CDCl3): δ = 165.9, 165.5, 165.1 (2 C), 164.9, 164.7, 163.8, and 160.2 (8 PhCO), 101.5
and 100.8 (2 C) (C-1,1',1''), 66.3 (OCH2CH2CH2N3), 62.5 and 62.2 (2 C) (C-6,6',6''), 47.7
(OCH2CH2CH2N3), 28.8 (OCH2CH2CH2N3); MS (MALDI-TOF): m/z 1442 [M+Na]
+.
3-Azidopropyl (2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→3)-(2-O-benzoyl-β-
D-glucopyranosyluronic acid)-(1→4)-2,3,6-tri-O-benzoyl-β-D-glucopyranoside (29):
To a solution of 28 (50 mg, 34 µmol) in CH2Cl2 (0.6 mL) were added TEMPO (catalytic
amount), and 70 µL of a solution of KBr (3.6 mg) and Bu4NBr (4.9 mg) in saturated
aqueous NaHCO3 (0.7 mL). The mixture was stirred vigorously at 0 °C, when a solution
of saturated aqueous NaCl (70 µL), saturated aqueous NaHCO3 (33 µL), and aqueous
NaOCl (13% Cl active; 90 µL) was added dropwise. After 45 min, the mixture was
acidified with 4 M HCl (pH 4), diluted with CH2Cl2, and the organic layer was washed
with 10% (w/v) aqueous NaCl, dried, filtered, and concentrated. The residue was purified
by column chromatography. Impurities were eluted with CH2Cl2/acetone (8:2), and 29 (38
mg, 76%) was eluted with CH2Cl2/acetone/HOAc (8:2:0.5). Rf 0.65
(CH2Cl2/acetone/HOAc 8:2:1); [α]D20= +25 (c = 1); 1H NMR (CDCl3): δ = 5.76, 5.64, and
5.53 (3 t, J2,3 = 9.6, J2'',3'' = 9.8, J3'',4'' = 9.3 Hz, each 1 H; H-3,3'',4''), 5.45 (dd, J1'',2'' = 7.9
Hz, 1 H; H-2''), 5.27 (dd, J1,2 = 7.7 Hz, 1 H; H-2), 5.18 (dd, J1',2' = 7.9 Hz, 1 H; H-2'), 4.86
(d, 1 H; H-1''), 4.68 (d, 1 H; H-1'), 4.58 (d, 1 H; H-1), 3.62 (d, J4',5' = 9.3 Hz, 1 H; H-5'),
3.12 (dt, 2 H; OCH2CH2CH2N3), 1.71-1.59 (m, 2 H; OCH2CH2CH2N3); 
13C NMR
(CDCl3): δ = 169.1 (C-6'), 166.0, 165.7, 165.5, 165.3, 165.1, 164.9, 164.7, and 163.8 (8
PhCO), 101.4, 100.7, and 100.6 (C-1,1',1''), 66.3 (OCH2CH2CH2N3), 62.5 and 62.1 (C-
6,6''), 47.7 (OCH2CH2CH2N3), 28.8 (OCH2CH2CH2N3); MS (MALDI-TOF): m/z 1456
[M+Na]+.
3-Aminopropyl (β-D-glucopyranosyl)-(1→3)-(β-D-glucopyranosyluronic acid)-(1→4)-
β-D-glucopyranoside (2): To a solution of 29 (50 mg, 33 µmol) in MeOH (3 mL) was
Synthesis of oligosaccharide-protein conjugates 49
added NaOMe until pH 11. After stirring for 16 h, TLC (EtOAc/MeOH/H2O 12:5:2)
showed the formation of a new spot (Rf 0.27), and the mixture was neutralised with
Dowex H+, filtered, and concentrated. A solution of the residue in water was washed with
CH2Cl2 (3x), and the aqueous layer was concentrated. MALDI-TOF analysis of the
residue showed a peak at m/z 624 [M+Na]+. Then, a solution of the residue in 0.1 M
NaOH (0.33 mL) was added dropwise to a suspension of 10% Pd/C (0.6 mg) and NaBH4
(2.7 mg) in bidistilled water (0.17 mL). After 45 min, when TLC (EtOAc/MeOH/H2O
12:5:3) showed the formation of a ninhydrin-positive spot on the baseline, the mixture was
acidified with Dowex H+ (pH 4), then loaded on a short column of Dowex 50 W × 2 (H+,
200-400 mesh). After elution of contaminants with water, elution with 1% NH4OH
afforded 2, after concentration and co-concentration with water (2x) (17 mg, 89%).
[α]D20= -18 (c = 0.8, H2O); MS (MALDI-TOF): m/z 575 [M+H]+, 597 [M+Na]+. For 1H
NMR data, see Table 1.
3-Azidopropyl (2-O-benzoyl-4,6-O-benzylidene-3-O-chloroacetyl-β-D-glucopyranosyl)
- (1→4) - (2,3,6-tri-O-benzoyl-β-D-glucopyranosyl) - (1→3) - (2-O-benzoyl-4,6-O-
benzylidene-β-D-glucopyranosyl) - (1→4) - 2,3,6-tri-O-benzoyl-β-D-glucopyranoside
(30): A solution of 21 (0.50 g, 0.47 mmol) and 23 (0.27 g, 0.29 mmol) in dry CH2Cl2 (4.4
mL), containing 4 Å molecular sieves, was stirred under Ar for 1 h. Then, TMSOTf (8.5
µL, 47 µmol) was added. After 15 min, the mixture was neutralised with dry pyridine,
filtered over cotton, diluted with CH2Cl2, and washed with 10% (w/v) aqueous NaCl. The
organic layer was dried, filtered, and concentrated. The residue was purified by column
chromatography (toluene/EtOAc 95:5) to obtain 30 (0.39 g, 75%). Rf 0.36 (toluene/EtOAc
85:15); [α]D20= +34 (c = 1); 1H NMR (CDCl3): δ = 5.58, 5.40, and 5.25 (3 t, J ≈ 9.5 Hz,
each 1 H; H-3,3'',3'''), 5.17 and 5.11 (2 s, each 1 H; 2 PhCH), 4.72, 4.55, 4.53, and 4.53 (4
d, J ≈ 7.7 Hz, each 1 H; H-1,1',1'',1'''), 3.87 and 3.81 (2 d, Jgem = 14.9 Hz, each 1 H;
ClCH2CO), 1.79-1.65 (m, 2 H; OCH2CH2CH2N3); 
13C NMR (CDCl3): δ = 136.4 and 136.2
(2 PhCH, quaternary C), 101.4 (2 C), 101.1 (2 C), 100.6, and 99.8 (2 PhCH, C-1,1',1'',1'''),
67.5 and 67.3 (C-6',6'''), 66.3 (OCH2CH2CH2N3), 62.0 and 61.9 (C-6,6''), 47.7
(OCH2CH2CH2N3), 40.2 (ClCH2CO), 28.7 (OCH2CH2CH2N3); MS (FAB): m/z 1834
[M+H]+, 1856 [M+Na]+.
3-Azidopropyl (2-O-benzoyl-4,6-O-benzylidene-β-D-glucopyranosyl) - (1→4) - (2,3,6-
tri-O-benzoyl-β-D-glucopyranosyl) - (1→3) - (2-O-benzoyl-4,6-O-benzylidene-β-D-
glucopyranosyl) - (1→4) - 2,3,6-tri-O-benzoyl-β-D-glucopyranoside (31): To a solution
of 30 (0.39 g, 0.22 mmol) in ethanol (5 mL) and pyridine (0.66 mL) was added thiourea
(50 mg). After stirring for 3 h at 90 °C, the mixture was cooled to room temperature, co-
concentrated with toluene, and the residue was purified by column chromatography
(toluene/EtOAc 95:5→toluene/EtOAc 9:1) to afford 31 (0.32 g, 84%). Rf 0.25
(toluene/EtOAc 8:2); [α]D20= +52 (c = 1); 1H NMR (CDCl3): δ = 5.58 and 5.39 (2 t, J ≈
9.5 Hz, each 1 H; H-3,3''), 5.17 and 5.13 (2 s, each 1 H; 2 PhCH), 4.73, 4.54 (2 H), and
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4.49 (3 d, J ≈ 7.8 Hz, 4 H; H-1,1',1'',1'''), 3.11 (bt, 2 H; OCH2CH2CH2N3), 1.70-1.59 (m, 2
H; OCH2CH2CH2N3); 
13C NMR (CDCl3): δ = 165.9, 165.6, 165.2, 165.1, 164.8 (2 C),
164.7, and 163.9 (8 PhCO), 136.4 (2 PhCH, quaternary C), 101.4 (3 C), 101.1, 100.6, and
100.0 (2 PhCH, C-1,1',1'',1'''), 67.4 (2 C) (C-6',6'''), 66.3 (OCH2CH2CH2N3), 62.1 (2 C) (C-
6,6''), 47.7 (OCH2CH2CH2N3), 28.7 (OCH2CH2CH2N3); MS (FAB): m/z 1758 [M+H]
+,
1780 [M+Na]+.
3-Azidopropyl (2-O-benzoyl-β-D-glucopyranosyl)-(1→4)-(2,3,6-tri-O-benzoyl-β-D-
glucopyranosyl)-(1→3)-(2-O-benzoyl-β-D-glucopyranosyl)-(1→4)-2,3,6-tri-O-benzoyl-
β-D-glucopyranoside (32): To a solution of 31 (0.20 g, 0.11 mmol) in CH2Cl2 (6.5 mL)
were added CF3COOH (0.12 mL) and H2O (10 µL). The mixture was stirred for 2.5 h,
diluted with CH2Cl2, washed with 10% (w/v) aqueous NaHCO3 (2 x) and 10% (w/v)
aqueous NaCl, and the organic layer was dried, filtered, and concentrated. The residue was
purified by column chromatography (toluene/EtOAc 1:1→toluene/EtOAc 3:7) to obtain
32 (0.12 g, 70%). Rf 0.14 (toluene/EtOAc 1:1); [α]D20= +36 (c = 1); 1H NMR (CDCl3): δ =
5.52 (bt, J ≈ 9.3 Hz, 2 H; H-3,3''), 5.31, 5.29, 5.05, and 4.91 (4 dd, each 1 H; H-2,2',2'',2'''),
4.63, 4.61, 4.54, and 4.45 (4 d, J ≈ 7.5 Hz, each 1 H; H-1,1',1'',1'''), 1.68-1.56 (m, 2 H;
OCH2CH2CH2N3); 
13C NMR (CDCl3): δ = 165.9, 165.8, 165.7, 165.1 (2 C), 165.0, 164.9,
and 163.9 (8 PhCO), 101.2, 100.7 (2 C), and 100.6 (C-1,1',1'',1'''), 66.3 (OCH2CH2CH2N3),
62.3 (2 C), 62.0, and 61.3 (C-6,6',6'',6'''), 47.7 (OCH2CH2CH2N3), 28.8
(OCH2CH2CH2N3). MS (FAB): m/z 1582 [M+H]
+, 1604 [M+Na]+.
3-Azidopropyl (2-O-benzoyl-β-D-glucopyranosyluronic acid)-(1→4)-(2,3,6-tri-O-
benzoyl-β-D-glucopyranosyl)-(1→3)-(2-O-benzoyl-β-D-glucopyranosyluronic acid)-
(1→4)-2,3,6-tri-O-benzoyl-β-D-glucopyranoside (33): To a solution of 32 (95 mg, 57
µmol) in CH2Cl2 (0.6 mL) were added TEMPO (catalytic amount), and 0.12 mL of a
solution of KBr (6.6 mg) and Bu4NBr (8.7 mg) in saturated aqueous NaHCO3 (1.2 mL).
The mixture was stirred vigorously at 0 °C, then a mixture of saturated aqueous NaCl
(0.12 mL), saturated aqueous NaHCO3 (0.06 mL), and aqueous NaOCl (13% Cl active;
0.15 mL) was added dropwise. After 45 min, the mixture was acidified with 4 M HCl (pH
4), diluted with CH2Cl2, and the organic layer was washed with 10% (w/v) aqueous NaCl,
dried, filtered, and concentrated. The residue was purified by column chromatography.
Impurities were eluted with CH2Cl2/acetone (8:2), and 33 (64 mg, 65%) was eluted with
CH2Cl2/acetone/HOAc (8:2:0.5). Rf 0.41 (CH2Cl2/acetone/HOAc 8:2:1).
A small sample was methylated with diazomethane for analysis. 1H NMR (CDCl3): δ =
5.56 (bt, J ≈ 9.3 Hz, 2 H; H-3,3''), 5.36, 5.28, 5.22, and 5.13 (4 dd, each 1 H; H-2,2',2'',2'''),
4.84, 4.66, 4.58, and 4.54 (4 d, J ≈ 7.8 Hz, each 1 H; H-1,1',1'',1'''), 3.39 and 3.34 (2 s,
each 3 H; 2 COOCH3), 3.11 (dt, 2 H; OCH2CH2CH2N3), 1.68-1.56 (m, 2 H;
OCH2CH2CH2N3). MS (MALDI-TOF): m/z 1610 [M+H]
+, 1632 [M+Na]+.
3-Aminopropyl (β-D-glucopyranosyluronic acid)-(1→4)-(β-D-glucopyranosyl)-(1→3)-
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(β-D-glucopyranosyluronic acid)-(1→4)-β-D-glucopyranoside (3): To a solution of 33
(75 mg, 43 µmol) in MeOH (3 mL) was added NaOMe until pH 11. After stirring for 16 h,
TLC (EtOAc/MeOH/H2O 12:5:3) showed the formation of a new spot (Rf 0.30), and the
mixture was neutralised with Dowex H+, filtered, and concentrated. A solution of the
residue in water was washed with CH2Cl2 (3x), and the aqueous layer was concentrated.
MALDI-TOF analysis of the residue showed a peak at m/z 800 [M+Na]+. Then, a solution
of the residue in 0.1 M NaOH (0.43 mL) was added dropwise to a suspension of 10%
Pd/C (0.8 mg) and NaBH4 (3.5 mg) in bidistilled water (0.22 mL). After 45 min, when
TLC (EtOAc/MeOH/H2O 12:5:3) showed the formation of a ninhydrin-positive spot on
the baseline, the mixture was acidified with Dowex H+ (pH 4), then loaded on a short
column of Dowex 50 W × 2 (H+, 200-400 mesh). After elution of contaminants with
water, elution with 1% NH4OH afforded 3 after concentration and co-concentration with
water (2x) (19 mg, 60%). [α]D20= +124 (c = 0.7, H2O); MS (MALDI-TOF): m/z 752
[M+H]+, 774 [M+Na]+. For 1H NMR data, see Table 1.
3-Aminopropyl β-D-glucopyranoside (35): To a solution of 16 (81 mg, 0.12 mmol) in
MeOH (3 mL) was added NaOMe until pH 10. After stirring for 2 h, when TLC
(EtOAc/MeOH/H2O 6:3:1) showed the formation of 34 (Rf 0.63), the mixture was
neutralised with Dowex H+, filtered, and concentrated. A solution of the residue in water
was washed with CH2Cl2 (3x), then the aqueous layer was concentrated, and a solution of
the residue (crude 34) in 0.1 M NaOH (1.1 mL) was added dropwise to a suspension of
10% Pd/C (2 mg) and NaBH4 (9.7 mg) in bidistilled water (0.5 mL). After 45 min, when
TLC (EtOAc/MeOH/H2O 12:5:3) showed the formation of 35 as a ninhydrin-positive spot
on the baseline, the mixture was acidified with Dowex H+ (pH 4) and loaded on a short
column of Dowex 50 W × 2 (H+, 200-400 mesh). Contaminants were eluted with water,
and after elution with 1% NH4OH, 35 was obtained after concentration and co-
concentration with water (2x) (25 mg, 88%). [α]D20= +6 (c = 0.2, H2O); MS (MALDI-
TOF): m/z 238 [M+H]+, 260 [M+Na]+. For 1H NMR data, see Table 1.
3-Aminopropyl β-D-glucopyranosiduronic acid (37): To a cooled solution (5 °C) of 34
(30 mg, 0.11 mmol) in H2O (3 mL) were added TEMPO (0.12 mg) and KBr (5.6 mg).
Aqueous NaOCl (13% Cl active; 0.37 mL) was brought to pH 10 by addition of 4 M HCl
and cooled to 5 °C. The two solutions were combined and pH 10 was maintained by
addition of 0.5 M NaOH. After stirring for 3 h at 5 °C, the mixture was neutralised with 4
M HCl and concentrated. Desalting of the mixture could not be achieved by size-exclusion
chromatography. Therefore, the crude residue was acetylated by stirring with Ac2O (1
mL) and pyridine (1 mL) for 4 h, and after concentration, the residue was purified by
column chromatography (toluene/EtOAc 7:3). To a solution of the residue in MeOH (1
mL) and H2O (0.5 mL) was added 0.5 M NaOH until pH 10 was reached. After stirring
overnight, Dowex H+ was added until pH 6, and the mixture was filtered and concentrated
to obtain 36. A solution of the residue in 0.1 M NaOH (1 mL) was added dropwise to a
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suspension of 10% Pd/C (2 mg) and NaBH4 (8.1 mg) in H2O (0.5 mL). After 30 min,
when TLC (EtOAc/MeOH/H2O 12:5:2) showed the formation of 37 as a ninhydrin-
positive spot on the baseline, the mixture was acidified with Dowex H+ (pH 4) and loaded
on a short column of Dowex 50 W × 2 (H+, 200-400 mesh). Contaminants were eluted
with water, and after elution with 1% NH4OH, 37 was obtained after concentration and
co-concentration with water (2x) (22 mg, 80%). [α]D20= -25 (c = 1, H2O); MS (MALDI-
TOF): m/z 252 [M+H]+, 274 [M+Na]+. For 1H NMR data, see Table 1.
General procedure for the elongation of 1, 2, 3, 35 and 37 with diethyl squarate: To a
solution of 3-aminopropyl glycoside (1 µmol) in 0.1 M sodium phosphate (40 µL for 35
and 37, 75 µL for 1-3; pH 6.9) was added a solution of diethyl squarate (1 µmol) in EtOH
(76.2 µL, stock solution of 24.9 µL diethyl squarate in 12.8 mL EtOH). After stirring for
16 h, EtOH was evaporated by flushing with N2. To the water layer was added H2O (35, 4
mL) or aqueous HOAc pH 4 (1-3, 37, 6 mL), and the mixture was loaded on a C18
Bakerbond spe column (500 mg). Rinsing with H2O (10 mL) eluted the starting material,
and elution with MeOH (4 mL) and evaporation of the solvent by flushing with N2,
afforded the pure elongated fragment that was used for the conjugation reaction.
General procedure for the conjugation of the elongated saccharides to a protein
carrier:
CRM197-conjugates: For a targeted oligosaccharide incorporation of about 11 mol mol
-1,
the elongated saccharide fragment (~1 µmol) was dissolved in 0.1 M sodium borate buffer
(400 µL; pH 9.5), and a solution of CRM197 (61.15 mg mL-1; 86 µL, 0.09 µmol) was
added. After stirring for two to three days, the mixture was diluted with H2O to a protein
concentration of 1 mg mL-1, samples were taken for MALDI-TOF analysis, and the
mixture was dialysed against 50 mM sodium phosphate buffer (pH 7.2). To obtain
different oligosaccharide loadings, the amount of elongated saccharide was varied. For
MALDI-TOF analysis, samples were mixed on the target plate in a ratio of 1:1 (v/v) with
the matrix 3,5-dimethoxy-4-hydroxycinnamic acid in 30% aqueous CH3CN containing
0.3% CF3COOH.
KLH-conjugates: The elongated saccharide fragment (~1 µmol) was dissolved in 0.1 M
sodium borate buffer (400 µL; pH 9.5), and a solution of KLH (50 mg mL-1; 75 µL for 1,
60 µL for 2, and 40 µL for 3) was added. After stirring for two to three days, the mixture
was diluted with 50 mM sodium phosphate buffer (pH 7.2) and dialysed against the same
buffer.
TT-conjugates: The elongated saccharide fragment (~1 µmol) was dissolved in 0.1 M
sodium borate buffer (300 µL; pH 9.5), and a solution of TT (6.12 mg mL-1; 0.61 mL for
1, 0.49 mL for 2, and 0.33 mL for 3) was added. The pH was adjusted to 9.5 by addition of
0.1 M NaOH. After stirring for two to three days, the reaction mixture was diluted with 50
mM sodium phosphate buffer (pH 7.2) and dialysed against the same buffer.
The protein concentrations of all conjugates were determined by the Pierce assay [34] and
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the carbohydrate content by MALDI-TOF (CRM197) or Dubois (KLH and TT) analysis
[33]. Coupling efficiencies (Tables 2 and 3) were expressed as percentage of the targeted
incorporation.
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Abstract
Di-, tri- and tetrasaccharides, synthesized according to the chemical structure of
pneumococcal polysaccharide type 3, were coupled to the cross-reacting material
(CRM197) of modified diphtheria toxin in different molar carbohydrate-protein
ratios using the squarate coupling method. To study protective immunity, female
BALB/c mice were immunized twice subcutaneously with a 3-week interval using
the amount of conjugates corresponding to 2.5 µg oligosaccharide per mouse. The
conjugates evoked polysaccharide type 3 (PS3) binding IgG antibodies that lasted
for at least 7 weeks after the booster. Immunogenicity was not influenced by the
carbohydrate-protein ratio. All mice with PS3 specific antibodies survived the
intraperitoneal challenge with S. pneumoniae type 3. Therefore, synthetic
oligosaccharide-protein conjugates might have potential as vaccines.
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Introduction
The encapsulated bacterium Streptococcus pneumoniae is still a major cause of
upper and lower respiratory tract infections. Of the 90 serotypes known, about 23
are causing the majority (~90 %) of pneumococcal infections such as otitis media,
pneumonia and meningitis [4]. S. pneumoniae type 3 strains are related to invasive
pneumococcal infection in adults [1,4] and are often used in experimental
meningitis [9] and otitis media models [7] in rabbits and rats. Furthermore, because
of the high virulence in mice, S. pneumoniae type 3 offers a good model to study
protective immunogenic properties of candidate vaccines [8,14,15].
Protection against encapsulated bacteria is primarily mediated by anticapsular
antibodies. However, capsular polysaccharides are thymus-independent type 2
antigens and thus induce low affinity antibodies that display a limited subclass
distribution. These antigens evoke no B-cell memory either. Vaccines consisting of
polysaccharides coupled to a protein carrier can circumvent these disadvantages
with an increased antibody response to capsular polysaccharides [3,11,16].
Neoglycoprotein preparations containing polysaccharides or oligosaccharide
fragments obtained by degradation of the polysaccharides are sometimes
contaminated with other pneumococcal components. They also have an ill-defined
structure due to multiple coupling sites or the use of oligosaccharide pools of
different chain lengths and they lose their reducing end upon conjugation to a
carrier. The use of small chemically synthesized oligosaccharides (OS) results in
conjugates with a precisely defined carbohydrate part. This offers a possibility to
evaluate the immunogenic properties of a conjugate vaccine by varying its specific
structural parameters, for example the length of the saccharide fragment and the
carbohydrate-protein ratio.
Materials and Methods
Oligosaccharide-protein conjugates were prepared as follows: the synthetic spacer-
containing monosaccharides β-D-Glcp-(1→O(CH2)3NH2 and β-D-GlcpA-
(1→O(CH2)3NH2, disaccharide β-D-GlcpA-(1→4)-β-D-Glcp-(1→O(CH2)3NH2,
trisaccharide β-D-Glcp-(1→3)-β-D-GlcpA-(1→4)-β-D-Glcp-(1→O(CH2)3NH2, and
tetrasaccharide β-D-GlcpA-(1→4)-β-D-Glcp-(1→4)-β-D-GlcpA-(1→4)-β-D-Glcp-
(1→O(CH2)3NH2 [6], representing fragments of the type 3 polysaccharide were
conjugated to the cross-reacting material (CRM197) of modified diphtheria toxin in
different molar carbohydrate-protein ratios using the squarate coupling method
[17]. The 3-aminopropyl glycoside (1 µmol) was dissolved in 0.1 M sodium
phosphate buffer (75 µL, pH 6.95), and a diethyl squarate solution (76.2 µL, 1
µmol) in EtOH (from 24.9 µL diethyl squarate in 12.8 mL EtOH) was added. After
stirring for16 h, EtOH was evaporated by flushing with N2, and the waterlayer was
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diluted with aq HOAc pH 4 (6 mL), and charged on a C18 Bakerbond speTM
column (500 mg). Rinsing with H2O (10 mL), elution with MeOH (4 mL), and
evaporation of the solvent by flushing with N2 afforded the pure, elongated
fragments. The elongated fragments were dissolved in 0.1 M borate buffer (400 µL,
pH 9.55) and the appropriate volume of CRM197 solution (61 mg/mL, from Chiron
vaccines, Siena, Italy) required for the target amount of oligosaccharide
incorporation was added. After stirring for two to three days, the mixture was
diluted with 50 mM sodium phosphate (pH 7.2) and dialyzed against the same
buffer. The protein concentrations were determined by the Pierce assay [13] and the
carbohydrate content by MALDI-TOF analysis. Schematic structures of the
conjugates are shown in Figure 1 and the carbohydrate-protein ratios in Table 1.
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Figure 1. Schematic structure of the saccharide-CRM197 conjugates.
Presented are the spacer-containing monosaccharides glucose and glucuronic acid,
and the di-, tri- and tetrasaccharide, representing fragments of the pneumococci
type 3 polysaccharide conjugated to CRM197 using the squarate coupling method.
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Table 1. Synthetic mono-, di-, tri-, and tetrasaccharide fragments of PS3 coupled to
CRM197 with different carbohydrate-protein ratios.
Conjugate[a] carbohydrate-protein ratios
     (µg/mg)          (mol/mol)
CRM-Glc 26 8.5
CRM-GlcA 22 6.6
CRM-Di 1 19 3.1
CRM-Di 2 41 6.7
CRM-Tri 1 44 4.9
CRM-Tri 2 61 6.8
CRM-Tri 3 107 12.0
CRM-Tetra 1 35 2.9
CRM-Tetra 2 80 6.7
CRM-Tetra 3 97 8.1
[a] After coupling and purification, conjugates were analyzed for protein content by
the Pierce assay and for carbohydrate content by MALDI-TOF analysis.
For the protection study inbred female BALB/c mice were obtained from the
Animal Laboratory of Utrecht University. The Ethics Committee on Animal
Experimentation of University Medical Center-Utrecht approved the animal
experiments described in this article. Mice of 8 to 10 weeks old were immunized
with the conjugates subcutaneously at four sites (2.5 µg saccharide per mouse) and
received a similar booster after 3 weeks. Control mice were injected with either
CRM197 alone, the monosaccharides Glc and GlcA coupled to CRM197, or the
buffer used for preparation of the conjugates. Blood samples were taken 1 day
before the booster and at week 2 and 5 after the booster. The mice were challenged
intraperitoneally 2 weeks after the last blood sampling with a 20 LD50 (400 c.f.u.)
dose of S. pneumoniae type 3 (ATTC 6303, Rockville, MD, USA). Survival of
mice was recorded daily for 14 days after which blood was withdrawn for
evaluation of the immune response after the infection.
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Antibodies binding to polysaccharide 3 (PS 3) were measured by ELISA. Plates
(Nunc Laboratories, Denmark) were coated with PS 3 (1 µg/mL in saline)
overnight at 37°C. After blocking with phosphate buffer solution pH 7.4 (PBS)-3%
gelatin, serum dilutions made in PBS, supplemented with 0.05% Tween 20 and 3%
Protifar (Nutricia, Zoetermeer, The Netherlands), were transferred to the coated
plates and incubated for 1 h at 37°C. After repeat washings the binding of IgM or
IgG antibodies was determined with goat-anti- mouse IgM or IgG coupled to
HRPO (Nordic Immunological Laboratories, CA, USA). The amount of bound
peroxidase was visualized by incubating with a solution of 3,3’,5,5’-
tetramethylbenzidine (Sigma Chemicals Co, St. Louis, MO, USA) and H2O2. After
20 min, the reaction was stopped with 0.1 M H2SO4 and optical density was
measured at 450 nm with a microplate reader (Bio-Rad, model 3550). Antibody
titres were defined as the log10 of the dilution giving twice the absorbance value
calculated against sera of control mice (immunized with the buffer), with a
minimum value of 0.2.
Results
Groups of four mice were immunized subcutaneously with oligosaccharide-protein
conjugates (2.5 µg carbohydrate per mouse). After the first immunization no IgM
or IgG PS3 binding antibodies were detected (data not shown). IgG antibodies were
present two weeks after the second immunization (data not shown) and titres did
not change after another three weeks. As shown in Table 2 all mice immunized
with the tri- and tetrasaccharide-CRM197 conjugates developed PS3 binding IgG
antibodies. In each of the two disaccharide-CRM197 immunized groups there was
one mouse in which antibodies were not detectable, even after the booster. The
mice immunized with the tenfold lower dose of the tetrasaccharide-2 conjugate
developed a slightly lower level of antibodies.
Upon intraperitoneal challenge with a lethal dose of S. pneumoniae type 3 all mice
with PS3-specific antibodies survived (Table 2). All control mice died within four
days, except two mice in the group injected with GlcA-CRM197. Two mice in each
of the disaccharide-CRM197 immunized groups, with no detectable antibodies, also
died. There was no influence of the saccharide density on the immunogenic
capacity of the conjugate vaccines.
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Table 2 Type-specific antibody response and outcome of infection in individual
mice.[a]
Conjugate 10 log IgG serum titers before
infection in individual mice
survival time of individual
mice in days
CRM <2 <2 <2 n.t.[b] 2 3 3 n.t.
CRM-Glc <2 <2 <2 <2 3 3 3 3
CRM-GlcA <2 <2 <2 <2 3 >14 >14 3
Buffer <2 <2 <2 n.t. 3 3 3 n.t.
CRM-Di 1 4.0 4.3 <2 4.2 >14 >14 4 >14
CRM-Di 2 2.8 3.1 <2 3.2 >14 >14 2 >14
CRM-Tri 1 4.6 4.0 3.4 3.7 >14 >14 >14 >14
CRM-Tri 2 4.7 4.0 4.7 4.5 >14 >14 >14 >14
CRM-Tri 3 4.5 4.3 4.4 4.3 >14 >14 >14 >14
CRM-Tetra 1 4.5 4.6 4.1 4.3 >14 >14 >14 >14
CRM-Tetra 2 3.4 4.1 4.7 3.4 >14 >14 >14 >14
CRM-Tetra 2
(0.25 µg)
n.t. <2.0 2.6 3.4 n.t. >14 >14 >14
CRM-Tetra 3 4.5 4.4 3.9 3.8 >14 >14 >14 >14
[a] Groups of 4 female BALB/c mice were immunized subcutaneously with 2.5 µg
saccharide as a protein conjugate. Control mice received CRM197 alone, CRM197
coupled to the monosaccharides Glc and GlcA or the buffer solution. One group
received a tenfold lower dose of CRM-Tetra 2 (0.25 µg saccharide). A similar
booster was given 3 weeks after the first injection. Blood samples were taken 2
weeks before the challenge and individual sera were tested for the presence of IgG
antibodies recognizing PS3. An intraperitoneal challenge with a 20 LD50 dose of
type 3 Streptococcus pneumoniae was given 7 weeks after the booster. Survival
was recorded daily for 14 days. [b] n.t. = not tested
Discussion
In earlier studies, Snippe et al. [15] demonstrated that a hexasaccharide, coupled
without spacer as a pentasaccharide to keyhole limpet haemocyanin (KLH), was
able to induce protective immunity against type 3 pneumococci in mice. A low
amount of IgM was measured one week after the first immunization and high levels
of IgG were detected after booster injections. Furthermore, Jansen et al. [2]
observed a protective immunity in mice after several injections with a synthetic
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tetrasaccharide-KLH conjugate related to type 6B polysaccharide whereas the di-
and trisaccharide-KLH conjugates induced a low antibody response with no or
partial protection against a lethal dose of type 6B pneumococci. Rabbits,
immunized with these conjugates developed antibodies, which could passively
protect mice. Our results show that for type 3, the disaccharide-conjugate is already
large enough to generate protection in mice without the use of adjuvant. The study
of Laferrière et al. [5] demonstrated that conjugation of a different carbohydrate
chain length (with an average length of 8, 16, 27 and 37 repeating units) derived
from type 3 polysaccharide to tetanus toxoid (TT) did not result in a distinct
immune response in rabbits. However, it should be noted that pools of average
chain lengths were used, which complicates interpretation of the results. Rabbits
immunized with those conjugates developed PS3 binding IgG antibodies but the
sera showed a low opsonophagocytic capacity. This suggests the absence of
protective antibodies since protection against pneumococci by type specific
antibodies is mediated by opsonization and phagocytosis of the bacteria. In the
previous study conjugates with carbohydrate chains of pneumococcal strains 6A,
18C, 19F and 23F induced in rabbits high levels of PS binding serum antibodies
with an effective opsonophagocytic capacity. Only in the case of the 19F-TT
conjugate a decrease in immunogenicity with increasing saccharide chain length
was observed. It was also demonstrated by Paoletti et al. [10] that in rabbits
immunized with on average 6, 14 and 25 repeating units of the polysaccharide of
group B Streptococcus type III conjugated to TT an opsonophagocytic immune
response could be evoked. These rabbit sera could passively protect mice against a
lethal dose of type III group B Streptococcus, although full protection was seen
only with the serum of 14-TT immunized rabbits. The study of Pozsgay et al. [12]
on Shigella dysenteriae type 1 using precisely defined synthetic oligosaccharide-
Human Serum Albumin (HSA) conjugates shows a different influence of the chain
length with different oligosaccharide loading, stressing the importance of varying
only one parameter. In our study we found a correlation between PS3 specific
antibodies and protective capacity of all conjugates. The mechanism of the
observed protection is not yet certain since the opsonophagocytic capacity of these
sera is still under investigation. Surprisingly, two mice immunized with the GlcA-
CRM197 conjugate did not develop detectable antibodies but were protected against
a lethal dose of S. pneumoniae. Two weeks after the infection, PS3 binding IgG
antibodies were present in serum taken from one of the protected mice (data not
shown), indicating that the mouse was primed by injection of the GlcA conjugate.
This suggests that GlcA is the immunodominant monosaccharide. A similar result
with a disaccharide conjugate was obtained by Wood and Kabat [18]. A low
immune response to dextran was observed in one out of four rabbits immunized
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with an isomaltose-stearylamine conjugate (stearyl-IM2). The reducing
monosaccharide was, however, lost during reductive amination, thus the terminal
monosaccharide glucose should be considered as the immunogenic moiety.
In our study, a change in carbohydrate-protein ratio of the conjugate vaccines did
not influence their immunogenic capacity. The study of Laferrière et al. [5] with
polysaccharide type 3 derived oligosaccharide-TT conjugates showed no relation
between the number of polysaccharide chains incorporated and the immunogenicity
of the conjugates. Investigations of Pozsgay et al. [12] with synthetic tetra-, octa-,
dodeca- and hexadecasaccharide fragments of the lipopolysaccharide (LPS) of
Shigella dysenteriae type 1 coupled to HSA showed high levels of LPS binding
IgG antibodies in mice after three injections except for the tetrasaccharide
conjugate which showed a low immunogenicity and was not further evaluated. The
influence of the carbohydrate-protein ratio was different for the three remaining
conjugates. The octasaccharide-HSA conjugate with the highest density evoked a
good immune response, while the dodeca- and hexadecasaccharide conjugates with
the median density showed to be the optimal immunogen. This is explained by the
authors by the ‘covering’ effect of the protein carrier by the saccharide chains,
which is related to the size of the saccharide and influences the availability of
antigenic peptides to associate with MHC class II molecules on B-cells and thus the
stimulation of T-cells. This could explain our results with short synthetic
saccharides that showed no differences in immunogenicity with different
carbohydrate-protein ratios, although, in the present study a different carrier protein
was used.
Studies performed with different oligosaccharide conjugate vaccines show that they
are good immunogenic, but the immunogenicity of these conjugates is not clearly
determined by chain length and saccharide density.
This indicates that the immunogenicity of saccharide conjugates depends on the
immunological properties of the saccharide and protein used. Furthermore,
oligosaccharides derived by acid hydrolysis of polysaccharides are mixtures of
oligosaccharides, differing in reducing and non-reducing ends. Also the coupling
methodology and the structure of the reducing monosaccharide after reduction can
influence the immunogenic properties of the conjugate. Saccharides synthesized
and coupled to the carrier protein in a well-controlled process, thereby varying only
one parameter, like used in our study, makes it possible to study the influence of
two parameters, chain length and density on the immunogenicity of conjugate
vaccines.
Important questions concerning the observed immune response remain and will be
subject for further study with regard to the nature of the protective immune
response we measured, such as opsonophagocytic capacity, subclass distribution
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and change in antigenic specificity, like the immune response against proteins and
other pneumococcal components in sera taken before and after challenge with
viable S. pneumoniae.
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4Synthesis of a hexasaccharide
fragment of the capsular
polysaccharide of Streptococcus
pneumoniae type 3
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Vliegenthart
Abstract
In the framework of the development of a new generation of neoglycoconjugate
vaccines against Streptococcus pneumoniae, the synthesis is described of a spacer-
containing hexasaccharide fragment related to the capsular polysaccharide of
Streptococcus pneumoniae type 3. β-D-GlcpA-(1→4)-β-D-Glcp-(1→3)-β-D-
GlcpA-(1→4)-β-D-Glcp-(1→3)-β-D-GlcpA-(1→4)-β-D-Glcp-(1→O-(CH2)3NH2
(1), comprising three repeating units, was synthesised via a blockwise strategy
employing suitably protected disaccharide building blocks. Carboxylic groups were
introduced by selective oxidation with TEMPO (2,2,6,6-tetramethyl-1-
piperidinyloxy) in the last reaction steps. Deprotection afforded target
hexasaccharide 1.
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Introduction
Diseases caused by encapsulated bacteria can be prevented by vaccination with
neoglycoconjugate vaccines as proven for Haemophilus influenzae type b [1],
Neisseria meningitidis type C [2] and Streptococcus pneumoniae serotypes [3].
These vaccines are prepared by conjugation of isolated polysaccharide or a mixture
of polysaccharide-derived oligosaccharides to a protein carrier. For a detailed
investigation of the immune response of this type of vaccines, neoglycoproteins
with a well-defined carbohydrate structure need to be available.
Neoglycoconjugates related to S. pneumoniae type 3 have been prepared by
coupling di-, tri- or tetrasaccharide fragments in several carbohydrate-protein ratios
to a non-toxic mutant of diphtheria toxin (CRM197) [4]. Whereas immunisation
experiments with these conjugates in mice showed that increasing IgG antibody
titres were found with increasing oligosaccharide chain length, no difference was
found with respect to the oligosaccharide loading [5].
The use of conjugates that contain larger oligosaccharide fragments than in the
study described above might lead to an improved immunogenicity. Furthermore,
human antibodies can recognise larger epitopes on the polysaccharide than do
animal antibodies, as shown for neoglycoproteins consisting of synthetic
oligosaccharides related to the capsular polysaccharide of S. pneumoniae type 23F
[6]. For these reasons, a program was started for the synthesis of a S. pneumoniae
type 3 related hexasaccharide fragment (1), comprising three cellobiuronic acid
repeating units (Figure 1).
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Figure 1. Target hexasaccharide 1 comprising three repeating units of the capsular
polysaccharide of Streptococcus pneumoniae type 3.
Results and discussion
Previously, the synthesis was described of tetrasaccharide acceptor 11 [4]. Two
disaccharide donors (6 and 10, Scheme 1) were tested for the coupling with 11 to
afford protected hexasaccharide 12 (Scheme 2).
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Scheme 1. Synthesis of disaccharide donors 6 and 10. Reagents and conditions: a)
CF3COOH, H2O, CH2Cl2, 88%; b) PhCOCl, Et3N, CH2Cl2, 50%; c) 10% TMSOTf,
CH2Cl2, 75%; d) 11% TMSOTf, CH2Cl2, 83%; e) i (PPh3)3Rh(I)Cl, DABCO,
CH3C6H5/EtOH/CH2Cl2 10:5:1, ii NIS, H2O, THF, 68%; f) Cl3CCN, DBU, CH2Cl2,
86%.
For the synthesis of disaccharide thioethyl donor 6, first monosaccharide acceptor 4
was prepared by debenzylidenation of 2 [7] using trifluoroacetic acid (→3, 88%),
and subsequent selective benzoylation using benzoyl chloride (→4, 50%).
Coupling of 4 with imidate donor 5 [4] using 10% TMSOTf as a promoter gave 6
in a yield of 75%. For the synthesis of disaccharide imidate donor 10, first 8 was
prepared in 83% yield by coupling of acceptor 7 [4] and donor 5 with 11%
TMSOTf as a promoter. Then, deallylation of 8 using
tris(triphenylphosphine)rhodium(I) chloride and N-iodosuccinimide (→ 9, 68%)
and subsequent trichloroacetimidation gave 10 (86%).
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Scheme 2. Synthesis of hexasaccharide 1. Reagents and conditions: a) 10%
TMSOTf, CH2Cl2, 63%; b) CF3COOH, H2O, CH2Cl2, 75%; c) TEMPO, aqueous
NaOCl, KBr, Bu4NBr, aqueous NaCl, aqueous NaHCO3, CH2Cl2, 70%; d) i
NaOMe, MeOH (pH 10), ii NaBH4, 10% Pd/C, 0.05 M NaOH, 61%.
For the preparation of protected hexasaccharide 12 (Scheme 2), tetrasaccharide
acceptor 11 [4] was coupled with donor 6 using N-iodosuccinimide and triflic acid
as a promoter system. Low yields of product (< 8%) were obtained when the
reaction was performed at 0 °C or lower temperatures. Hexasaccharide 12 could,
however, be obtained in a yield of 63% by coupling of 11 with disaccharide
imidate donor 10 using 10% TMSOTf as a promoter at room temperature. After
debenzylidenation of 12 using trifluoroacetic acid (→13, 75%), the free primary
hydroxyl functions were oxidised. Treatment of 13 with TEMPO and sodium
hypochlorite [8] was found to be efficient for the oxidation of the three primary
hydroxyl groups in the presence of secondary functions, and 14 was obtained in
70% yield. 1H NMR analysis after methylation with diazomethane showed three
singlets at δ = 3.39, 3.30 and 3.23 (COOCH3). Debenzoylation of 14 with sodium
methoxide and reduction of the azide using sodium borohydride and 10% Pd/C
afforded target hexasaccharide 1 in 61% yield. The identity of the compound was
established by 1H NMR spectroscopy (Table 1) and mass spectrometry.
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Table 1. 500 MHz 1H NMR data of 1 at 305K (in ppm)[a]. J1,2 couplings are
presented in parentheses.
H-1 H-2 H-3 H-4 H-5 H-6a H-6b
Glca 4.50
(7.8)
3.33 3.64 3.61 n.d.[b] 3.98 3.80
GlcAb 4.53
(8.1)
3.56 3.79 n.d n.d
Glcc 4.82
(8.0)
3.38 3.65 3.62 n.d 3.98 3.80
GlcAd 4.53
(8.1)
3.56 3.79 n.d n.d
Glce 4.82
(8.0)
3.38 3.65 3.62 n.d 3.98 3.80
GlcAf 4.50
(7.8)
3.36 3.51 3.51 3.75
[a] The signals for the 3-aminopropyl spacer are: δ = 4.05 and 3.83
(OCH2CH2CH2NH2), 3.16 (OCH2CH2CH2NH2), 2.01 (OCH2CH2CH2NH2). [b] n.d.
= not determined.
In conclusion, a versatile synthetic route was developed using a blockwise strategy
for the preparation of hexasaccharide fragment 1, representing three repeating units
of the capsular polysaccharide of S. pneumoniae type 3. The carboxylic acids were
efficiently introduced by selective oxidation using TEMPO.
Acknowledgements
This work was supported by the European Union program VACNET (grant ERB
BIO 4CT960158).
Experimental section
General: All chemicals were of reagent grade, and were used without any further
purification. Reactions were monitored by TLC on Silica gel 60 F254 (Merck); compounds
were visualised, after examination under UV light, by heating with 10% (v/v) ethanolic
H2SO4, orcinol (2 mg mL
-1) in 20% (v/v) methanolic H2SO4, or ninhydrin (1.5 mg mL
-1)
in BuOH/H2O/HOAc (38:1.75:0.25). In the work-up procedures of reaction mixtures,
organic solutions were washed with appropriate amounts of the indicated aqueous
solutions, then dried (MgSO4), and concentrated under reduced pressure at 20-40 °C on a
water-bath. Column chromatography was performed on Silica gel 60 (Merck, 0.063-0.200
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mm). Optical rotations were measured in CHCl3, unless stated otherwise, with a Perkin-
Elmer 241 polarimeter, using a 10-cm l-mL cell. 1H NMR spectra in CDCl3 were recorded
at 27 °C with a Bruker AC 300 spectrometer; the δH values are given in ppm relative to the
signal for internal Me4Si (δ = 0). 13C (APT, 75 MHz) NMR spectra in CDCl3 were
recorded at 27 °C with a Bruker AC 300 spectrometer; indicated ppm values for δC are
relative to the signal of CDCl3 (δ = 76.9). The 1H NMR spectrum of 1 was recorded in
D2O at 32 °C with a Bruker AMX 500 spectrometer, and the δH values are given in ppm
relative to the signal for internal acetone (δ = 2.225). Two-dimensional TOCSY and
ROESY spectra were recorded using a Bruker AMX 500 apparatus (500 MHz) to assign
the spectra of compounds 1, 12, 13, and 14. Residues a-f (Figure 1) were assigned on the
basis of interglycosidic ROESY cross-peaks. Matrix-assisted laser desorption ionisation
time-of-flight (MALDI-TOF) spectra were obtained on a Voyager-DE mass
spectrometer using 2,4-dihydroxybenzoic acid (DHB) in H2O as a matrix. Elemental
analyses were carried out by H. Kolbe Mikroanalytisches Laboratorium (Mülheim an der
Ruhr, Germany).
Ethyl 2,3-di-O-benzoyl-1-thio-β-D-glucopyranoside (3): To a solution of ethyl 2,3-di-O-
benzoyl-4,6-O-benzylidene-1-thio-β-D-glucopyranoside 2 [7] (1.37 g, 2.63 mmol) in
CH2Cl2 (36 mL) were added CF3COOH (1.5 mL) and H2O (0.2 mL). The mixture was
stirred for 16 h, diluted with CH2Cl2, washed with 10% (w/v) aqueous NaHCO3 until
neutral pH and 10% (w/v) aqueous NaCl, and the organic layer was dried, filtered, and
concentrated. The residue was purified by column chromatography (CH2Cl2/MeOH 98:2)
to obtain 3 (1.0 g, 88%). Rf 0.05 (CH2Cl2/EtOAc 9:1); [α]D20= +76 (c = 1); 1H NMR
(CDCl3): δ = 7.97-7.93 and 7.53-7.34 (2 m, 10 H; 2 PhCO), 4.74 (d, J1,2 = 9.8 Hz, 1 H; H-
1), 2.76-2.73 (m, 2 H; SCH2CH3), 1.26 (t, 3 H; SCH2CH3); 
13C NMR (CDCl3): δ = 167.4
and 165.2 (2 PhCO), 129.1 and 128.7 (2 PhCO, quaternary C), 83.6 (C-1), 79.9, 78.2,
70.1, and 69.9 (C-2,3,4,5), 62.3 (C-6), 24.3 (SCH2CH3), 14.8 (SCH2CH3); elemental
analysis calcd (%) for C22H24O7S (432.4): C 61.11, H 5.59; found C 60.99, H 5.74.
Ethyl 2,3,6-tri-O-benzoyl-1-thio-β-D-glucopyranoside (4): To a solution of 3 (0.95 g,
2.2 mmol) in CH2Cl2 (50 mL) and Et3N (0.37 mL) at 0 °C was added dropwise a solution
of benzoyl chloride (0.27 mL, 2.3 mmol) in CH2Cl2 (10 mL). After stirring for 24 h, the
mixture was diluted with CH2Cl2, washed with 10% (w/v) aqueous NaCl, and the organic
layer was dried, filtered, and concentrated. The crude residue was purified by column
chromatography (CH2Cl2/EtOAc 95:5) to give 4 (0.6 g, 50%). Rf 0.51 (CH2Cl2/EtOAc
9:1); [α]D20= +60 (c = 1); 1H NMR (CDCl3): δ = 8.05-7.91 and 7.46-7.28 (2 m, 15 H; 3
PhCO), 5.60 and 5.47 (2 t, J2,3, J3,4 = 9.5, 9.7 Hz, each 1 H; H-2,3), 4.82 (d, J1,2 = 9.9 Hz,
1 H; H-1), 2.82-2.64 (m, 2 H; SCH2CH3), 1.24 (t, 3 H; SCH2CH3); 
13C NMR (CDCl3): δ
= 166.8, 166.7, and 165.2 (3 PhCO), 83.4 (C-1), 78.2, 77.2, 70.2, and 69.3 (C-2,3,4,5),
63.6 (C-6), 24.1 (SCH2CH3), 14.8 (SCH2CH3); elemental analysis calcd (%) for
C29H28O8S (536.5): C 64.92, H 5.26; found C 65.05, H 5.31.
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Ethyl (2,3-di-O-benzoyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1→4)-2,3,6-tri-O-
benzoyl-1-thio-β-D-glucopyranoside (6): A solution of 4 (50 mg, 0.09 mmol) and 2,3-di-
O-benzoyl-4,6-O-benzylidene-D-glucopyranosyl trichloroacetimidate 5 [4] (87 mg, 0.14
mmol) in dry CH2Cl2 (2 mL), containing 4 Å molecular sieves, was stirred under Ar for 1
h. Then, TMSOTf (2.5 µL, 14 µmol) was added. After 30 min, the mixture was neutralised
with dry pyridine, filtered over cotton, diluted with CH2Cl2, and washed with 10% (w/v)
aqueous NaCl. The organic layer was dried, filtered, and concentrated. The residue was
purified by column chromatography (toluene/EtOAc 95:5) to obtain 6 (67 mg, 75%). Rf
0.76 (CH2Cl2/EtOAc 9:1); [α]D20= +41 (c = 1); 1H NMR (CDCl3): δ = 8.05-7.85 and
7.49-7.31 (2 m, 30 H; PhCH, 5 PhCO), 5.74, 5.61, and 5.42 (3 t, J2,3, J3,4, J3',4' = 9.3, 9.6,
9.8 Hz, each 1 H; H-2,3,3'), 5.44 (dd, J1',2' = 7.7, J2',3' = 9.5 Hz, 1 H; H-2'), 5.20 (s, 1 H;
PhCH), 4.83 (d, 1 H; H-1'), 4.68 (d, J1,2 = 9.9 Hz, 1 H; H-1), 4.49 (dd, J5,6a = 2.1, J6a,6b =
12.2 Hz, 1 H; H-6a), 4.40 (dd, J5,6b = 4.8 Hz, 1 H; H-6b), 3.77 (ddd, 1 H; H-5), 3.61 (dd,
J5',6a' = 4.9, J6a',6b' = 10.6 Hz, 1 H; H-6a'), 3.32 (ddd, J5',6b' = 10.4 Hz, 1 H; H-5'), 2.82 (dd,
1 H; H-6b'), 2.70-2.56 (m, 2 H; SCH2CH3), 1.16 (t, 3 H; SCH2CH3); 
13C NMR (CDCl3): δ
= 136.4 (PhCH, quaternary C), 101.7 and 101.1 (PhCH, C-1'), 83.3 (C-1), 67.5 (C-6'),
62.5 (C-6), 24.2 (SCH2CH3), 14.8 (SCH2CH3); elemental analysis calcd (%) for
C56H50O15S (995.0): C 67.59, H 5.06; found C 67.56, H 5.01.
Allyl (2,3-di-O-benzoyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1→4)-2,3,6-tri-O-
benzoyl-β-D-glucopyranoside (8): A solution of allyl 2,3,6-tri-O-benzoyl-β-D-
glucopyranoside 7 [4] (0.48 g, 0.93 mmol) and 2,3-di-O-benzoyl-4,6-O-benzylidene-D-
glucopyranosyl trichloroacetimidate 5 [4] (1.02 g, 1.64 mmol) in dry CH2Cl2 (15 mL),
containing 4 Å molecular sieves, was stirred under Ar for 1 h. Then, TMSOTf (35 µL,
0.19 mmol) was added. After 45 min, the mixture was neutralised with dry pyridine,
filtered over cotton, diluted with CH2Cl2, and washed with 10% (w/v) aqueous NaCl. The
organic layer was dried, filtered, and concentrated. The residue was purified by column
chromatography (toluene/EtOAc 95:5) to obtain 8 (0.76 g, 83%). Rf 0.37 (toluene/EtOAc
9:1); [α]D20= +27 (c = 1); 1H NMR (CDCl3): δ = 8.05-7.85 and 7.50-7.25 (2 m, 30 H;
PhCH, 5 PhCO), 5.78-5.65 (m, 1 H; OCH2CH=CH2), 5.72 and 5.60 (2 t, J2,3 = J2',3' = 9.6,
J3,4 = J3',4' = 9.5 Hz, each 1 H; H-3,3'), 5.43 and 5.40 (2 dd, J1,2, J1',2' = 7.7, 7.8 Hz, each 1
H; H-2,2'), 5.21 (s, 1 H; PhCH), 5.17-5.10 and 5.08-5.03 (2 m, each 1 H; OCH2CH=CH2),
4.83 and 4.72 (2 d, each 1 H; H-1,1'), 4.49 (dd, J5,6a = 2.1, J6a,6b = 12.1 Hz, 1 H; H-6a),
4.39 (dd, J5,6b = 4.5 Hz, 1 H; H-6b), 4.27-4.20 and 4.07-3.99 (2 m, each 1 H;
OCH2CH=CH2), 4.11 and 3.63 (2 t, J4,5, J4',5' = 9.2, 9.5 Hz, each 1 H; H-4,4'), 3.76 (ddd, 1
H; H-5), 3.61 (dd, J5',6a' = 4.6, J6a',6b' = 10.6 Hz, 1 H; H-6a'), 3.31 (ddd, J5',6b' = 10.6 Hz, 1
H; H-5'), 2.83 (t, 1 H; H-6b'); 13C NMR (CDCl3): δ = 165.4, 165.2, 165.0, 164.9, and
164.7 (5 PhCO), 136.4 (PhCH, quaternary C), 117.5 (OCH2CH=CH2), 101.7, 101.0, and
99.2 (PhCH, C-1,1'), 69.7 (OCH2CH=CH2), 67.4 (C-6'), 62.2 (C-6). Elemental analysis
calcd (%) for C57H50O16 (991.0): C 69.08, H 5.08; found C 69.16, H 5.05.
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(2,3-Di-O-benzoyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1→4)-2,3,6-tri-O-benzoyl-
D-glucopyranose (9): To a solution of 8 (1.5 g, 1.5 mmol) in absolute EtOH (40 mL),
toluene (80 mL), and CH2Cl2 (8 mL) were added a catalytic amount of
diazabicyclo[2.2.2]octane (DABCO) and tris(triphenylphosphine)rhodium(I) chloride (0.4
g). After stirring at boiling under reflux for 4 h, the mixture was concentrated. The residue
was dissolved in THF (75 mL), and water (10 mL) and NIS (0.6 g) were added. After 20
min, the mixture was concentrated, diluted with CH2Cl2, washed with 10% (w/v) aqueous
NaHSO3 (2 x) and 10% (w/v) aqueous NaCl, and the organic layer was dried, filtered, and
concentrated. The crude residue was purified by column chromatography. Impurities were
eluted with toluene/EtOAc (95:5), and 9 was obtained as a light brown syrup by elution
with toluene/EtOAc (9:1) (0.99 g, 68%). Rf 0.17
α/0.08ß (toluene/EtOAc 8:2); 1H NMR
(CDCl3): δ = 8.08-7.85 and 7.49-7.23 (2 m, 30 H; PhCH, 5 PhCO), 5.63 (t, J3',4' = 9.6 Hz,
1 H; H-3'), 5.46 (dd, J1',2' = 7.7, J2',3' = 9.5 Hz, 1 H; H-2'), 5.23 (s, 1 H; PhCH), 4.89 (d, 1
H; H-1'), 4.49 (dd, J5,6a = 2.0, J6a,6b = 12.3 Hz, 1 H; H-6a), 4.40 (dd, J5,6b = 3.8 Hz, 1 H;
H-6b), 3.63 (dd, J5',6a' = 4.9, J6a',6b' = 10.6 Hz, 1 H; H-6a'), 3.32 (dt, J5',6b' = 10.4 Hz, 1 H;
H-5'), 2.94 (t, 1 H; H-6b'); 13C NMR (CDCl3): δ = 165.8, 165.4, 165.0 (2 C), and 164.9 (5
PhCO), 136.5 (PhCH, quaternary C), 101.9 and 101.1 (PhCH, C-1'), 95.5 and 90.1 (C-
1α,1ß), 67.7 (C-6'), 62.0 (C-6); elemental analysis calcd (%) for C54H46O16 (951.0): C
68.21, H 4.87; found C 68.16, H 5.02.
(2,3-Di-O-benzoyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1→4)-2,3,6-tri-O-benzoyl-
α-D-glucopyranosyl trichloroacetimidate (10): To a solution of 9 (1.0 g, 1.1 mmol) in
dry CH2Cl2 (14 mL) were added Cl3CCN (1.2 mL) and DBU (40 µL). After stirring for 16
h, the mixture was concentrated and the residue was purified by column chromatography
(toluene/EtOAc 88:12) to yield 10 (0.99 g, 86%). Rf 0.32 (toluene/EtOAc 9:1); [α]D20=
+83 (c = 1); 1H NMR (CDCl3): δ = 8.55 (s, 1 H; NH), 8.08-7.85 and 7.47-7.16 (2 m, 30 H;
PhCH, 5 PhCO), 6.68 (d, J1,2 = 3.7 Hz, 1 H; H-1), 6.12 (dd, J2,3 = 10.2, J3,4 = 8.6 Hz, 1 H;
H-3), 5.66 (t, J2',3' = J3',4' = 9.6 Hz, 1 H; H-3'), 5.49 (dd, 1 H; H-2), 5.48 (dd, J1',2' = 7.7 Hz,
1 H; H-2'), 5.25 (s, 1 H; PhCH), 4.95 (d, 1 H; H-1'), 4.54 (dd, J5,6a = 2.0, J6a,6b = 12.2 Hz,
1 H; H-6a), 4.44 (dd, J5,6b = 3.8 Hz, 1 H; H-6b), 4.30 (ddd, J4,5 = 10.0 Hz, 1 H; H-5), 4.22
(dd, 1 H; H-4), 3.69 (t, J4',5' = 9.5 Hz, 1 H; H-4'), 3.64 (dd, J5',6a' = 4.8, J6a',6b' = 10.5 Hz, 1
H; H-6a'), 3.34 (dt, J5',6b' = 10.3 Hz, 1 H; H-5'), 2.99 (t, 1 H; H-6b'); 
13C NMR (CDCl3): δ
= 165.4, 165.3 (2 C), and 164.8 (2 C) (5 PhCO), 160.3 (OC(NH)CCl3), 136.4 (PhCH,
quaternary C), 101.8 and 101.1 (PhCH, C-1'), 92.8 (C-1), 67.6 (C-6'), 61.6 (C-6).
3-Azidopropyl (2,3-di-O-benzoyl-4,6-O-benzylidene-β-D-glucopyranosyl) - (1→4) -
(2,3,6-tri-O-benzoyl-β-D-glucopyranosyl) - (1→3) - (2-O-benzoyl-4,6-O-benzylidene-
β-D-glucopyranosyl) - (1→4) - (2,3,6-tri-O-benzoyl-β-D-glucopyranosyl) - (1→3) - (2-
O-benzoyl-4,6-O-benzylidene-β-D-glucopyranosyl) - (1→4) - 2,3,6-tri-O-benzoyl-β-D-
glucopyranoside (12): A solution of 10 (70 mg, 63 µmol) and 11 [4] (65 mg, 35 µmol) in
dry CH2Cl2 (1 mL), containing 4 Å molecular sieves, was stirred under Ar for 1 h. Then,
TMSOTf (1.1 µL, 6 µmol) was added. After 30 min, the mixture was neutralised with dry
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pyridine, filtered over cotton, diluted with CH2Cl2, and washed with 10% (w/v) aqueous
NaCl. The organic layer was dried, filtered, and concentrated. The residue was purified by
column chromatography (toluene/EtOAc 95:5) to obtain 12 (59 mg, 63%). Rf 0.46
(toluene/EtOAc 9:1); [α]D20= +59 (c = 1); 1H NMR (CDCl3): δ = 5.56 (t, 1 H; H-3a), 5.45
(t, 1 H; H-3f), 5.38 (t, 1 H; H-3e), 5.29 (t, 1 H; H-3c), 5.26 (H-2a,2f), 5.16 (H-2e), 5.15 (H-
2b), 5.14 (H-2c), 5.12 (2 H) and 5.09 (2 s, 3 PhCH), 5.06 (H-2d), 4.67 (d, J1,2 = 7.8 Hz, 1
H; H-1e), 4.64 (d, J1,2 = 7.8 Hz, 1 H; H-1
c), 4.59 (d, J1,2 = 7.8 Hz, 1 H; H-1
f), 4.54 (d, J1,2 =
7.8 Hz, 1 H; H-1a), 4.50 (d, J1,2 = 7.8 Hz, 1 H; H-1
b), 4.34 (d, J1,2 = 7.8 Hz, 1 H; H-1
d),
3.97 (t, 1 H; H-4e), 3.90 (t, 2 H; H-4a,3b), 3.85 (t, 1 H; H-3d), 3.84 (t, 1 H; H-4c), 3.77 and
3.45 (OCH2CH2CH2N3), 3.55 (H-5
a), 3.25 (H-5e), 3.21 (H-5c), 3.12 (OCH2CH2CH2N3),
3.05 (H-5b), 2.93 (H-5d), 2.66 (H-6f), 2.65 (H-6b), 2.53 (H-6d), 1.72-1.57 (m, 2 H;
OCH2CH2CH2N3); 
13C NMR (CDCl3): δ = 136.4 (PhCH, quaternary C), 101.4, 101.3 (2
C), 101.1, 100.9 (2 C), 100.6, 99.8, and 99.7 (3 PhCH, C-1a,1b,1c,1d,1e,1f), 66.2
(OCH2CH2CH2N3), 47.6 (OCH2CH2CH2N3), 28.7 (OCH2CH2CH2N3); MS (MALDI-TOF):
m/z 2713 [M+Na]+.
3-Azidopropyl (2,3-di-O-benzoyl-β-D-glucopyranosyl) - (1→4) - (2,3,6-tri-O-benzoyl-
β-D-glucopyranosyl) - (1→3) - (2-O-benzoyl-β-D-glucopyranosyl) - (1→4) - (2,3,6-tri-
O-benzoyl-β-D-glucopyranosyl) - (1→3) - (2-O-benzoyl-β-D-glucopyranosyl) - (1→4) -
2,3,6-tri-O-benzoyl-β-D-glucopyranoside (13): To a solution of 12 (84 mg, 31 µmol) in
CH2Cl2 (0.85 mL) were added CF3COOH (75 µL) and H2O (75 µL). The mixture was
stirred for 4 h, diluted with CH2Cl2, washed with 10% (w/v) aqueous NaHCO3 until
neutral pH and 10% (w/v) aqueous NaCl, and the organic layer was dried, filtered, and
concentrated. The residue was purified by column chromatography (toluene/EtOAc
6:4→4:6) to obtain 13 (55 mg, 75%). Rf 0.21 (toluene/EtOAc 1:1); [α]D20= +45 (c = 1);
1H NMR (CDCl3): δ = 5.57 (t, 1 H; H-3e), 5.50 (t, 1 H; H-3a), 5.39 (t, 1 H; H-3c), 5.33 (dd,
1 H; H-2f), 5.31 (dd, 1 H; H-2a), 5.30 (dd, 1 H; H-2e), 5.25 (t, 1 H; H-3f), 5.23 (dd, 1 H; H-
2c), 5.03 (bt, 2 H; H-2b,2d), 4.76 (d, J1,2 = 7.7 Hz, 1 H; H-1
f), 4.63 (2 H; H-1e,6e), 4.53 (d,
1 H; H-1a), 4.52 (d, 1 H; H-1c), 4.43 (d, J1,2 = 8.0 Hz, 1 H; H-1
b), 4.42 (d, J1,2 = 8.0 Hz, 1
H; H-1d), 4.31 (3 H; H-6aa,6ac,6e), 4.18 (dd, 1 H; H-6ba), 4.14 (dd, 1 H; H-6bc), 3.99 (t, 1
H; H-4e), 3.98 (t, 1 H; H-4a), 3.83 (t, 1 H; H-4c), 3.82 (H-5e), 3.78 and 3.45
(OCH2CH2CH2N3), 3.73 (H-4
f), 3.58 (t, 1 H; H-3d), 3.56 (H-5c), 3.54 (H-5a), 3.51 (t, 1 H;
H-3b), 3.36 (H-4d), 3.32 (H-4b), 3.23 (H-5f), 3.15-3.09 (m, 2 H; OCH2CH2CH2N3), 3.00
(H-5d), 2.96 (H-5b), 1.72-1.55 (m, 2 H; OCH2CH2CH2N3); 
13C NMR (CDCl3): δ = 101.1
(2 C), 100.6 (3 C), and 100.5 (C-1a,1b,1c,1d,1e,1f), 66.2 (OCH2CH2CH2N3), 62.2, 62.1,
62.0 (2 C), 61.8, and 61.3 (C-6a,6b,6c,6d,6e,6f), 47.6 (OCH2CH2CH2N3), 28.7
(OCH2CH2CH2N3); MS (MALDI-TOF): m/z 2440 [M+Na]
+.
3-Azidopropyl (2,3-di-O-benzoyl-β-D-glucopyranosyluronic acid) - (1→4)-(2,3,6-tri-
O-benzoyl-β-D-glucopyranosyl) - (1→3) - (2-O-benzoyl-β-D-glucopyranosyluronic
acid) - (1→4) - (2,3,6-tri-O-benzoyl-β-D-glucopyranosyl) - (1→3) - (2-O-benzoyl-β-D-
glucopyranosyluronic acid) - (1→4) - 2,3,6-tri-O-benzoyl-β-D-glucopyranoside (14):
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To a solution of 13 (50 mg, 21 µmol) in CH2Cl2 (0.22 mL) were added TEMPO (catalytic
amount), and 40 µL of a solution of KBr (2.4 mg) and Bu4NBr (3.2 mg) in saturated
aqueous NaHCO3 (0.4 mL). The mixture was stirred vigorously at 0 °C, when 122 µL of a
solution of saturated aqueous NaCl (0.44 mL), saturated aqueous NaHCO3 (0.22 mL), and
aqueous NaOCl (13% Cl active; 0.56 mL) was added dropwise. After 45 min, the mixture
was acidified with 4 M HCl (pH 4), diluted with CH2Cl2, and the organic layer was
washed with 10% (w/v) aqueous NaCl, dried, filtered, and concentrated. The residue was
purified by column chromatography. Impurities were eluted with CH2Cl2/acetone (8:2),
and 14 (35 mg, 70%) was eluted with CH2Cl2/acetone/HOAc (8:2:0.5). Rf 0.05
(CH2Cl2/acetone/HOAc 8:2:1); MS (MALDI-TOF): m/z 2490 [M+Na]
+, 2512 [M-
H+2Na]+, 2534 [M-2H+3Na]+, 2556 [M-3H+4Na]+.
A small amount was methylated with diazomethane in methanol for analysis. 1H NMR
(CDCl3): δ = 5.55 (t, 1 H; H-3e), 5.54 (t, 1 H; H-3a), 5.39 (t, 1 H; H-3c), 5.36 (2 H; H-
2f,3f), 5.26 (dd, J1,2 = 7.8, J2,3 = 9.6 Hz, 1 H; H-2
e), 5.20 (dd, J1,2 = 7.8, J2,3 = 9.5 Hz, 1 H;
H-2a), 5.15 (dd, J2,3 = 9.7 Hz, 1 H; H-2
c), 5.08 (2 t, each 1 H; H-2b,2d), 4.83 (d, J1,2 = 7.6
Hz, 1 H; H-1f), 4.65 (d, 1 H; H-1e), 4.61 (dd, 1H; H-6e), 4.53 (d, J1,2 = 8.0 Hz, 2 H; H-
1b,1c), 4.52 (d, 1 H; H-1a), 4.48 (d, J1,2 = 7.9 Hz, 1 H; H-1
d), 4.38 (dd, 1 H; H-6aa), 4.33
(dd, 1 H; H-6ac), 4.28 (dd, 1 H; H-6be), 4.17 (dd, 1 H; H-6ba), 4.13 (dd, 1 H; H-6bc), 4.10
(t, 1 H; H-4e), 4.04 (t, 1 H; H-4a), 3.91 (H-4f), 3.90 (t, 1 H; H-4c), 3.81 (H-5e), 3.78 and
3.44 (OCH2CH2CH2N3), 3.76 (H-4
d), 3.74 (H-4b), 3.69 (H-5f), 3.63 (t, 1 H; H-3d), 3.57 (t,
1 H; H-3b), 3.56 (H-5c), 3.55 (H-5a), 3.51 (d, J4,5 = 9.6 Hz, 1 H; H-5
d), 3.49 (d, J4,5 = 9.6
Hz, 1 H; H-5b), 3.39, 3.30, and 3.23 (3 s, each 3 H; COOCH3), 3.09 (OCH2CH2CH2N3),
1.70-1.59 (m, 2 H; OCH2CH2CH2N3).
3-Aminopropyl (β-D-glucopyranosyluronic acid)-(1→4)-(β-D-glucopyranosyl)-(1→3)-
(β-D-glucopyranosyluronic acid)-(1→4)-(β-D-glucopyranosyl)-(1→3)-(β-D-
glucopyranosyluronic acid)-(1→4)-β-D-glucopyranoside (1): To a solution of 14 (20
mg, 8 µmol) in MeOH (3 mL) was added NaOMe until pH 10, and after 5 h, water (1 mL)
was added. After stirring for 16 h, TLC (EtOAc/MeOH/H2O 12:5:3) showed the formation
of a new spot (Rf 0.1), and the mixture was neutralised with Dowex H
+, filtered, and
concentrated. A solution of the residue in water was washed with CH2Cl2 (3x), and the
aqueous layer was concentrated. Then, a solution of the residue in 0.1 M NaOH (0.4 mL)
was added dropwise to a suspension of 10% Pd/C (0.8 mg) and NaBH4 (3.5 mg) in
bidistilled water (0.3 mL). After 2 h, when TLC (EtOAc/MeOH/H2O 12:5:3) showed the
formation of a ninhydrin-positive spot on the baseline, the mixture was acidified with
Dowex H+ (pH 4), then loaded on a short column of Dowex 50 W × 2 (H+, 200-400
mesh). After elution of contaminants with water, elution with 1% NH4OH afforded 1 after
concentration and lyophilisation from water (2x) (5.4 mg, 61%). [α]D20= -17 (c = 0.4,
H2O); MS (MALDI-TOF): m/z 1091 [M+H]
+, 1113 [M+Na]+, 1135 [M-H+2Na]+, 1157
[M-2H+3Na]+. For 1H NMR data, see Table 1.
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Abstract
A series of well-defined oligosaccharide fragments of the capsular polysaccharide
of Streptococcus pneumoniae type 3 has been generated. Partial acid hydrolysis of
the capsular polysaccharide, followed by fractionation of the oligosaccharide
mixture by Sepharose Q ion-exchange chromatography yielded fragments
containing one to seven [→3)-β-D-GlcpA-(1→4)-β-D-Glcp-(1→] repeating units.
The isolated fragments were analysed for purity by high-pH anion-exchange
chromatography with pulsed amperometric detection (HPAEC-PAD) using an
IonPac AS11 column, and their structures were verified by 1H NMR spectroscopy
and nano-electrospray mass spectrometry. The oligosaccharides can be used to
produce neoglycoprotein vaccines with a defined carbohydrate part. These products
are easier to analyse and will facilitate the investigation of the effect of the
saccharide part on the immune response of conjugate vaccines.
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Introduction
The Gram-positive pathogenic bacterium Streptococcus pneumoniae causes
diseases like otitis media, pneumonia and meningitis. Particularly young children,
the elderly and immunocompromised patients are at high risk towards
pneumococcal infections. Protection against pneumococci is conferred by
antibodies against the polysaccharide capsule surrounding the bacterium.
Carbohydrate material derived from this capsule is used in neoglycoprotein
vaccines that induce a serotype-specific antibody response against the
polysaccharide. Currently, vaccines exist against Haemophilus influenzae type b
[1], Neisseria meningitidis type C [2], and Streptococcus pneumoniae serotypes [3].
These neoglycoproteins are prepared by conjugation of isolated capsular
polysaccharides or a mixture of polysaccharide-derived oligosaccharides to a
protein carrier. The polysaccharide-protein conjugates have complex structures,
whereas the oligosaccharide-protein conjugates contain mixtures of carbohydrate
with respect to chain length and presented epitope. Especially in the case of a
pneumococcal conjugate vaccine, wherein many serotypes have to be included, the
presence of mixtures complicates the analysis of the conjugates. Such analyses are
increasingly important for product control. Furthermore, the lack of defined
saccharide fragments hampers the investigation of the immune response at a
molecular level. For these reasons, pure carbohydrate fragments with a unique
structure are needed. Thus, methods for the isolation of pure fragments and for
screening of the purity need to be developed [4,5]. Especially, methods like NMR
spectroscopy and mass spectrometry [6], combined with chromatographic
techniques like HPAEC-PAD [7] are suitable for characterising carbohydrate
material used in conjugate vaccines [8].
The capsular polysaccharide (CPS) of S. pneumoniae type 3 consists of [→3)-β-D-
GlcpA-(1→4)-β-D-Glcp-(1→] repeating units [9,10]. Partial acid hydrolysis of the
polysaccharide has been described before [11-13] yielding fragments of increasing
degree of oligomerisation with glucuronic acid at the nonreducing end, i.e. epitope
A (Figure 1). Enzymatic digestion of the polysaccharide using an enzyme from
Bacillus palustris [11,12,14-16] generates fragments of increasing chain lengths
having the alternative epitope B (Figure 1). Chemical synthesis has been performed
to obtain short defined fragments [17-20]. Oligosaccharides have been conjugated
to a carrier protein as mixtures of different chain lengths via their reducing end [21]
or via multiple point attachment [22], forming lattice type structures. A more
chemically defined conjugate consisted of a hexasaccharide coupled to a protein via
reductive amination [23].
The use of conjugates containing oligosaccharides with uniform chain length and
unique structure will facilitate product control and enable the investigation of the
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immunological effect of the specific carbohydrate structure. Here, the isolation and
characterisation of a series of oligosaccharide fragments are reported, containing
one to seven repeating units from the CPS of S. pneumoniae type 3.
O
HO
OH
OH
n
O
O
OH
HO
O
COOH
O
HO
OH
OH
O
OH
O
COOH
O
HO
A
B
Figure 1. Two repeating units of the CPS of Streptococcus pneumoniae type 3.
Epitope A of increasing oligomerisation can be obtained by partial acid hydrolysis,
and epitope B of increasing oligomerisation by depolymerisation with an enzyme
from Bacillus palustris.
Materials and methods
Reagents
Capsular polysaccharide (CPS) of S. pneumoniae type 3 (Pn 3) was obtained from
Chiron Vaccines (Siena, Italy). Trifluoroacetic acid and sulfuric acid (conc.) were
purchased from Merck, and phenol from Fluka. All chemicals were of the highest
purity commercially available.
Partial acid hydrolysis
To a solution of Pn 3 CPS (50 mg) in bidistilled water (25 mL) was added 0.6 M
trifluoroacetic acid (25 mL), and the mixture was heated for 3 h at 100°C, then
lyophilised. Lyophilisation from bidistilled water was repeated three times.
FPLC ion-exchange chromatography using Mono Q or Sepharose Q
The oligosaccharide mixtures were fractionated by ion-exchange chromatography
on a Pharmacia Biotech FPLC system equipped with a 500 µL or 10 mL sample
loop. Before use, solvents were filtered over a 0.22 µm filter and degassed by
flushing with helium. Samples were dissolved in bidistilled water and injected on
the column through a 0.22 µm filter. Analytical scale fractionation of the
oligosaccharide mixture (1 mg/mL) was performed by injection of 2 mL on a
prepacked 1 mL gelbed Mono Q® HR 5/5 column (Pharmacia). Fractions were
eluted with a flow rate of 0.5 mL/min, by isocratic elution with water for 4 mL,
followed by a gradient of 0-500 mM NaCl from 4-84 mL. Fractions of 0.5 mL were
collected and analysed for carbohydrate content by a phenol-sulfuric acid assay
[24].
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Preparative scale fractionation of the oligosaccharide mixture (5.0 mg/mL) was
performed by injection of 10 mL on a 20 mL gelbed Sepharose Q® HR 16/10
column (Pharmacia). Fractions were eluted with a flow rate of 5.0 mL/min, by
isocratic elution with water for 80 mL, followed by a gradient of 0-213 mM NaCl
from 80-750 mL. Fractions of 5.0 mL were collected and analysed for carbohydrate
content by a phenol-sulfuric acid assay. Fractions containing pure oligosaccharides
as observed by HPAEC-PAD and fractions containing a side-product (vide infra)
were collected separately, lyophilised, redissolved in water, and desalted by
Toyopearl® HW-40S (TosoHaas) size-exclusion chromatography in 5 mM
ammonium acetate.
High-pH anion-exchange chromatography with pulsed amperometric detection
(HPAEC-PAD)
The oligosaccharide mixture, fractions from ion-exchange chromatography, and the
pooled fractions were analysed by injection with an AS 3500 autosampler on a
Dionex DX-500 chromatographic system fitted with a GP40 gradient pump and an
ED40 electrochemical detector (PAD detection) with a working gold electrode.
Detection was performed using the following pulse potentials and durations: E1 =
0.1 V (400 ms); E2 = -0.2 V (20 ms); E3 = 0.6 V (10 ms); E4 = -0.1 V (60 ms).
Integration occurred from 200 to 400 ms during E1 application. The system was
equipped with a CarboPac PA10 or an IonPac AS11 column (4 x 250 mm) in
combination with a CarboPac PA10 or an IonPac AS11 guard column,
respectively, and operated at room temperature. The eluent was degassed with
helium and pressurised continuously with the eluent degas module of Dionex.
Samples injected on a PA10 column were run with 100 mM NaOH at a flow rate of
1.0 mL/min and a gradient of sodium acetate from 0-700 mM in 10.5 min, from
700-800 mM in 9.5 min, and isocratically at 800 mM for 10 min. Samples injected
on an AS11 column were run in 10 mM NaOH at a flow rate of 1.0 mL/min with a
gradient of 10-100 mM NaOH in 54 min.
1H NMR Spectroscopy
Prior to analysis, oligosaccharide samples were dissolved in 2H2O (99.9 atom %
2H) to a concentration of 5 mg/mL. The polysaccharide sample was dissolved in
2H2O (99.9 atom % 
2H) containing 100 mM NaCl to a concentration of 0.5 mg/mL.
Resolution-enhanced 1D 1H NMR spectra were recorded on a Bruker AMX-500
spectrometer at probe temperatures of 278, 300 or 353 K. Chemical shifts (δ) are
expressed in ppm relative to internal acetone (δ 2.225).
Nano-electrospray mass spectrometry
Electrospray ionisation (ESI) mass spectrometric analyses were performed on a
Thermoquest / Finnigan LC-Q ion trap mass spectrometer equipped with a Protana
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nanoES sample probe. Samples in methanol-water (1:1) with an approximate
concentration of 10 to 30 pmol/µL were prepared as follows. From a solution of the
oligosaccharide in bidistilled water (2 µg/µL), 5 µL aliquots were diluted to 500 µL
with methanol-water (1:1). For each experiment, 2 µL were loaded into the
capillary. The capillary temperature was set to 180 °C. Spectra were taken in the
negative-ion mode with a cone voltage of 1.5 kV and a capillary voltage of -46.0 V.
Results
Partial acid hydrolysis and fractionation of the oligosaccharide mixture by ion-
exchange chromatography
The partial acid hydrolysis of Pn 3 CPS with 0.3 M trifluoroacetic acid was
followed in time. The composition of the oligosaccharide mixture after 3 h of
hydrolysis as analysed by HPAEC-PAD is shown in Figure 2.
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Figure 2. HPAEC-PAD profiles of the oligosaccharide mixture obtained by partial
acid hydrolysis of Pn 3 CPS using (a) CarboPac PA10 or (b) IonPac AS11.
Numbers indicate the size of the oligosaccharide fragments expressed in repeating
units.
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Using a CarboPac PA10 column, a high salt gradient was needed for the elution of
fragments up to six repeating units (Figure 2a). Better results were obtained when
using an IonPac AS11 column (Figure 2b). Fragments of over 20 repeating units
were shown as isolated peaks. Small additional peaks for fragments of 1-9
repeating units indicated the presence of side-products (vide infra).
In Figure 3a, the fractionation of the oligosaccharide mixture by ion-exchange
chromatography on analytical scale with a Mono Q HR 5/5 ion-exchange column is
shown. The composition of the individual fractions of a peak was analysed by
HPAEC-PAD on IonPac AS11. The side-products as mentioned above were shown
to reside in the faster eluting fractions of a MonoQ peak. A similar fractionation
pattern of the oligosaccharide mixture as observed for Mono Q was obtained on a
preparative scale using a Sepharose Q HR 16/10 ion-exchange column (Figure 3b).
Fractions belonging to one peak were collected thereby omitting the fractions
contaminated with side-product, which were collected separately.
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Figure 3. Ion-exchange chromatograms of the oligosaccharide mixture obtained by
partial acid hydrolysis of Pn 3 CPS on (a) Mono Q and (b) Sepharose Q. Numbers
correspond to the size of the oligosaccharide fragments expressed in repeating
units.
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Purity analysis of the isolated fragments from Sepharose Q by HPAEC-PAD on
IonPac AS11
The purity of the pooled fractions was analysed by HPAEC-PAD. In Figure 4, the
IonPac AS11 profiles are shown of the pure and of the side-product-containing
fractions.
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Figure 4. HPAEC-PAD profiles of pooled side-product containing Sepharose Q
fractions on IonPac AS11. Pooled fractions containing pure products are shown as
inserts, 2.5x reduced in size. Numbers correspond to the size of the oligosaccharide
fragments expressed in repeating units.
Characterisation of the oligosaccharides by 1H NMR spectroscopy and nano-
electrospray mass spectrometry
1H NMR spectroscopy and nano-electrospray mass spectrometry were used for the
characterisation of the oligosaccharides. The 1D 1H NMR spectra of the
oligosaccharides having a glucuronic acid residue at the non-reducing end and a
glucose residue at the reducing end (e.g. tetradecasaccharide, Figure 5a) and the
polysaccharide (Figure 5b) were in good agreement. Due to the high viscosity of
the
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polysaccharide, proton signals were only resolved upon addition of sodium
chloride (100 mM) and at a probe temperature of 353 K.
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Figure 5. 500 MHz 1H NMR spectra of (a) the tetradecasaccharide fragment at
300K and (b) the native polysaccharide at 353K. The anomeric protons are
indicated.
In Figure 6, the anomeric regions of the 1D 1H NMR spectra of the (GlcA-Glc)n
oligosaccharides (n = 1-7) are shown. The positions of the anomeric signals were in
good agreement with literature data of comparable synthetic saccharides [19], and
their chemical shifts are reported in Table 1. Nano-electrospray mass spectrometry
confirmed the molecular masses of the oligosaccharide fragments. In Table 2, their
molecular masses are reported.
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Figure 6. Anomeric regions of the 1H NMR spectra at 300K of the di- to
tetradecasaccharide fragments (n=1-7) and the capsular polysaccharide (353K).
Numbers refer to the structure in Figure 5.
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Table 1. 500 MHz 1H NMR data of the anomeric protons of the (GlcA-Glc)n
oligosaccharide fragments (n = 1-7) at 300K and of the CPS at 353K. Chemical
shifts are given in ppm, coupling constants (in parentheses) are in Hz. Bold
numbers correspond to Figure 6.
n=1 n=2 n=3 n=4 n=5 n=6 n=7 CPS
1α 5.218
(3.7)
5.217
(3.7)
5.217
(3.7)
5.217
(3.7)
5.216
(3.7)
5.216
(3.7)
5.216
(3.7)
−
1β 4.659
(8.2)
4.657
(7.9)
4.657
(7.9)
4.658
(7.9)
4.657
(8.0)
4.656
(8.3)
4.657
(7.9)
−
3 − 4.820
(8.0)
4.825
(8.0)
4.826
(7.9)
4.823
(8.0)
4.824
(8.0)
4.822
(8.0)
4.803
(7.6)
4 4.512
(8.0)
4.510
(8.0)
4.503
(8.0)
4.505
(8.0)
4.503
(7.9)
4.503
(8.0)
4.504
(7.9)
−
2 − 4.541
(8.0)
4.536
(8.0)
4.538
(7.9)
4.536
(8.0)
4.535 4.536 4.549
(7.7)
− − 4.531
(7.9)
4.531
(8.0)
4.529
(8.0)
4.530
(8.0)
4.530
(7.7)
−
Table 2. Molecular masses of the (GlcA-Glc)n oligosaccharide fragments (n = 1-7),
as determined by nano-electrospray mass spectrometry in the negative-ion mode.
n Calculated [M-H]-
1 356.09 355.2
2 694.18 693.3
3 1032.26 1031.3
4 1370.35 1369.4
5 1708.43 1707.4
6 2046.51 1022.3 [M-2H]2-
7 2384.60 1191.5 [M-2H]2-
In Figure 7, the structures of the possible side-products (vide supra) resulting from
partial acid hydrolysis of Pn 3 CPS are shown. The fractions containing as major
product the fragments of one and two repeating units, contaminated with side-
product as observed by HPAEC-PAD, were characterised by 1D 1H NMR
spectroscopy (Figures 8a and 8b, respectively). With respect to the side-product,
the signals at 4.803 ppm (Figure 8a) and 4.805 ppm (Figure 8b) represent glucose
Hydrolysis of pneumococcal type 3 polysaccharide 91
at the nonreducing end, the signal at 4.534 ppm (Figure 8a) stems from internal
glucuronic acid. This indicates the presence of Glc-GlcA-Glc and Glc-GlcA-Glc-
GlcA-Glc sequences (structures I, Figure 7). These side-products originate from
cleavage of the β-D-GlcpA-(1→4)-β-D-Glcp linkage. In the mass spectrum of the
side-product-containing fraction (n = 2, Figure 9a), besides the ion at m/z 693.5 an
additional ion at m/z 855.3 is shown. This corresponds to the molecular ion ([M-H]-
) of GlcA2Glc3, which confirms the identity of the side-products having a glucose
residue at the nonreducing end (Figure 7; structure I).
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Figure 7. Structures of the possible side products.
Careful inspection of the 1D 1H NMR spectrum of the pure tetrasaccharide shows a
minor additional signal at 5.231 ppm (Figure 8c), indicating the α-anomeric proton
of glucuronic acid, and thus, the presence of a GlcA-Glc-GlcA sequence with
structure II (Figure 7). In the mass spectrum of the pure tetrasaccharide (Figure 9b)
an ion of low abundance is observed at m/z 531.1, corresponding to the molecular
ion ([M-H]-) of GlcA2Glc. This confirms the molecular mass and structure of the
trisaccharide.
The amounts of the two side-products co-eluting with the tetrasaccharide fragment,
i.e. Glc-GlcA-Glc-GlcA-Glc and GlcA-Glc-GlcA, was estimated to be ~2% each,
relative to the total amount of tetrasaccharide as derived from 1H NMR.
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Figure 8. 1H NMR spectra at 278K of the β-anomeric protons of the fractions of (a)
one and (b) two repeating units containing a side-product; (c) 1H NMR spectrum at
300K of the α-anomeric protons of the tetrasaccharide fragment. Numbers refer to
structures in Figure 7.
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Figure 9. Nano-electrospray mass spectra of the fractions containing (a) the
tetrasaccharide fragment and (b) the tetrasaccharide fragment and the side-product.
n.i. = not identified.
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Conclusion
We have reported the isolation of a series of (GlcA-Glc)n oligosaccharides of
increasing degree of oligomerisation (n = 1-7) from a partial acid hydrolysate of the
capsular polysaccharide of S. pneumoniae type 3. The purity of the pooled
fragments was determined by HPAEC-PAD using an IonPac AS11 column. The
structure of the oligosaccharide fragments was assigned by nano-electrospray mass
spectrometry and 1H NMR spectroscopy. In earlier studies, partial acid hydrolysis
of the capsular polysaccharide of S. pneumoniae type 3 was found to lead to a
specific cleavage of the (1→3)-linkage. However, the use of modern analytical and
physicochemical methods permitted the identification of side-products originating
from cleavage of the β-D-GlcpA-(1→4)-β-D-Glcp linkage. The oligosaccharides
can be used as standards in analytical assays and for the preparation of
neoglycoproteins with a defined carbohydrate part that can be used for
immunisation studies and to investigate the immunological effect of the saccharide
in conjugate vaccines.
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Abstract
The recognition of capsular polysaccharide antigens by immunoglobulins on the B-
cell surface is the first step in the immune response against encapsulated bacteria.
To investigate the carbohydrate-immunoglobulin interaction, glycoclusters were
synthesised containing one, two or three copies of the disaccharide repeating unit of
the capsular polysaccharide of Streptococcus pneumoniae type 3. To this end, β-D-
GlcpA-(1→4)-β-D-Glcp-(1→O-(CH2)3NH2 was synthesised and coupled to 4-(2-
carboxyethyl)-4-nitropimelic acid as a scaffold. Mono-, di-, and trivalent structures
were isolated and their interaction with the monoclonal antibody IgG 3.3 was
studied with surface plasmon resonance. The di- and trivalent compounds showed a
slight increase in binding compared to the monovalent one, whereas the uncoupled
disaccharide showed a low affinity.
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Introduction
The first step in the immune response against encapsulated bacteria is the
interaction of antibodies with carbohydrate epitopes on the capsular
polysaccharide. Previously, we have shown that CRM197-conjugates of the
synthetic disaccharide β-D-GlcpA-(1→4)-β-D-Glcp-(1→O-(CH2)3NH2,
representing one repeating unit of the capsular polysaccharide of Streptococcus
pneumoniae type 3, were able to generate a protective immune response in mice[1].
In this study, the disaccharides on the surface of the carrier protein were randomly
presented in a multivalent fashion with an oligosaccharide loading of 3.1 or 6.7.
Glycodendrimers or glycodendrons [2] can be used as more defined structures to
explore the influence of multivalency in the binding of the disaccharide to
immunoglobulins. Such multivalent arrays of oligosaccharides have been
developed for studying the spatial requirements for binding of oligosaccharides to
lectins [3,4], and in a few cases for studying carbohydrate-antibody interactions
[5,6].
In the present study, we prepared glycoclusters containing the repeating unit β-D-
GlcpA-(1→4)-β-D-Glcp of the CPS ([→3)-β-D-GlcpA-(1→4)-β-D-Glcp-(1→]) of
S. pneumoniae type 3 for investigating their interaction with a polysaccharide-
specific antibody. Glycosidic linkages can be applied to connect carbohydrates to a
core structure [7]. More often, however, a spacer-containing oligosaccharide is
attached to a scaffold. As a first approach, we synthesised mono-, di-, and trivalent
structures with 4-(2-carboxyethyl)-4-nitropimelic acid [8] as the core molecule.
This compound has three carboxylic groups available for the formation of amide
bonds. Reduction of the nitro group [9] allows coupling to spacers, carrier proteins,
peptides or surfaces.
Results
Synthesis of glycoclusters
For the preparation of the mono-, di-, and trivalent structures 16-18, first, the
spacer-containing disaccharide β-D-GlcpA-(1→4)-β-D-Glcp-(1→O-(CH2)3NH2
(14) was synthesised via a precursor disaccharide involving the coupling of
glucopyranosyl donor 11 and 3-azidopropyl glucopyranoside acceptor 9. For the
introduction of the 3-azidopropyl spacer, differently activated glucose derivatives
were coupled to 3-azido-1-propanol [10] (Scheme 1). Ethyl 2,3,4,6-tetra-O-
benzoyl-1-thio-β-D-glucopyranoside (1) reacted with 3-azido-1-propanol in 50%
yield (→6) using N-iodosuccinimide and triflic acid as a promoter, whereas 2,3,4,6-
tetra-O-benzoyl-α-D-glucopyranosyl bromide (2) gave 6 in a high isolated yield of
84% using silver triflate as a promoter. It should be noted that coupling of 3-azido-
Synthesis of glycoclusters 99
1-propanol with 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide (3) using
silver triflate as a promoter or with 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl
imidate (4) using TMSOTf as a promoter, or with the corresponding thioethyl
glucoside (5) promoted by N-iodosuccinimide and triflic acid resulted mainly in the
formation of orthoester and hydrolysis products of the donor and therefore in low
yields of product (<20%).
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BzO
OBz
R1
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AcO
AcO
AcO
OAc
R2
HO N3
R1
R2
5 R1 = SEt, R2 = H
3 R1 = H, R2 = Br
4 R1 = H, R2 =  OC(NH)CCl3
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O
R1O
R1O
R2O
OR3
7 R1 = H, R2 = R3 = PhCH
O N3
8 R1 = Bz, R2 = R3 = H
9 R1 = R3 = Bz, R2 = H
d
e
c
6 R1 = R2 = R3 = Bz1 R1 = SEt, R2 = H
2 R1 = H, R2 = Br
Scheme 1. Reagents and conditions: (a) 1, NIS, AgOTf, CH2Cl2–toluene (1:8),
50%. (b) 2, AgOTf, CH2Cl2–toluene (1:8), 84%. (c) i NaOMe, MeOH, ii
PhCH(OMe)2, pTsOH, DMF, 70%. (d) i PhCOCl, Et3N, CH2Cl2, ii CF3COOH,
H2O, CH2Cl2, 92%. (e) PhCOCl, imidazole, CH2Cl2, 96%.
Debenzoylation of 6 with sodium methoxide and benzylidenation using
benzaldehyde dimethyl acetal afforded 7 (70%). Subsequent benzoylation with
benzoyl chloride and debenzylidenation with trifluoroacetic acid gave 8 in a yield
of 92%. Treatment of 8 with benzoyl imidazole as described before [10] afforded 9
(96%).
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Coupling of 9 with thioethyl donor 10 [11] (Scheme 2) promoted by N-
iodosuccinimide and triflic acid gave disaccharide 11 in a yield of 65%.
Debenzylidenation of 11 with trifluoroacetic acid (→12, 87%), and subsequent
selective oxidation of HO-6 in the presence of HO-4 using TEMPO [12] and
sodium hypochlorite afforded 13 (85%). Deprotection of 13 was performed in two
steps. First, debenzoylation was achieved with sodium methoxide, then, the azide
was reduced using sodium borohydride and 10% Pd/C to give 14 in a yield of 88%.
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Scheme 2. Reagents and conditions: (a) NIS, TfOH, CH2Cl2-Et2O (3:1), 65%. (b)
CF3COOH, H2O, CH2Cl2, 87%. (c) TEMPO, aqueous NaOCl, KBr, Bu4NBr,
aqueous NaCl, aqueous NaHCO3, CH2Cl2, 85%. (d) i NaOMe, MeOH (pH 11), ii
NaBH4, 10% Pd/C, 0.1 M NaOH, 88%.
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For the preparation of glycoclusters (Scheme 3), disaccharide 14 was coupled to
succinimide activated 4-(2-carboxyethyl)-4-nitropimelic acid (15) in pyridine at 65
°C for 8 h or 2 days, respectively. When the reaction was allowed to proceed for 8
h, the mono- (16), di- (17) and trisubstituted (18) products were formed in a ratio of
3:3:1. After stirring for 2 days, a ratio of 0:1:3 was obtained. The compounds could
be isolated by Sephadex LH-20 size-exclusion chromatography in methanol.
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Scheme 3. Reagents and conditions: (a) C6H5N, 65 °C, 8 h. (b) C6H5N, 65 °C, 2
days.
Surface plasmon resonance analysis
The binding of the synthesised compounds (14, 16-18) to a monoclonal antibody
(IgG 3.3), specific for the capsular polysaccharide of S. pneumoniae type 3, was
studied with surface plasmon resonance (SPR). Since the coupling of the IgG
antibody to a CM5 chip did not result in an active surface, the sensor chip was
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coated with a synthetic neoglycoprotein. This conjugate was prepared by coupling
of the synthetic tetrasaccharide β-D-GlcpA-(1→4)-β-D-Glcp-(1→3)-β-D-GlcpA-
(1→4)-β-D-Glcp-(1→O-(CH2)3NH2, containing two repeating units of the
polysaccharide of S. pneumoniae type 3, to a non-toxic mutant of diphtheria toxin
(cross-reacting material, CRM197) with an oligosaccharide loading of 6.7 [10]. A
glucose-CRM197 conjugate (loading 8.1) was used as the reference surface. Low
capacity surfaces were generated of both conjugates (160-170 response units) to
avoid artefacts that could complicate the analysis [13].
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Figure 1. SPR response curves obtained for binding to a tetrasaccharide-CRM197
surface of (a) IgG 3.3 in various concentrations and (b) 0.5 µM IgG 3.3 in the
presence of trivalent 18 at increasing concentrations.
In Figure 1a, a typical sensorgram is shown for the binding of IgG 3.3 in various
concentrations to the tetrasaccharide-CRM197 surface. For studying the interaction
of the monoclonal antibody with the synthesised structures (14, 16-18), IgG 3.3
was passed over the neoglycoprotein surface at a fixed concentration of 0.5 µM,
premixed with various concentrations of synthetic ligand. In Figure 1b, the
response curves for the binding of IgG 3.3 to the tetrasaccharide-CRM197 surface is
shown in the presence of increasing concentrations 18. The maximum binding level
at the end of injection was plotted against the ligand concentration (Figure 2).
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Figure 2. Binding level at the end of injection for binding of IgG 3.3 to a
tetrasaccharide-CRM197 surface at different concentrations of synthetic ligand. The
mono- (16, π), di- (17,  ), and trivalent (18, ′) structures and disaccharide 14 (×)
were tested.
The scaffold-containing structures showed concentrations at 50% inhibition (IC50)
of 70 µM for 16, 47 µM for 17, and 43 µM for 18, respectively. Thus, the di- and
trivalent compounds showed a 1.5 times higher affinity compared to the
monovalent one. The free disaccharide (14) affected the binding of IgG 3.3 to the
tetrasaccharide-CRM197 surface only slightly (IC50 >> 400 µM). To assure that the
difference between the conjugated structures (16-18) and the free disaccharide (14)
was not caused by aspecific interactions of the scaffold with the monoclonal
antibody, 4-(2-carboxyethyl)-4-nitropimelic acid was tested as a ligand. This
compound, however, did not influence the binding of IgG 3.3 to the
tetrasaccharide-CRM197 surface at concentrations of 0.5 or 1.0 mM.
Conclusions
Compounds have been synthesised containing one, two or three copies of the
disaccharide β-D-GlcpA-(1→4)-β-D-Glcp-(1→O-(CH2)3NH2, which is the
repeating unit of the capsular polysaccharide of the bacterium S. pneumoniae type
3. The interactions of disaccharide 14 and the mono-, di-, and trivalent molecules
16-18 with the monoclonal antibody IgG 3.3 were studied using surface plasmon
resonance.
As compared by their IC50 values, divalent 17 showed a higher affinity for IgG 3.3
than monovalent 16 by a factor of about 1.5. Increasing the valency as in trivalent
18 did not further increase the affinity. A comparison of the binding of structures
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16-18 (IC50 43-70 µM) with the binding of the free disaccharide 14 (IC50 >> 400
µM) showed that introduction of the hydrophobic scaffold caused a large increase
in affinity of the disaccharide for IgG 3.3. Previous studies have shown that
increased binding of oligosaccharides to lectins could be achieved by the
introduction of a hydrophobic spacer, as for example the coupling of a nitrophenyl
group to mannose [14], the use of aromatic core molecules [15] or by varying the
spacer length [16].
In the current study the binding of glycoclusters to antibody has been investigated
in solution. As it has been shown that binding effects can be dependent on the test
system used [17,18] and on the mode of presentation of the receptor, i.e. in solution
or on a surface [19], future studies will deal with the interaction of the synthesised
compounds with surface bound immunoglobulins using a different type of assay.
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Experimental
General procedures
All reagents were used as obtained commercially, without any further purification. All
solvents were distilled from appropriate drying agents. Reactions were monitored by TLC
on Silica gel 60 F254 (Merck); after examination under UV light, compounds were
visualised by heating with 10% (v/v) ethanolic H2SO4, orcinol (2 mg mL
-1) in 20% (v/v)
methanolic H2SO4, or ninhydrin (1.5 mg mL
-1) in BuOH-H2O-HOAc (38:1.75:0.25). In
the work-up procedures of reaction mixtures, organic solutions were washed with
appropriate amounts of the indicated aqueous solutions, then dried with MgSO4, and
concentrated under reduced pressure at 20-40 °C on a water-bath. Column
chromatography was performed on Silica gel 60 (Merck, 0.063-0.200 mm). Optical
rotations were measured with a Perkin-Elmer 241 polarimeter, using a 10-cm l-mL cell, in
H2O for 14, 16-18 and in CHCl3 for all other compounds; [α]D values are given in 10-1 deg
cm2 g-1. 1H NMR spectra (300 MHz) and 13C (APT, 75 MHz) NMR spectra were recorded
in CDCl3 at 300 K with a Bruker AC 300 spectrometer; indicated values for δH are given
in ppm relative to the signal for internal Me4Si (δ 0) and for δC relative to the signal of
CDCl3 (δ 76.9). 1H NMR data of 14, 16-18 were derived from 2D TOCSY and ROESY
spectra, measured on a Bruker AMX 500 apparatus (500 MHz) at 300 K in D2O, and δH
values are given in ppm relative to internal acetone (δ 2.225). All J values are given in Hz.
Mass spectral data were obtained from a Thermoquest / Finnigan LC-Q ion trap mass
spectrometer equipped with a Protana nanoES sample probe. Spectra were taken in the
negative-ion mode. From a 2 µg µL-1 solution of the oligosaccharide fragment in
bidistilled water was taken 5 µL that were further diluted to 500 µL with methanol-water
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(1:1). For each experiment, 2 µL were loaded into the capillary. Elemental analyses were
carried out by H. Kolbe Mikroanalytisches Laboratorium (Mülheim an der Ruhr,
Germany).
3-Azidopropyl 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranoside (6): A solution of silver
triflate (3.95 g, 15.4 mmol) in dry toluene (66 mL) was added to a dried (2 h in vacuo)
mixture of 3-azido-1-propanol [10] (5.7 g, 56 mmol) and 4Å molecular sieves. After 30
min, a solution of 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl bromide (2) (8.9 g, 13.2
mmol) in dry CH2Cl2 (8.2 mL) was added, and the mixture was stirred for 1 h. Then, the
mixture was neutralised with pyridine, diluted with EtOAc, washed with 5% aqueous
NaHSO3 and 5% aqueous NaCl, and the organic layer was dried, filtered, and
concentrated. The residue was purified by column chromatography (toluene-EtOAc 95:5)
to afford 6 (7.7 g, 84%). [α]D20= +21 (c 1.1); Rf 0.53 (toluene-EtOAc 85:15); (Found: C,
65.5; H, 4.8. Calc. for C37H33O10N3: C, 65.4; H, 4.9%); δH(CDCl3) 8.05-7.82 and 7.55-
7.28 (20 H, 2 m, 4 PhCO), 5.90 and 5.67 (each 1 H, 2 t, J3,4, J4,5 9.7, H-3,4), 5.52 (1 H,
dd, J1,2 7.8, J2,3 9.8, H-2), 4.84 (1 H, d, H-1), 4.65 (1 H, dd, J6a,6b 12.1, J5,6a 3.2, H-6
a),
4.50 (1 H, dd, J5,6b 5.1, H-6
b), 4.16 (1 H, ddd, H-5), 4.03-3.96 and 3.66-3.60 (each 1 H, 2
m, OCH2CH2CH2N3), 3.24 (2 H, dt, OCH2CH2CH2N3), 1.85-1.72 (2 H, m,
OCH2CH2CH2N3); δC(CDCl3) 165.7, 165.1, and 165.0 (2 C) (4 PhCO), 101.2 (C-1), 66.6
(OCH2CH2CH2N3), 63.0 (C-6), 47.8 (OCH2CH2CH2N3), 28.9 (OCH2CH2CH2N3).
3-Azidopropyl 4,6-O-benzylidene-β-D-glucopyranoside (7): To a solution of 6 (6.2 g,
9.1 mmol) in MeOH (60 mL) was added solid sodium methoxide until pH 9 was reached.
After 2 h, when TLC (CH2Cl2-MeOH 9:1) showed the formation of a new spot (Rf 0.13),
the mixture was neutralised with Dowex H+, filtered, and concentrated. To a solution of
the residue in DMF (40 mL) were added benzaldehyde dimethyl acetal (BDMA) (2.7 ml,
18 mmol) and p-TsOH (until pH 4) under argon. After stirring for 25 h, the mixture was
neutralised with solid Na2CO3, filtered, and co-concentrated with toluene. The residue was
purified by column chromatography (toluene-EtOAc 6:4) to obtain 7 (2.24 g, 70%).
[α]D20= -38 (c 0.2); Rf 0.15 (toluene-EtOAc 6:4); (Found: C, 54.5; H, 6.1. Calc. for
C16H21O6N3: C, 54.7; H, 6.0%); δH(CDCl3) 7.50-7.46 and 7.38-7.34 (5 H, 2 m, PhCH),
5.51 (1 H, s, PhCH), 4.37 (1 H, d, J1,2 7.7, H-1), 4.33 (1 H, dd, J6a,6b 10.2, J5,6a 4.8, H-6
a),
3.96 and 3.67 (each 1 H, 2 dt, OCH2CH2CH2N3), 3.77 and 3.52 (each 1 H, 2 t, J3,4, J4,5
9.1, H-3,4), 3.76 (1 H, t, J5,6b 9.9, H-6
b), 3.47 (1 H, J2,3 9.0, dd, H-2), 3.41 (2 H, t,
OCH2CH2CH2N3), 1.93-1.85 (2 H, m, OCH2CH2CH2N3); δC(CDCl3) 136.8 (PhCH,
quaternary C), 129.2, 128.2 (2 C), and 126.2 (2 C) (PhCH), 103.1 (PhCH), 101.8 (C-1),
68.5 (C-6), 67.0 (OCH2CH2CH2N3), 48.2 (OCH2CH2CH2N3), 28.9 (OCH2CH2CH2N3).
3-Azidopropyl 2,3-di-O-benzoyl-β-D-glucopyranoside (8): To a solution of 7 (1.7 g, 4.8
mmol) in CH2Cl2 (30 mL) and Et3N (4 mL) was added dropwise benzoyl chloride (1.7
mL, 14.5 mmol). After stirring for 4 h, the mixture was diluted with CH2Cl2, washed
twice with 10% aqueous NaCl, and the organic layer was dried, filtered, and concentrated
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(Rf 0.72, toluene-EtOAc 6:4). To a solution of the residue in CH2Cl2 (7 mL) were added
CF3COOH (2.7 mL) and H2O (0.4 mL). After 4 h, the mixture was diluted with CH2Cl2,
washed with 10% aqueous NaHCO3 until neutral pH and 10% aqueous NaCl, and the
organic layer was dried, filtered, and concentrated. The residue was purified by column
chromatography (CH2Cl2-EtOAc 9:1) to obtain 8 (2.1 g, 92%). [α]D20= +33 (c 1); Rf 0.15
(toluene-EtOAc 6:4); (Found: C, 58.7; H, 5.3. Calc. for C23H25O8N3: C, 58.6; H, 5.3%);
δH(CDCl3) 8.10-7.94 and 7.51-7.33 (10 H, 2 m, 2 PhCO), 5.45 (1 H, t, J3,4 9.8, H-3), 5.39
(1 H, dd, J1,2 7.6, J2,3 9.7, H-2), 4.73 (1 H, d, H-1), 3.28-3.21 (2 H, m, OCH2CH2CH2N3),
1.79-1.74 (2 H, m, OCH2CH2CH2N3); δC(CDCl3) 167.3 and 165.2 (2 PhCO), 100.9 (C-1),
66.3 (OCH2CH2CH2N3), 62.0 (C-6), 47.7 (OCH2CH2CH2N3), 28.8 (OCH2CH2CH2N3).
3-Azidopropyl (2,3-di-O-benzoyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1→4)-
2,3,6-tri-O-benzoyl-β-D-glucopyranoside (11): A mixture of 3-azidopropyl 2,3,6-tri-O-
benzoyl-β-D-glucopyranoside 9 [10] (0.20 g, 0.35 mmol), ethyl 2,3-di-O-benzoyl-4,6-O-
benzylidene-1-thio-β-D-glucopyranoside 10 [11] (0.28 g, 0.52 mmol), and 4Å molecular
sieves in CH2Cl2 (1.8 mL) was stirred for 30 min under argon. Then, 1.8 mL of a solution of
NIS (0.44 g, 1.95 mmol) and TfOH (12.5 µl) in CH2Cl2-Et2O (10 mL, 1:1) was added at 0 oC.
After 15 min, the mixture was neutralised with pyridine, diluted with CH2Cl2, washed with
10% aqueous NaHSO3 (2x) and 10% aqueous NaCl, and the organic layer was dried,
filtered, and concentrated. The crude product was purified by column chromatography
(toluene-EtOAc 9:1) to give 11 (0.23 g, 65%). [α]D20= +15 (c 0.6); Rf 0.33 (toluene-EtOAc
9:1); (Found: C, 65.9; H, 5.15. Calc. for C57H51O16N3: C, 66.2; H, 5.0%); δH(CDCl3)
8.06-7.85 and 7.50-7.25 (30 H, 2 m, 5 PhCO, PhCH), 5.72 (dd) and 5.61 (t) (each 1 H,
J2,3, J2',3' 9.5, 9.8, H-3,3'), 5.43 and 5.36 (each 1 H, 2 dd, J1,2, J1',2' 7.7, 7.9, H-2,2'), 5.21 (1
H, s, PhCH), 4.84 and 4.66 (each 1 H, 2 d, H-1,1'), 4.51 (1 H, dd, J6a,6b 12.0, J5,6a 1.9, H-
6a), 4.39 (1 H, dd, J5,6b 4.5, H-6
b), 3.88-3.81 and 3.55-3.48 (each 1 H, 2 m,
OCH2CH2CH2N3), 3.16 (2 H, dt, OCH2CH2CH2N3), 1.78-1.63 (2 H, m,
OCH2CH2CH2N3); δC(CDCl3) 165.6, 165.3, 165.1, 165.0, and 164.8 (5 PhCO), 136.5
(PhCH, quaternary C), 101.8, 101.1, and 100.8 (PhCH, C-1,1'), 67.6 (C-6'), 66.4
(OCH2CH2CH2N3), 62.1 (C-6), 47.8 (OCH2CH2CH2N3), 28.8 (OCH2CH2CH2N3).
3-Azidopropyl (2,3-di-O-benzoyl-β-D-glucopyranosyl)-(1→4)-2,3,6-tri-O-benzoyl-β-D-
glucopyranoside (12): To a solution of 11 (0.23 g, 0.22 mmol) in CH2Cl2 (13 mL) were
added CF3COOH (0.15 mL) and H2O (0.2 mL). After stirring for 3 h, the mixture was
diluted with CH2Cl2, washed with 10% aqueous NaHCO3 (2 x) and 10% aqueous NaCl,
and the organic layer was dried, filtered, and concentrated. The residue was purified by
column chromatography (toluene-EtOAc 9:1→1:1) to obtain 12 (0.19 g, 87%). [α]D20=
+61 (c 1); Rf 0.11 (toluene-EtOAc 8:2); (Found: C, 63.6; H, 5.1. Calc. for C50H47O16N3:
C, 63.5; H, 5.0%); δH(CDCl3) 8.04-7.88 and 7.50-7.33 (25 H, 2 m, 5 PhCO), 5.71 and
5.24 (each 1 H, 2 t, J2,3, J2',3' 9.6, 9.7, H-3,3'), 5.38 and 5.37 (each 1 H, 2 dd, J1,2 = J1',2' =
7.8, H-2,2'), 4.80 and 4.66 (each 1 H, 2 d, H-1,1'), 4.60 (1 H, dd, J6a,6b 12.1, J5,6a 2.1, H-
6a), 4.41 (1 H, dd, J5,6b 4.8, H-6
b), 3.89-3.82 and 3.55-3.48 (each 1 H, 2 m,
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OCH2CH2CH2N3), 3.17 (2 H, dt, OCH2CH2CH2N3), 1.74-1.67 (2 H, m,
OCH2CH2CH2N3); δC(CDCl3) 100.8 and 100.7 (C-1,1'), 66.4 (OCH2CH2CH2N3), 62.3
and 61.4 (C-6,6'), 47.8 (OCH2CH2CH2N3), 28.8 (OCH2CH2CH2N3).
3-Azidopropyl (2,3-di-O-benzoyl-β-D-glucopyranosyluronic acid)-(1→4)-2,3,6-tri-O-
benzoyl-β-D-glucopyranoside (13): To a solution of 12 (0.14 g, 0.15 mmol) in CH2Cl2
(1.4 mL) were added a catalytic amount of TEMPO, KBr (1.7 mg), Bu4NBr (2.3 mg) and
saturated aqueous NaHCO3 (0.3 mL). The mixture was stirred vigorously at 0 °C, when a
mixture of saturated aqueous NaCl (0.3 mL), saturated aqueous NaHCO3 (0.17 mL) and
aqueous NaOCl (13% Cl active; 0.39 mL) was added dropwise over 15 min. After stirring
for 45 min, the mixture was acidified to pH 4 with 4 M HCl, diluted with CH2Cl2, and the
organic layer was washed with 10% aqueous NaCl, dried, filtered, and concentrated. The
residue was purified by column chromatography. Impurities were eluted with CH2Cl2-
acetone (8:2), and 13 (0.12 g, 85%) was eluted with CH2Cl2-acetone-HOAc (8:2:0.5).
[α]D20= +63 (c 2.1); Rf 0.50 (CH2Cl2-acetone-HOAc 8:2:1); (Found: C, 62.5; H, 4.9. Calc.
for C50H45O17N3: C, 62.6; H, 4.7%); δH(CDCl3) 7.97-7.82 and 7.55-7.31 (25 H, 2 m, 5
PhCO), 5.86 and 5.47 (each 1 H, 2 t, J2,3, J2',3' 9.0, 9.3, H-3,3'), 5.39 and 5.32 (each 1 H, 2
t, J1,2, J1',2' 7.2, 7.5, H-2,2'), 5.00 and 4.74 (each 1 H, 2 d, H-1,1'), 3.14 (2 H, br t,
OCH2CH2CH2N3), 1.75-1.60 (2 H, m, OCH2CH2CH2N3); δC(CDCl3) 101.1 and 100.6 (C-
1,1'), 66.4 (OCH2CH2CH2N3), 62.1 (C-6), 47.8 (OCH2CH2CH2N3), 28.8
(OCH2CH2CH2N3).
3-Aminopropyl β-D-glucopyranosyluronic acid-(1→4)-β-D-glucopyranoside (14): To a
solution of 13 (0.12 g, 0.12 mmol) in MeOH (12 mL) was added NaOMe until pH 11.
After stirring for 1.5 h, TLC (EtOAc-MeOH-H2O 12:5:3) showed the formation of a new
spot (Rf 0.35), and the mixture was neutralised with Dowex H
+, filtered, and concentrated.
A solution of the residue in water was washed with CH2Cl2 (3x), and the aqueous layer
was concentrated. MALDI-TOF analysis of the residue showed a peak at m/z 462
(M+Na)+. Then, a solution of the residue in 0.1 M NaOH (1.3 mL) was added dropwise to
a suspension of 10% Pd/C (2.5 mg) and NaBH4 (10 mg) in bidistilled water (0.6 mL).
After 4 h, when TLC (EtOAc-MeOH-H2O 12:5:3) showed the formation of a ninhydrin-
positive spot on the baseline, the mixture was acidified with Dowex H+ (pH 4) and
charged on a short column of Dowex 50 W × 2 (H+, 200-400 mesh). After elution of
contaminants with water, 14 was eluted with 1% NH4OH. After concentration of the
solvent and co-concentration of the residue with water (2x), 14 was obtained (49 mg,
88%). δH(D2O) 4.51 (2 H, d, J1,2 = J1',2' = 7.7, H-1,1'), 4.05 and 3.82 (OCH2CH2CH2NH2),
3.98 (1 H, br d, J5,6a < 1, J6a,6b 12.1, H-6
a), 3.81 (H-6b), 3.75 (1 H, d, J4',5' 8.8, H-5'), 3.66
(H-3), 3.61 (H-4), 3.52 (H-3',4'), 3.36 (1 H, t, H-2'), 3.33 (1 H, t, H-2), 3.16 (2 H, t,
OCH2CH2CH2NH2), 2.04-1.96 (2 H, m, OCH2CH2CH2NH2); m/z (MALDI-TOF) 414
(M+H)+, 436 (M+Na)+.
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Preparation of 16, 17 and 18
A suspension of disaccharide 14 (32 mg, 77 µmol) and 4-(2-carboxyethyl)-4-nitroheptane-
1,7-dicarboxylic acid-tris-(N-hydroxysuccinimide) ester 15 (6.3 mg, 11.1 µmol) in
pyridine (7 mL) was stirred at 65 °C for 8 h or 2 days, respectively. Then, the mixture was
concentrated, dissolved in aqueous HOAc (2 mL, pH 4) and charged on a C18 Bakerbond
spe column (500 mg). After elution of 14 with water (10 mL), the scaffold-containing
compounds were obtained by elution with MeOH (5 mL), concentration and lyophilisation
from water. Reaction for 8 h afforded 16 (3.2 mg, 35 %), 17 (5.1 mg, 35%), and 18 (2.3
mg, 12 %). Reaction for 2 days afforded 17 (1.5 mg, 16%) and 18 (13 mg, 63 %).
16: [α]D20= -17° (c 0.4); δH(D2O) see 18, 2.35-2.31 (4 H, m, 2 HOC(O)CH2CH2C); m/z
(ES LC-Q) 671.5 (M-H)-.
17: [α]D20= -18° (c 0.5); δH(D2O) see 18, 2.35-2.32 (2 H, m, HOC(O)CH2CH2C); m/z (ES
LC-Q) 1066.3 (M-H)-.
18: [α]D20= -24° (c 0.5); δH(D2O) 4.51 (3 H, d, J1',2' 8.0, 3 H-1'), 4.48 (3 H, J1,2 8.0, 3 H-
1), 3.97 (3 H, br d, J5,6a < 1, J6a,6b 11.9, 3 H-6
a), 3.94 and 3.71 (each 3 H, 2 dt, 3
OCH2CH2), 3.81 (3 H-6
b), 3.77 (3 H-5'), 3.65 (3 H-3), 3.60 (3 H-4), 3.53 (3 H-3',4') 3.36
(3 H, t, 3 H-2'), 3.31 (3 H, t, 3 H-2), 3.28 (6 H, t, 3 CH2CH2NH), 2.26 (12 H, m, 3
C(O)CH2CH2C), 1.82 (6 H, m, 3 OCH2CH2); m/z (ES LC-Q) 1461.5 (M-H)
-.
SPR analysis
Instrumentation and reagents
A BIAcore 2000 instrument, BIAevaluation software 3.0 and sensor chip CM5 were from
Pharmacia Biosensor AB (Uppsala, Sweden). The monoclonal antibody IgG 3.3, specific
for the capsular polysaccharide of S. pneumoniae type 3, was prepared by Jansen et al.
[20].
Immobilisation of the conjugates on the chip
After equilibration of the sensor surface with PBS buffer (pH 7.4) at a flow rate of 5 µL
min-1, the surface was activated with a 35-µL pulse of a mixture of freshly prepared 0.1 M
N-hydroxysuccinimide and 0.1 M N-ethyl-N'-(dimethylaminopropyl) carbodiimide (1:1).
A 2.0 µM neoglycoprotein solution in 100 mM NaOAc buffer (pH 5.0) was passed over
the surface until sufficient incorporation was reached (< 5 µL). Remaining N-
hydroxysuccinimide esters were blocked by injection of 1.0 M ethanolamine
hydrochloride (pH 8.5) for 10 min. The level of bound neoglycoprotein was found to be
170 response units (RU) for the tetrasaccharide-CRM197 conjugate and 160 RU for the
glucose-CRM197 conjugate.
SPR detection
All analyses were performed in duplo at a flow rate of 20 µL min-1 using PBS buffer (pH
7.4) as eluent in a Method run. As indicated in Figure 1a, various concentrations of IgG
3.3 were injected for 12 min (720 µL) over the tetrasaccharide-CRM197 surface using the
INJECT command. Regeneration was performed with a 50-µL pulse of saturated aqueous
NaCl. As indicated in Figure 2, IgG 3.3 (0.5 µM) was premixed with various
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concentrations of synthetic ligand, and 200 µL were passed over the surface using the
INJECT command. Regeneration was performed with a 50-µL pulse of saturated aqueous
NaCl.
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7The use of diazabicyclo[2.2.2]octane
as a novel highly selective
dechloroacetylation reagent
Dirk J. Lefeber, Johannis P. Kamerling, and Johannes F.G. Vliegenthart
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In a study directed toward the use of the chloroacetyl protecting group in
carbohydrate synthesis, the sterically hindered tertiary amine
diazabicyclo[2.2.2]octane (DABCO) was found to give complete and selective
cleavage of the chloroacetyl group in the presence of other ester functions such as
benzoyl and acetyl groups at primary and/or secondary positions.
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Introduction
The chloroacetyl group is used for the temporary protection of hydroxyl groups, as
it is a very base-sensitive group that can be selectively cleaved in the presence of
other acyl functions by a number of methods. In addition to, for example, aqueous
ammonia [1] or hydrazine acetate [2], the most widely used deprotection reagent is
thiourea [3]. The latter reaction is easy to perform but requires relatively long
reaction times. The nucleophilic sulfur of thiourea displaces the chloride atom of
the chloroacetyl group, and one of the amine functions subsequently attacks the
ester bond intramolecularly [4]. Deprotection using hydrazine dithiocarbonate
(HDTC), introduced by van Boeckel et al. [5], is based on the same reaction
mechanism. It gives rise to fast and clean reactions but requires the preparation of
the reagent just before use, since it is only stable for 15-20 min [6]. This paper
reports a novel dechloroacetylation reagent, diazabicyclo[2.2.2]octane (DABCO),
which turned out to be highly selective, fast, and easy to handle.
Results and discussion
In the course of the synthesis of oligosaccharides, we were confronted with
problems in the deallylation of compound 1 to give 2 (Figure 1). The yield of the
isomerization of the double bond using tristriphenylphosphine rhodium(I) chloride
and DABCO (3 equiv) in refluxing ethanol was low, due to the formation of the
dechloroacetylated monosaccharide derivative 3, as shown by 1H NMR (Figure 1)
[7]. This observation stimulated further investigations toward the use of DABCO as
a general dechloroacetylation reagent.
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Figure 1. Deallylation of 1 (→2) and the formed side product 3.
Complete dechloroacetylation of 1 to give 4 (Figure 2) was achieved by incubating
0.02 M 1 in ethanol in the absence of Wilkinson’s catalyst with 5 equiv of DABCO
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at room temperature for 6 h [8]. Isomerization of the double bond without affecting
the chloroacetyl group was achieved by reaction of 5 mM 1 with Wilkinson’s
catalyst without DABCO in refluxing ethanol or by using only a catalytic amount
of DABCO in either refluxing ethanol or refluxing 1:1 ethanol−toluene, the latter
solvent system slowing down the dechloroacetylation. After reaction of the
intermediate with N-iodosuccinimide and water, 2 was obtained in 77% yield [9].
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Figure 2. Dechloroacetylation of 1 afforded 4 and in some cases the migrated
product 5.
To gain insight into the factors influencing the reaction time needed for complete
dechloroacetylation of 1 in ethanol, several parameters were varied (Table 1).
Table 1. Effect of the amount of DABCO, temperature, and concentration on the
reaction time of the dechloroacetylation of 1 as carried out in ethanol.
Entry DABCO
(equiv)
Temp (°C) Time (min) Concn (M)
1 5 20 360 0.02
2 20 20 120 0.02
3 10 20 240 0.02
4 10 55 40 0.02
5 10 70 15 0.02
6 15 55 30 0.02
7 15 55 <10 0.06
By increasing the amount of DABCO, the reaction time was shortened from 6 to 2
h (Table 1, entries 1 and 2). Furthermore, the temperature of the reaction mixture
had a marked influence on the reaction rate (entries 3, 4, and 5), and thereby on the
reaction time. Using 15 equiv of DABCO at 55 °C, a sufficiently short reaction
time was obtained (entry 6). By increasing the concentration of 1 from 0.02 to 0.06
M (Table 1, entries 6 and 7), the reaction time was further decreased from 30 min
to less than 10 min. In all cases a quantitative conversion was detected from TLC
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and 1H NMR, after neutralization of the reaction mixtures with Dowex H+,
filtration, and concentration. No migration of the benzoyl group from O-2 to O-3
was observed. Only after 3 days of stirring, in the case of entries 1 and 2, about 5%
migration (4→5, Figure 2) could be seen [10]. This migration also started to occur
after more than 4 h of stirring for entries 4-6. Only in the case of entry 7, some
migration was already found after 30 min. Therefore, in view of reaction time and
practical ease, we preferred the reaction conditions described for entry 6.
To compare the effectiveness of DABCO with thiourea, the following experiments
were performed. According to the commonly used dechloroacetylation with
thiourea, 3 equiv of reagent, either thiourea or DABCO, was reacted with 0.03 M 1
in 5:1 ethanol−pyridine at 70 °C. Although in both cases excellent isolated yields
were obtained, the use of DABCO resulted in much faster dechloroacetylation
(Table 2, entries 1 and 2). Also following the established procedure (Table 1, entry
6), DABCO was found to give a much faster dechloroacetylation (Table 2, entries 3
and 4).
Table 2. Comparison of DABCO and thiourea in the dechloroacetylation of 1.
Entry Reagent Solvent Time
(min)
Yield
(%)
1 thiourea ethanol/pyridine 90 93
2 DABCO ethanol/pyridine <10 95
3 thiourea ethanol 270 97
4 DABCO ethanol 30 94
In additional studies, two other tertiary amines, triethylamine (TEA) and N,N-
diisopropylethylamine (DIPEA), were examined for their dechloroacetylating
properties (Table 3).
Table 3. Dechloroacetylation of 1 using the tertiary amines TEA or DIPEA.
Entry Base Solvent Temp (°C) Time (h) Yield (%)[a] (1:4:5)
1 TEA ethanol 20 16 25:65:10
2 TEA dichloromethane 20 1.5 no reaction
3 DIPEA ethanol 20 16 25:65:10
4 DIPEA dichloromethane 20 1.5 no reaction
[a] estimated from TLC
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Incubation of 1 with 15 equiv of TEA or DIPEA in ethanol at room temperature
resulted in partial dechloroacetylation. Before the dechloroacetylation was
complete, about 10% migration of the benzoyl group had occurred from O-2 to O-
3, resulting in the formation of 5 (Table 3, entries 1 and 3). In dichloromethane, no
reaction was observed within 1.5 h at room temperature (Table 3, entries 2 and 4).
These results clearly show that the selectivity of DABCO in the
dechloroacetylation of 1 does not result solely from being a tertiary amine.
To further explore the generality of the procedure, compounds 6 and 8 (Figure 3)
were subjected to the following reaction conditions [11]: (A) 0.02 M 6 or 8, 15
equiv of DABCO, 55 °C, ethanol; and (B) 0.04 M 6 or 8, 1 equiv of DABCO, 55
°C, 5:1 ethanol−pyridine.
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Figure 3. Dechloroacetylation of 6 and 8.
Dechloroacetylation of 6 was found to be complete in 45 min using method A.
Using method B, which is much milder, 2 h were needed for the conversion of 6 to
7. In both cases the isolated yield was 95% [12]. Compound 8 was
dechloroacetylated in 75 min using method A and in 2.5 h using method B. The
isolated yields were 95% and 97%, respectively [13]. No migration could be
observed by 1H NMR. Although method A is much faster than method B, method
B may be used when more basic conditions are expected to cause problems.
Performing the reaction according to method B without DABCO, complete
dechloroacetylation of 6 and 8 required 6 and 7 h, respectively. This observation
indicates that pyridine alone is also able to affect the chloroacetyl group but that
DABCO greatly accelerates the reaction. Ethylenediamine, o-phenylenediamine,
and 2-mercaptoethylamine [14] have also been mentioned as dechloroacetylation
reagents. However, those reactions were performed with a large excess of pyridine
and TEA in methanol. Our findings with pyridine and TEA show that these
reagents themselves might not be the actual dechloroacetylating agents.
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Conclusions
The results clearly show that the use of DABCO as dechloroacetylating agent
provides a good method in addition to the commonly used reagents. Benzoyl and
acetyl groups at primary and/or secondary positions are stable under the reaction
conditions employed. The procedure is fast, highly selective, and easy to perform.
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Summary
Bacteria containing a polysaccharide capsule e.g. Streptococcus pneumoniae,
Neisseria menigitidis and Haemophilus influenzae can cause severe diseases like
meningitis, pneumonia and otitis media. Especially young children are susceptible.
A vaccine that consists of isolated polysaccharides from several S. pneumoniae
serotypes affords protection in adults, but it is not effective in high risk groups such
as young children. Neoglycoprotein vaccines against several encapsulated bacteria
are now available, containing carbohydrate material derived from the
polysaccharide capsule conjugated to a protein carrier. It has been well established
that these neoglycoprotein vaccines have a marked impact on reduction of diseases,
also in the high risk groups. However, the mechanisms underlying the immune
response of this type of vaccines is still poorly understood. This is mainly due to
the heterogeneity of the commercial vaccines, which hampers the investigation of
the immune response at a molecular level. Furthermore, this heterogeneity
complicates the analysis of the products, which is needed for routine product
control. Finally, the use of carbohydrate material isolated from biological sources
has the risk of being contaminated. To address these problems, neoglycoconjugates
with a defined structure have to become available.
In this research program, neoglycoproteins have been prepared according to the
structure of the capsular polysaccharide (CPS) of Streptococcus pneumoniae type
3. This serotype is present in both the 23-valent polysaccharide and 11-valent
conjugate vaccines. Furthermore, it is often used to study the protective capacity of
experimental vaccines because of its high virulence in mice. The capsular
polysaccharide of this type is built up from disaccharide repeating units with the
structure [→3)-β-D-GlcpA-(1→4)-β-D-Glcp-(1→]. Both chemical synthesis and
partial acid hydrolysis of the CPS have been carried out to obtain well-defined
oligosaccharides. Neoglycoproteins were prepared containing the synthetic
carbohydrates and their immunogenicity in mice was studied. Furthermore,
glycoclusters were synthesised as an interesting class of defined compounds and
their binding to the monoclonal antibody IgG 3.3 was investigated using surface
plasmon resonance. Finally, a dechloroacetylation procedure was explored, needed
for the synthesis of the oligosaccharides.
In Chapter 1 the background of the bacterium Streptococcus pneumoniae is
presented, including the course of infection, epidemiology, and vaccination.
Furthermore, the preparation and analysis of neoglycoproteins are discussed and
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the structural factors of the vaccine that might influence its immunogenicity.
Finally, the research on experimental S. pneumoniae type 3 vaccines is reviewed.
In Chapter 2 the development of a versatile synthetic strategy is described for the
preparation of oligosaccharide fragments related to the CPS of S. pneumoniae type
3. Furthermore, their conjugation to carrier proteins in varying carbohydrate-
protein ratios is reported. In this study, spacer-containing mono-, di-, tri-, and
tetrasaccharide fragments have been synthesised. To this end, suitably protected D-
glucose derivatives were coupled to obtain disaccharide building blocks for the
stepwise construction of a protected oligosaccharide. For the coupling reactions,
trichloroacetimidate donors were used with trimethylsilyl trifluoromethanesulfonate
as a promoter. Benzylidene groups were introduced to protect HO-6 for
introduction of carboxylic groups. Protected glucose moieties were converted into
glucuronic acid by oxidation with TEMPO. Deprotected compounds were
conjugated to CRM197, TT or KLH via diethyl squarate, whereby the CRM197-
conjugates varied in oligosaccharide loading ranging from 3-12.
In Chapter 3 the results are reported obtained by immunisation of mice with the
CRM197-conjugates. Groups of four mice were immunised twice subcutaneously,
with a 3-week interval with each of the CRM197-conjugates without adjuvant.
Antibody titers were determined by a phagocytosis assay. A challenge experiment
with a lethal dosis of S. pneumoniae type 3 was used to establish the protective
capacity of the raised antibodies. The tri- and tetrasaccharide conjugates afforded
complete protection, while the disaccharide conjugates afforded 75% protection.
No difference in protective immunity was observed for conjugates with different
oligosaccharide loading ranging from 3-12.
In Chapter 4 the synthesis is described of a hexasaccharide fragment related to the
capsular polysaccharide of S. pneumoniae type 3 to investigate the influence of a
further increase of the saccharide chain length on the immunogenicity of the
conjugates (Chapter 3). The synthesis of the hexasaccharide was achieved by using
the synthetic strategy as described in Chapter 2, employing disaccharide building
blocks, and TEMPO oxidation to convert protected glucose derivatives into
glucuronic acid.
In Chapter 5 an approach is presented for the analysis and isolation of pure
fragments from a mixture obtained by partial acid hydrolysis of the CPS of S.
pneumoniae type 3. Oligosaccharides of 1-7 repeating units were isolated on basis
of their charge using anion-exchange chromatography on a Sepharose Q column.
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High-pH anion-exchange chromatography using an AS11 column was used for the
analysis of mixture composition and purity control. The purity and identity of the
products was confirmed by 1H NMR spectroscopy and nano-electrospray mass
spectrometry.
In Chapter 6 the preparation of glycoclusters is reported containing a disaccharide
repeating unit of the CPS of S. pneumoniae type 3 to study the interaction of
antibody with multivalent structures. To this end, the spacer-containing
disaccharide repeating unit was synthesised and coupled to 4-(2-carboxyethyl)-4-
nitropimelic acid. Mono-, di-, and trivalent compounds were isolated and their
interaction with the monoclonal antibody IgG 3.3 was studied by surface plasmon
resonance. Clustering of the disaccharides in this way resulted in a slightly higher
affinity, whereas introduction of the hydrophobic scaffold caused a large increase
in affinity.
In Chapter 7 a novel dechloroacetylation procedure is described developed during
the synthesis of the saccharide fragments as described in Chapter 2. The scope of
this reaction, based on the use of diazabicyclo[2.2.2]octane (DABCO), was
explored. Efficient removal of the chloroacetyl group in the presence of acetate or
benzoate esters was accomplished in 30 min using 15 equivalents of DABCO in
ethanol at 55 °C.
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Samenvatting
Bacteriën met een polysacharide kapsel, bijvoorbeeld Streptococcus pneumoniae,
Neisseria menigitidis en Haemophilus influenzae, kunnen ernstige ziektes
veroorzaken zoals meningitis, longontsteking en middenoorontsteking. Vooral
jonge kinderen zijn vatbaar voor deze ziektes. Een vaccin, dat bestaat uit
geïsoleerde polysachariden van verschillende serotypes van S. pneumoniae, biedt
volwassenen bescherming, maar is niet effectief in groepen met verhoogd risico
zoals jonge kinderen. Tegen verschillende van deze ingekapselde bacteriën zijn nu
glycoproteïne vaccins beschikbaar, die opgebouwd zijn uit koolhydraten afkomstig
uit het kapsel gekoppeld aan een drager eiwit. Deze neoglycoproteïne vaccins
hebben een dramatische daling van het aantal ziektes tot gevolg gehad, ook in de
risicogroepen. Echter, de mechanismen die ten grondslag liggen aan de
immuunrespons van dit type vaccins worden nog maar slecht begrepen. De
hoofdreden hiervan is de heterogeniteit van de commerciële vaccins, die de
bestudering van de immuunrespons op moleculair niveau belemmerd. Ook
bemoeilijkt deze heterogeniteit de analyse van producten, hetgeen nodig is voor
routinematige controles. Ten slotte bestaat bij het gebruik van koolhydraten uit
biologisch materiaal het risico van verontreinigingen. Om deze problemen aan te
pakken moeten neoglycoconjugaten met een gedefinieerde structuur beschikbaar
komen.
In dit onderzoek zijn neoglycoproteïnen gemaakt naar de structuur van het
polysacharide kapsel van Streptococcus pneumoniae type 3. Dit serotype is
aanwezig in de 23-valente polysacharide vaccins en in de 11-valente conjugaat
vaccins. Bovendien wordt dit type vaak gebruikt om het beschermend vermogen
van experimentele vaccins te bestuderen, aangezien het sterk virulent is in muizen.
Het polysacharide kapsel is opgebouwd uit repeterende eenheden van het
disacharide [→3)-β-D-GlcpA-(1→4)-β-D-Glcp-(1→]. Zowel chemische synthese
als partiële zure hydrolyse van het polysacharide zijn uitgevoerd om goed
gedefinieerde oligosachariden te verkrijgen. Met de synthetische koolhydraten
werden neoglycoproteïnen gemaakt, waarvan de immunogeniciteit werd bestudeerd
in muizen. Ook werden glycoclusters gesynthetiseerd als een interessante klasse
van gedefinieerde verbindingen en de binding van deze structuren aan het
monoklonale antilichaam IgG 3.3 werd onderzocht met surface plasmon resonantie.
Ten slotte werd een methode voor dechloroacetylering bestudeerd, die ontwikkeld
werd voor de synthese van de oligosacharide fragmenten.
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In Hoofdstuk 1 wordt een achtergrond gegeven over de bacterie Streptococcus
pneumoniae. Deze omvat het verloop van een infectie, de epidemiologie en
vaccinatie. Bovendien worden de bereiding en analyse van neoglycoproteïnen
bediscussieerd alsmede de structuurelementen van het vaccin die de
immunogeniciteit kunnen beïnvloeden. Ten slotte wordt een samenvatting gegeven
van de experimentele vaccins met betrekking tot S. pneumoniae type 3.
In Hoofdstuk 2 wordt de ontwikkeling beschreven van een flexibele syntheseroute
om oligosacharide fragmenten te maken gerelateerd aan het polysacharide kapsel
van S. pneumoniae type 3. Ook wordt de koppeling van deze fragmenten aan drager
eiwitten vermeld in verschillende koolhydraat-eiwit verhoudingen. In deze studie
zijn spacer-bevattende mono-, di-, tri- en tetrasacharide fragmenten
gesynthetiseerd. Daartoe werden beschermde D-glucose derivaten gekoppeld tot
disacharide bouwstenen voor de stapsgewijze opbouw van een beschermd
oligosacharide. Voor de koppelingsreacties werden trichloroacetimidaat donoren
gebruikt met trimethylsilyl trifluoromethaansulfonaat als promoter. Benzylideen
groepen werden geïntroduceerd om de HO-6 positie te beschermen waar carboxyl
groepen geïntroduceerd moeten worden. Beschermde glucose eenheden werden in
glucuronzuur omgezet door oxidatie met TEMPO. Ontschermde verbindingen
werden geconjugeerd aan CRM197, TT of KLH via diethyl squaraat, waarbij de
CRM197 conjugaten in oligosacharide belading varieerden van 3-12.
In Hoofdstuk 3 worden de resultaten gepresenteerd die verkregen zijn met de
immunisatie van muizen met de CRM197 conjugaten. Groepen van vier muizen
werden twee keer subcutaan geïmmuniseerd met een tussenperiode van 3 weken
met elk van de CRM197 conjugaten zonder adjuvans. Antilichaamtiters werden
bepaald met een phagocytose assay. Een challenge experiment met een lethale
dosis van S. pneumoniae type 3 werd gebruikt om het beschermend vermogen van
de opgewekte antilichamen te bepalen. De tri- en tetrasacharide conjugaten gaven
volledige bescherming, terwijl de disacharide conjugaten 75% bescherming boden.
Er werd geen verschil in beschermende immuniteit waargenomen tussen
conjugaten met verschillende oligosacharide belading variërend van 3-12.
In Hoofdstuk 4 wordt de synthese beschreven van een hexasacharide fragment
gerelateerd aan het polysacharide kapsel van S. pneumoniae type 3 om de invloed
te onderzoeken van een grotere ketenlengte op de immunogeniciteit van de
conjugaten (Chapter 3). De synthese van het hexasacharide werd bereikt door
gebruik te maken van de syntheseroute die beschreven staat in Hoofdstuk 2,
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waarbij gebruik wordt gemaakt van disacharide bouwstenen en oxidatie met
TEMPO om beschermde glucose derivaten in glucuronzuur om te zetten.
In Hoofdstuk 5 wordt een methode beschreven om zuivere fragmenten te
verkrijgen van het polysacharide kapsel van S. pneumoniae type 3 door partiële
zure hydrolyse. Oligosachariden van 1-7 repeterende eenheden werden geïsoleerd
op basis van hun lading door gebruik te maken van
anionenwisselingschromatografie op een Sepharose Q kolom. Hoge pH
anionenwisselingschromatografie met een AS11 kolom werd gebruikt voor de
analyse van de samenstelling van mengsels en voor de zuiverheidscontrole. De
zuiverheid en identiteit van de producten werden bevestigd met 1H NMR
spectroscopie en nano-electrospray massa spectrometrie.
In Hoofdstuk 6 wordt de bereiding van glycoclusters met een disacharide
repeterende eenheid van het polysacharide kapsel van S. pneumoniae type 3
besproken om de interactie van een antilichaam met multivalente stoffen te
bestuderen. Daartoe werd een spacer-bevattend disacharide gesynthetiseerd en
gekoppeld aan 4-(2-carboxyethyl)-4-nitropimelic acid. Mono-, di- en trivalente
stoffen werden geïsoleerd en hun interactie met het monoklonale antilichaam IgG
3.3 werd bestudeerd met surface plasmon resonantie. Het op deze manier clusteren
van de disachariden resulteerde in een minimale verhoging van de affiniteit, terwijl
introductie van de hydrophobe spacer een sterke verhoging veroorzaakte.
In Hoofdstuk 7 wordt een nieuwe dechloroacetyleringsreactie beschreven die
ontwikkeld werd tijdens de synthese van de oligosacharide fragmenten zoals
beschreven in Hoofdstuk 2. De mogelijkheden van deze reactie die gebaseerd is op
het gebruik van diazabicyclo[2.2.2]octaan (DABCO) werden verkend. Een
efficiënte verwijdering van de chloroacetyl groep in aanwezigheid van acetaat of
benzoaat esters werd tot stand gebracht in 30 min met behulp van 15 equivalenten
DABCO in ethanol bij 55 °C.
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